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Abstract

There is increasing evidence linking chronic pain to altered levels of central
nervous system (CNS) inflammation and increased levels of perceived pain, anxiety,
depression and sleep disturbance. However the inflammatory molecules responsible for
physiologic and psychological components of chronic pain still warrant identification and
exploration. Using central inflammation as a paramount factor in the creation and
maintenance of chronic pain, this study aimed to investigate and describe the physical
and psychological aspects of chronic pain associated with CNS inflammation.
Using a cross-sectional correlational design, cerebrospinal fluid (CSF)
inflammatory cytokine patterns present in 8 chronic pain participants were compared to
inflammatory cytokine patterns present in 30 control CSF samples using multivariate
analysis of variance (MANOVA), with analysis of variance (ANOVA) analysis as a
follow-up. Levels of depression, anxiety, sleep disturbance and pain were measured in
approximately 8 chronic pain patients and correlated to CSF levels of inflammatory
cytokines using Pearson's r, or Spearman's Rho correlations. Demographic information
was also explored for relationships to central inflammation and descriptive statistics were
examined for responses.
To our knowledge, this is the first study to describe increased CSF levels of
Interleukin-8 (IL-8) in a population of majority Failed Back Surgery Syndrome chronic
pain patients (F (I, 36) ~ 14.89, p < 0.001, partial 11 2 ~ 0.293). Gender (F (1,6) ~ 7.782, p
~ 0.032, 11 2 ~ 0.565), socioeconomic status (r ~ -0.823, p ~ 0.012) and educational level (r
~

0.727, p

~

0.041) were also correlated with central levels of inflammation, indicating

that central physiologic changes may be related to host sex and psychosocial factors. All

participants reported poor sleep quality and took at least one opioid medication,
indicating that sleep and opioids may scaffold a portion of the chronic pain paradigm.
This study richly describes the dynamic experience of chronic pain through the
lens of Psychoneuroimmunology. Incorporating both physiologic and psychological
aspects of the disease, this study describes an association between chronic pain, central
inflammation, gender, socioeconomic status, opioid medications and poor sleep quality.
Thus, the future of pain treatment must consider these aspects when treating patients and
look to future studies for possible new treatment options which target these factors.

Keywords: inflammation, cytokines, chronic pain, sleep quality, gender, socioeconomic
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Chapter 1: PROBLEM
Significance

Chronic pain is a health concern of tremendous scope. An estimated 116 million
Americans suffer from, and are disabled by this chronic illness (Tsang et al., 2008) at a
cost of $630 billion in lost work revenue, sick time and health care costs (Gaskin &
Richard, 2011 ). Most important, is the cost in quality of life that the patient pays.
Patients report not only a wide spectrum of painful symptoms, but also suffer the
negative psychological effects of constant pain. Current modalities utilized to treat these
patients both physically and psychologically are limited, and are often ineffective for a
large portion of the chronic pain population. Recent investigations reported in chronic
pain literature have revealed a new direction for therapeutic advancement: central
nervous system (CNS) inflammatory mechanisms that are believed to exacerbate and
prolong neuropathic pain states (Kreutzberg, 1996; Reeve, Patel, Fox, Walker, & Urban,
2000; Samad, Wang, Broom, & Woolf, 2004; Watkins & Maier, 2003; Watkins,
Milligan, & Maier, 2001) also influence anxiety (Baker et al., 2001; Camara et al. 2015),
depression (Bonne et al., 2011; Levine et al., 1999; Lindqvist et al., 2009) and sleep
disturbances (Dauvilliers et al., 2014). Though preclinical data is accumulating, there
remains a dearth of human data in this rapidly developing area of investigation which
links central inflammation, chronic pain and the psychology of pain.
This study investigated the emerging relationships between chronic pain
syndromes and the role of central inflammation, through examination of cerebrospinal
fluid (CSF) patterns of inflammatory mediator molecules. More specifically, this study
1

investigated whether human CNS levels of pro- and anti-inflammatory cytokines were
similar to those described in chronic pain-induced animal studies (Inoue et al., 1999;
Morioka et al., 2002; Raghavendra, Tanga, & DeLeo 2004; Song & Zhao, 2001). This
study also explored the relationships between central inflammation and the psychological
responses to the chronic pain experience (pain perception, anxiety, depression and sleep
quality). This was accomplished using the Short-Form McGill Pain Questionnaire
(Melzack, 1975; Melzack, 1987), by scoring on the Hamilton Anxiety Rating Scale
(Hamilton, 1959), Beck Depression Inventory-II (Beck, Ward, Mendeson, Mock &
Arbough, 1961) and the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk,
Berman, & Kupfer, 1989). Keeping central inflammation paramount to the chronic pain
experience, this study examined the relationship of central inflammation to chronic pain
and the psychology that accompanies chronic pain.
This exploration of psychological and physiologic interaction was supported by a
discipline that links the mind and body known as Psychoneuroimmunology. As a field
of study, psychoneuroimmunology explores the interactions between behavioral, neural,
endocrine and immune processes. Psychoneuroimmunology is a rapidly growing
specialty within psychology tasked with exploring the adaptive processes of
physiological and behavioral responses to physical and psychological environmental
stressors (Ader, 2000). Because there is a scarcity of human evidence supporting the link
between physical and psychological pain, and central levels of inflammatory mediator
molecules associated with these constructs, this study provided evidence of this
multimodal relationship utilizing psychoneuroimmunology as a foundational research
2

paradigm.
Increased knowledge of the relationships between the psychoneuroimmune
responses to prolonged pain states propagated by central inflammatory mechanisms, will
lead to information pertinent to more effective analgesic and psychological treatment of
these patients. It was the goal of this study to explore and describe the
psychoneuroimmune relationship of central inflammation, chronic pain, anxiety,
depression and sleep disturbance in the chronic pain population.
Purpose and Specific Aims

The purpose of this study was to examine and characterize the relationships
between the physical and psychological components of chronic pain and inflammatory
mediator molecules, more specifically cytokines called interleukins (ILs) and tumor
necrosis factor-alpha (TNF-u). Specific aims of this study include the following:
1) Investigation of altered CSF levels of pro-inflammatory cytokines including
interleukin-! (IL-1 ), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor
necrosis factor-alpha (TNF-u) in patients with chronic pain as compared to
control samples;
2) Investigation of alterations in levels of anti-inflammatory interleukin-! 0 (IL
10) in chronic pain patients as compared to control samples ofCSF.
This study also aimed to explore the relationship between central inflammation
and the psychological responses to chronic pain as evidenced by results gathered from the
following psychological tests:
1) The experience of chronic pain as measured by the Short Form McGill Pain
3

Questionnaire (SF-MPQ);
2) Pain-related anxiety levels as measured by scores on the Hamilton Anxiety
Rating Scale (HAM-A);
3) The presence or absence of depression as measured by the Beck Depression
Inventory-II (BDI-II);
4) Sleep disturbances in chronic pain patients as measured by the Pittsburgh
Sleep Quality Index (PSQI).
The secondary aims of this study included assessing for relationships between the
participant demographics, type of chronic pain diagnosis, length of diagnosis, type(s) of
medication(s) used to treat chronic pain and length of time taking those medication(s) to
levels of central inflammation.

Hypotheses
1. Patients with chronic pain syndromes will have elevated CSF levels of
pro-inflammatory cytokines IL-1, IL-6, IL-8 and TNF-u as detected with
Multiplex assay analysis when compared to control samples of CSF.
2. Patients with chronic pain syndromes will have decreased CSF levels of anti
inflammatory cytokine IL-10 as detected with Multiplex assay analysis when
compared to control samples of CSF.
3. There will be a positive correlation between the severity of perceived pain as
measured by the Short Form-McGill Pain Questionnaire (SF-MPQ), anxiety
as measured by scores on the Hamilton Anxiety Rating Scale (HAM-A),
extent of depression as measured by the Beck Depression Inventory-II (BDI

4

II), and sleep disturbance as measured by the Pittsburgh Sleep Quality Index
(PSQI), and levels of pro-inflammatory cytokines in the CSF.
4. There will be an inverse correlation between the severity of perceived pain as
measured by the Short Form-McGill Pain Questionnaire (SF-MPQ), anxiety
as measured by scores on the Hamilton Anxiety Rating Scale (HAM-A),
degrees of depression as measured by the Beck Depression Inventory-II (BDI
II), and sleep disturbance as measured by the Pittsburgh Sleep Quality Index
(PSQI), and levels of anti-inflammatory IL-10 in CSF.
5. Prolonged length of diagnosis, opioid medications used to treat chronic pain
and prolonged length of time taking medication(s) will positively correlate
with increased levels of pro-inflammatory cytokines in the CSF of chronic
pain patients.
6. There will be an inverse relationship between central levels of anti
inflammatory IL-10 and prolonged length of diagnosis, opioid medications
used to treat chronic pain and prolonged length of time taking medication(s).
Theoretical Perspective

For the purpose of this study, the presence of chronic pain was held as the
paramount stressor that was integrated into an amalgam of biological and behavioral
factors influencing the overall health and disease status of the patient. Pain is defined by
the International Association of the Study of Pain (IASP) as "an unpleasant sensory and
emotional experience associated with actual or potential tissue damage, or described in
terms of such damage" (Merskey & Bogduk, 1994). Given thatthe definition of pain by
5

IASP incorporates sensory, emotional and biologic components, the
Psychoneuroimmunology (PNI) theoretical framework was adopted as a basis for this
study because of its multifaceted approach to the health outcome of a patient. More
specifically, McCain and colleagues' generic theoretical framework of PNI was adapted
and utilized to help guide this study (Figure 1) (McCain, Gray, Walter, & Robins, 2005).
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Figure 1. The Psychoneuroimmunology Theoretical Framework adapted from McCain,

Gray, Walter, & Robins, 2005, p. 13.

Their framework identifies the patterns, processes and consequences of stress and
coping as they relate to the multidimensional psychobehavioral-neuroendocrine-immune
system interactions that relate to health dynamics (McCain et al., 2005). The PNI
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framework scaffolds this investigation by defining the association between the mind and
body. As a framework, it merges psychological variables such as anxiety and depression
with the perceived stress of pain and relates the neuroendocrine mediators that influence
sleep quality and pain levels as it applies to the chronic pain condition. As a framework,
it also correlates the measurable irrununological inflammatory markers in the chronic
pain study population. Applied to this study, pain and symptoms of depression, anxiety
and sleep deprivation can thus be compared to the central biological markers of
inflammation associated with chronic pain in a cross-sectioual study process (see Figure
2).
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Within the PNI theoretical perspective, chronic pain is approached as a
multifaceted dynamic condition with many involved factors including psychological,
neuroendocrine and immunologic components. When considering the factors of pain,
anxiety, depression, sleep deprivation, and altered levels of inflammatory biomarkers in
the presence of chronic pain, causal pathways are unclear, but these factors have been
found to contribute to, or be associated with the chronic pain process in both humans and
animals (Baker et al., 2001; Dworkin & Gitlin, 1991; Heffner, France, Trost, Ng, &
Pigeon, 2011; Meller, Dykstra, Grzybycki, Murphy, & Gebhart, 1994). The PNI
theoretical framework by McCain et al. (2005) acknowledges these relationships and
makes them explicit in an iterative, fluid continuum. Use of the PNI theoretical
framework thus provides this study a mechanism to bring these multidisciplinary
components together in a more inclusive view of the chronic pain process rather than
detail the complex physiological and pathophysiological interactions as independent
underlying processes.
Psychoneuroimmunology as a paradigm in nursing research supports the premise
that there is bidirectional neuroendocrine-immune system interaction (Rabin, Choen,
Ganguli, Lysle, & Cunnick, 1989) that justifies psychobehavioral nursing interventions
designed to address stress and coping, considering an associated physiological basis
(McCain et al., 2005). Psychoneuroimmunology combines the Lazarus and Folkman
(1984) cognitive-transactional model of stress with psychology, behavioral, and
pathophysiologic processes of the patient's health status. The mind-body interaction
(Zeller, McCain & Swanson, 1996) inferred in PNI has been shown in animal and human
8

models in a myriad of multidisciplinary studies: From the inception of the concept of
PNI (Solomon & Moos, 1964) to the work that demonstrated behavioral conditioning's
influence on the immune system (Ader & Cohen, 1975), PNI is still a relatively new
theory in nursing research. However, it is one that incorporates a more holistic view of
specific stressors and the effect on the patient's health spectrum.
Within the PNI framework described by McCain and colleagues (2005), the
identified cofactors are those components that have the potential to predispose an
individual to certain stress, coping and health patterns (potential cofactors) or the health
related features of one's life (pretreatment critical cofactors). The potential demographic
cofactors identified in this study were: the patients' age, gender, race, education level,
socioeconomic status (SES), level of activity as measured by metabolic equivalents
(METS), and body mass index (BMI). The pretreatment critical cofactors identified
included: the cause or diagnosis of chronic pain, the length of diagnosis, type(s) of
medication(s) utilized to treat the chronic pain symptoms, and the length of time taking
medication(s) for chronic pain relief. The psychological --"psycho"-- component of the
psychoneuroimmunology model includes sociobehavioral components such as negative
affect and distress (McCain et al., 2005). The perceived stress of chronic pain and the
effectiveness of the patients coping patterns will be measured by their experience of pain
through the Short Form-McGill Pain Questionnaire, their level of anxiety via the
Hamilton Anxiety Rating Scale, the extent of depression related to the chronic pain
symptoms by the Beck Depression Inventory-II, and their sleep quality via the Pittsburgh
Sleep Quality Index. The neurological --"neuro"-- and "immunology" components of the
9

McCain PNI theoretical framework focus on the physiological responses to psychosocial
stressors, the effect of stress on the immune system, and the interrelationship between the
neuroendocrine and immune system (McCain et al., 2005). The physiologic responses to
the stressor of chronic pain (which amalgamates the effect of stress on the immune
system and the interrelationship between the neuroendocrine and immune system) will be
measured through patterns of CNS inflammatory cytokines.
Seminal literature demonstrates there is a central neurological component related
to the biomarkers measured in this study with the initiation, maintenance and quality of
sleep (Fontana, Kristensen, Dubs, Gemsa, & Weber, 1982; Ishimori, 1909;
Pappenheimer, Miller, & Goodrich, 1967). Within the PNI framework, and because of
the fluid, interrelated interaction of the components within this model, sleep (as measured
by the Pittsburgh Sleep Quality Index), will also be regarded within the neuroendocrine
function of this framework.
The biological markers investigated by this study will be patterns of biomarkers
called cytokines, more specifically IL-1, IL-6, IL-8, IL-10 and TNF-u. These biomarkers
are released by both peripheral and central immune cells in response to a wide array of
physiologic insults, however nociceptive central sensitization common in chronic pain
models has been associated with the release of these biomarkers specific only to CNS
cells called glia (Zhang et al., 2008). Thus, the PNI framework correctly identifies these
CNS cytokines in the neurological --"neuro"-- categorical point of reference within the
PNI framework for this specific study. Once glia release inflammatory biomarkers, it is
known that these molecules contribute a wide array of immunologic functions. The PNI
10

framework also correctly maintains these biomarkers as neuroimmune mediators properly
categorized under the "neuroimmunology" component of the theoretical framework. The
neuroimmune mediators will be measured in this study using Multiplex assay analysis to
assess levels of cytokines within the CSF of patients, presumably reflecting inter-related
central neuronal and immunological functions. Through triangulation of the various
results, this study yields novel information about relationships between chronic pain, the
perception of pain, anxiety, depression, sleep deprivation and central biomarker
mediators all under the architecture of the PNI framework.

11

Chapter 2: REVIEW OF THE LITERATURE
Background
Chronic Pain in America
Chronic pain is the loose definition of devastating symptomatology that affects an
estimated 116 million Americans (Tsang et al., 2008) and spans across all socioeconomic
boundaries, educational levels, cultural, gender and age demographics (Pleis, Ward, &
Lucas, 2010). Its causes are indiscriminate, its effects on sufferers can be incapacitating
and intolerable. Currently there is no cure for the pain these patients suffer, no remedy or
vaccination to restore an enjoyable quality oflife.
A developing body of neuroimmune research demonstrates mounting evidence of
alternative pain pathways that perpetuate the chronic pain state via physiologic self
propagating, or positive feedback mechanisms. Much of this new evidence points to the
inflammatory process involving the signaling molecules secreted by neuronal cells called
glia. Investigative work on glial cells has identified a selection of various molecules
involved in positive feedback loops responsible for chronic pain, and has established that
the underlying mechanisms involved render our current methods of fighting pain
ineffective. As previously discussed, some of the proposed responsible molecules
secreted by glial cells are called pro-inflammatory mediator molecules, specifically
interleukin- I (IL-I), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor
alpha (TNF- a). Multiple preclinical investigations have demonstrated that ifthe effects
of these pro-inflammatory mediator molecules are blocked using various approaches,
symptoms of chronic pain can be reversed and the analgesic functions of opioid
12

treatments return.
In addition to widespread and indiscriminate effects, chronic pain also holds an
astonishingly high price tag for our health care system. The Institute of Medicine has
reported that chronic pain is estimated to cost society an estimated $630 billion annually
in health care related costs and loss of productivity (Gaskin & Richard, 2011). In the
United States, chronic pain accounts for millions of sufferers; more than all diabetic,
coronary heart disease, stroke and cancer patients combined (Tsang et al., 2008). A
myriad of anatomical areas are affected by chronic pain (National Centers for Health
Statistics, 2006) with a spectrum of severity and quality of pain, making this disease
difficult to treat with current practices. The psychological impact of unrelenting pain is
also devastatingly prohibitive to a favorable quality of life. A 2006 survey completed by
the American Pain Foundation, described more than half of the respondents felt they had
little or no control over their pain and reported breakthrough pain at least once a day that
severely impacted their quality of life and overall wellbeing (David Michaelson &
Company, LLC, 2006). This potentially can lead to the overall feeling of loss of control,
helplessness and apprehension, which can compound the negative impact pain holds over
the sufferer's life. The survey also disclosed that over half of those surveyed reported
that their pain impacted on their overall enjoyment oflife, with over 75% reported feeling
depressed because of their pain and 74% relaying their pain impacted their energy levels
(David Michaelson & Company, LLC, 2006). Clearly chronic pain symptoms are not
just incapacitating to the physical being, but spreads through the entire existence of the
sufferer and impact all aspects of life.
13

Physiologic Pain Verses Chronic Pain

Pain is an elegant mechanism developed as a protective measure to preserve
cellular function and life. When pain pathways work as they were intended, pain signals
transmit from the periphery through the body to the central nervous system (CNS) for
processing. Through a complex series of cellular interactions, pain perception
(nociception) is the body's way of removing itself from a dangerous situation. In this
way, pain, the proper perception of pain, and thus the proper withdrawal reaction to
painful stimuli has aided in our species' survival and propagation. However, there are
many instances in which individuals' pain perception and reaction to painful stimuli
have, through no fault of their own, developed into chronic states of pain that serve no
survival or protective benefit. Many individuals with chronic pain can exhibit
hyperalgesia, a state in which there is an increased sensitivity to painful stimuli and can,
additionally, report allodynia, the sensation of pain in response to a stimuli not normally
responsible for pain.
A barrage of aberrant pathways contributes to the initiation and maintenance of
nociception in chronic pain states and one of the mechanisms responsible for, and
described in the literature is through glial cell activity. Immune cells known as glia are
located in the CNS in close proximity to neurons. Until recently, glia were thought to
exclusively contribute to the structure and nourishment of neurons (Barres, 1991; Kandel,
1991 ). Current literature has shown that glia do more than just nourish and provide
structure to neurons; glial cells are immunologic cells that are activated following tissue
injury, illness or inflammation (Tsuda, Inoue, & Salter, 2005; Watkins & Maier, 2000),
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and have been shown to be a fundamental component for enhanced pain perception
(Watkins & Maier, 2003). Once activated, glial cells release a cascade of molecules,
more prominently pro-inflammatory cytokines, which have been shown to excite pain
transmission and experience (Kreutzberg, 1996; Watkins, Milligan, & Maier, 2001 ). The
same pro-inflammatory cytokines can ramp up dorsal horn neurons in pain transmission
(Reeve, Patel, Fox, Walker, & Urban, 2000; Samad, Wang, Broom, & Woolf, 2004), they
increase the release of neurotransmitters from sensory afferent nerves responsible for
pain response (Inoue et al., 1999; Morioka et al., 2002) and may enhance pain via
upregulation of AMPA (2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4-yl) propanoic acid)
and NMDA (N-Methyl-D-aspartate) receptor expression and activity (Beattie et al., 2002;
Samad et al., 2004, Viviani et al., 2003; Wang, et al., 2005).
Cytokines and Chronic Pain

Cytokines are polypeptide, nonstructural proteins that are small (5-140 kDa) and
effective at minute concentrations (pM) (Clark, Old, & Malcangio, 2013). They span a
spectrum of physiologic functions that are limited in function only by the types of cells
that express their receptors (Dinarello, 2007). Because of the vast physiologic
effectiveness of cytokines, these soluble messenger proteins have extreme duality: They
can be immensely protective (as in the case of immune defense of a host against
infection) or highly lethal (as in the cases of cellular apoptosis, sepsis and specific
cancers). Cytokines are further denoted by their propensity to be pro-inflammatory, or
anti-inflammatory, and subdivided into larger protein families (such as interferons,
interleukins, chemokines, mesenchymal growth factors, adipokines or the tumor necrosis
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factor family) (Dinarello, 2007).
The interleukin (IL) family is perhaps one of the largest cytokine families that
includes over 30 cytokines, both pro- and anti-inflammatory (Dinarello, 2007).
Interleukin-I (IL-1) is a relatively small pro-inflammatory cytokine (17.5 kDa)that also
has the ability to initiate the expression and secretion of other pro-inflammatory
cytokines. It belongs to a larger IL-1 gene family that is responsible for a myriad of
functions including physiologic temperature regulation, T cell immunity against infection
and hepatic protein synthesis (Dinarello, 2007). This pro-inflammatory cytokine is
primarily secreted by glial cells in the CNS (Felts et al., 2005; Zhang et al., 2008),
although there is data to show neuronal expression as well (DeLeo, Colburn, & Rickman,
1997; Sweitzer, Colburn, Rutkowski, & DeLeo, 1999). Additionally, neurons, glia and
astrocytes all contain IL-1 receptors (Gruber-Schoffnegger et al., 2013; Zhang et al.,
2008), making these CNS cells prime locations for IL-1 synthesis, secretion and cellular
action. In order for neurons and astrocytes to express IL-1, an additional enzyme class
called matrix metalloproteases has to cleave the inactive precursor (pro-IL-1) to produce
the physiologically active form of the cytokine (Kawasaki et al., 2008). Not surprisingly,
preclinical trials have demonstrated that rodents that genetically lack IL-113, IL-la, the
IL-1 receptor, or overexpress IL-1 receptor antagonist, all fail to develop either
mechanical hypersensitivity, or mechanical and thermal pain behaviors when exposed to
an experimentally induced nerve injury (Honore et al., 2006; Wolf, Gabay, Tai, Yirmiya,
& Shavit, 2006). Thus, IL-1 plays an unequivocal role in central processes of the pain

expenence.
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Tumor necrosis factor-alpha (TNF-a) is a pro-inflammatory cytokine that is part
of a group of over 20 proteins called the tumor necrosis factor superfamily (Dinarello,
2007). It is a relatively small cytokine (17 kDa) and is produced peripherally by
macrophages (Aggarwal, Gupta, & Kim, 2012), and centrally by neurons and glial cells
(Ohtori, Takahashi, Moriya, & Myers, 2004; Xu, Xin, Zang, Wu, & Liu, 2006). Tumor
necrosis factor-alpha also has extreme duality in it's function under normal physiology:
It aids host immunity, but also has been implicated in sepsis (Eichacker et al., 2002),

cancers, cardiovascular, neurologic, pulmonary, autoimmune and metabolic disorders
(Aggarwal et al., 2012). Under normative conditions, CNS expression ofTNF-a is
minimal, however in response to nerve injury, TNF-a induces dorsal horn glia to release
additional pro-inflammatory cytokines and increase neuronal sensitivity (Andrade et al.,
2011; Clark et al., 2013; Inoue, 2006).
In contrast to the other cytokines discussed above, Interleukin-I 0 (IL-I 0) is an
anti-inflammatory cytokine. Originally classified as a T-helper-2 (Th2) cytokine, it is
now known that the functions of IL-10 encompass more than T cells. The actions of this
cytokine are principally derived from the type of cell that produces it, the type of cell that
responds to it and the inflammatory cytokine milieu in which it is released (Mosser &
Zhang, 2008). This anti-inflammatory cytokine is expressed by mast cells, macrophages,
natural killer (NK) cells, eosinophils, neutrophils and glial cells (Saraiva & O'Garra,
2010). It is a potent regulator of immune responses; IL-10 attends to conditions ranging
from parasites to allergens (Saraiva & O'Garra, 2010), and is in many ways the
physiologic antidote to pro-inflammatory cytokines and overactive immune responses, as
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it suppresses Interferon Gamma (IFN-g), IL-1, TNF-a and IL-6 (Dinarello, 2007).
Dysregulation ofIL-10 thus leads to autoimmune and inflammatory conditions and
diseases (Clark et al., 2013; Mosser & Zhang, 2008; Saraiva & O'Garra, 2010). In
response to CNS pathology and certain chronic pain states, levels ofIL-10 are increased
via activation of glial cells (Ledeboer et al., 2003)most likely to combat the transient rise
in pro-inflammatory cytokines. However in other chronic pain conditions, IL-10
concentrations have been noted to be lower when compared to healthy controls
(Alexander, Perreault, Reichenberger, & Schwartzman, 2007; Backonja, Coe, Muller, &
Schell, 2008). Thus, the literature illustrates that the intrinsic anti-inflammatory
regulatory mechanism of IL-10 is corrupted or altered in some processes of chronic pain.
Chronic Pain Treatment & Glial Cells

Interestingly, preclinical studies have also shown that glial cells contribute not
only to nociception upon insult (Meller, Dykstra, Grzybycki, Murphy, & Gebhart, 1994),
but also perpetuate the maintenance of pain when it is treated with opioids. Multiple
studies have shown that upon administration of chronic opioids to pain-induced rodents,
there was an increase in glial cell activity in the CNS (Raghavendra, Rutkowski, &
DeLeo, 2002; Song & Zhao, 2001; Tai et al., 2006). Glia have also been shown to
upregulate pro-inflammatory cytokines production and release in the CNS when the
organism is treated with longstanding systemic or intrathecal opioids; this increase of
cytokine production and release in the CNS has been shown to contribute to opioid
tolerance and withdrawal induced pain enhancement (Johnston et al., 2004; Raghavendra,
Tanga, & De Leo 2004; Song & Zhao, 2001 ). These investigations suggest that not only
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are glia partially responsible for the maintenance of chronic pain symptoms, but they are
also responsible for decreasing the efficacy of one of the most prominent treatments of
pain-opioid drugs. Thus, when a chronic pain-induced rodent is treated for pain, over
time the very treatment that relieves the pain will be part of a self propagating cascade of
events that will be responsible for perpetuating the pain, increasing the level of pain,
decreasing the effectiveness of treatment (through opioid tolerance) and creating painful
responses to stressors that normally should have no painful reaction (allodynia).
Glial Cell Inhibition in Treatment of Chronic Pain

Inhibiting glia cells is not an option in the treatment of chronic pain because the
full physiologic function of these cells is not well understood. Animal model studies
show that arresting glial cell function in vivo using fluorocitrate, a glial metabolic
inhibitor, suppresses glial cells from amino acid uptake and can result in host seizures.
Minocycline, a microglia inhibitor and antibiotic, may prevent glial hyperactivation but it
cannot be utilized in cases where there is established neuropathic pain (Milligan et al.,
2006). Consequently, a body of research has shifted its approach from directly inhibiting
glial cells to investigating what effects could be rendered by targeting the pro
inflammatory mediators released by glia. The results of animal model studies show
phenomenal promise for future treatment of chronic pain: Several studies have proposed
that morphine tolerance can be slowed or reversed by knocking out the signaling of the
glia-produced pro-inflammatory cytokine IL-1, or by blocking IL-1 with a receptor
antagonist (IL-lra) (Hutchinson et al., 2008; Shavit, Wolf, Goshen, Livshits, & Yirmiya,
2005). Thus, animal model studies illustrate a cellular relationship that could be explored
19

for future treatment of chronic pain, but human research is still lacking.
Preclinical Verses Human Chronic Pain Studies

Unlike the animal model of pain research, where a chronic pain state can be
surgically created in a precise manner, such as a chronic constriction injury of the sciatic
nerve performed commonly in rodents, human studies have to account for the wide
spectrum of pain states and symptoms, the cause( s) of pain and the location( s) of pain.
Likewise, rodent studies are also able to meticulously treat a cohort of rodents with the
same treatment, medication and dose in a measurable protocol; human studies have to
adjust for the individual treatment regimens that utilize many types of medications, at
varying doses or holistic treatments that manipulate varying physiologic processes.
Additionally, rodent studies are performed in a homogenous population of genetically
similar organisms; human studies incorporate varying physiologic and psychological
factors associated with pain. Unlike the rodent models in chronic pain research, humans
cannot be sacrificed for direct measurement of pro-inflammatory cytokines, and thus the
two methods available for cytokine data collection in human models is limited to serum
and cerebrospinal fluid (CSF) analysis. The wide variance in types of pain states,
medications used for treating pain, co-existing physiologic and psychological variables
and the indirect methods of gathering data limit human studies. Preclinical studies,
however, offer limited value to understanding the relationship of chronic pain and levels
of cytokines in humans. Rodent studies offer no insight into the relationship between the
psychology of pain and the neuroimmune responses of chronic pain. Anxiety, depression
and sleep disturbances are ascertained in rodent models with a certain degree of
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interpretation. Rodent models also do not clearly describe what will occur in human
physiology. While animal studies may provide a basic understanding of a phenomenon,
human studies are nevertheless paramount in progressing towards translation into
treatment modalities.
Human Chronic Pain Studies & Inflammation

The human research on pro-inflammatory cytokines is very limited and
developing now. Prior human studies focused on measuring pro-inflammatory cytokines
through serum analysis secondary to the decreased invasiveness and ease of collection.
However, several of these studies discovered confounding levels of cytokines that were
measured in the serum verses CSF of the study participants: levels of cytokines found to
be high in the CSF were found to be low or undetectable in the serum and vice versa
(Backonja et al., 2008; Brisby, Olmarker, Larsson, Nutu, & Rydevik, 2002; Kadetoff,
Lampa, Westman, Andersson, & Kosek, 2012; Ludwig, Binder, Steinmann, Wasner, &
Baron, 2008; Lundborg, Hahn-Zoric, Biber, & Hansson, 2010; Rozen & Swidan, 2007;
Zin, Nissen, Moore, & Smith, 2010). Possible reasons include cytokine production via
peripheral physiologic processes, which may or may not be related to nociception, verses
cytokine production via glia in the CNS in response to pain signaling. This study will
focus on CSF analysis because of the role of CNS processing in chronic pain, and the
accompanying central location of glia, cytokines, and neurons. This approach proves
more logical than examining serum levels of mediator molecules-subject to multiple
competing physiological stimulin of peripheral immune cells-as a means of supportive
analysis for developing pain literature.
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Currently CSF has been examined in patients with complex regional pain
syndrome (Alexander et al., 2007; Alexander, van Rijn, van Hilten, Perreault, &
Schwartzman, 2005; Backonja et al., 2008; Munts et al., 2008), fibromyalgia (Bjersing,
Dehlin, Erlandsson, Bokarewa, & Mannerkorpi, 2012; Kadetoff et al., 2012), those
receiving intrathecal opioid infusions for pain management (Zin et al., 2010), persistent
headache (Rozen & Swidan, 2007), neuropathic pain related to previous spinal surgery
(McCarthy, Connor, & McCrory, 2013; Capelle, Weigel, Schmelz, & Krauss, 2009),
sciatica (Brisby et al., 2002), lumbar radiculopathy (Nagashima, Morio, Yamane, Nanjo,
& Teshima, 2009; Ohtori et al., 2011), polyneuropathy (Ludwig et al., 2008), post

herpetic neuralgia (Kikuchi, Kotani, Sato, Takamura, Sakai, & Matsuki, 1999; Kotani et
al., 2000; Rijsdijk et al., 2013) and chronic osteoarthritis pain (Buvanendran et al., 2006;
Lundborg et al., 2010; Yeager et al., 1999). Additional studies analyzing human CSF can
be found summarized by Bjurstrom et al. (2014). Grouping of study participants based
on diagnosis may control for some error by standardizing the type of pain, quality,
location, causes and triggers as well as the treatment for the specific pain. This study
included all forms of chronic pain patients with the intention of grouping the types and
causes of pain before determining the most meaningful analysis methodology. In
general, the preceding studies demonstrated that IL-1, IL-6, IL-8 and TNF-a were found
to be elevated in the CSF of human study participants, but more evidence is still needed
to corroborate the behavior of these molecules in pain syndromes. Other research has
demonstrated a decrease in CSF levels of anti-inflammatory IL-10 (Alexander et al.,
2007). This current study targeted IL-1, IL-6, IL-8, TNF-u and IL-10 for analysis and
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focused on providing supportive human data for the chronic pain population. By
measuring CSF rather than serum, grouping patients based on their diagnosis of pain and
basing the cytokine analysis on previous investigations, this study provides a greater
understanding of the developing role cytokines play in chronic pain.
Evidence Supporting Inflammatory Contributions to Anxiety and Depression

As previously mentioned, preclinical studies provide little insight into how
psychological states (i.e., anxiety and depression) relate to the neuroimmune response of
chronic pain in humans. All types of anxiety and depression cannot be directly
ascertained in any rodent model, and is an integral component in the pain process and
definitive treatment plan of chronic pain. Part of the psychoneuroimmunologic
component to pain is the interaction between inflammation, cytokines and the behavioral
complex known as sickness behavior or sickness response. Feelings of sickness can be
characterized by fatigue, decrease appetite, fever, lack of mobility, sleep disturbances,
depression and an inability to concentrate (Dantzer, 2001; Hart, 1988; Watkins & Maier,
2000). Though the neuroimmune-mediated sickness behavior/response may promote
unsavory feelings, this natural response to illness is ultimately protective as it aids in
healing and is usually short-lived with resolution of the offending illness. However, like
chronic pain, when the protective mechanism of the sickness behavior/response goes
awry, feelings of depression and anxiety can be perpetuated longer than the illness or
stress. If the psychological effects of anxiety and depression are related to the illness or
stress of pain, the mechanism is still unclear. Inflammatory cytokines offer one possible
explanatory link between all of the psychoneuroimmune responses and pain, but central
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levels of cytokines in humans have not been extensively studied thus far. In addition to
the relationship of chronic pain to altered levels of centrally-produced cytokines, anxiety
and depression must be examined in humans to determine their relationship to chronic
pain and central inflammation.
Inflammation & Anxiety

While a majority of research and attention has focused on the relationship
between chronic pain and depression (Dersh, Polatin, & Gatchel, 2002), there is literature
that supports associations with chronic pain and anxiety disorders. In a large,
retrospective analysis of over five thousand participants, Mc Williams and colleagues
found there was a stronger association of chronic pain and panic disorder (PD) and post
traumatic stress disorder (PTSD) than depression (Mc Williams, Cox, & Enns, 2003).
Thus, this study and other literature suggest the possibility that efforts to treat chronic
pain should be combined with anxiolytic treatment.
Peripheral levels of inflammatory cytokines have been examined with conflicting
results in human studies related to anxiety disorders. While some investigations
examining relationships between anxiety and systemic cytokines levels have shown
increases in serum levels

ofIL-1~

and IL-6 (Maes et al., 1999; Spivak et al., 1997),

results of other studies are contrary to those findings (Koh & Lee, 2004; van Duinen et
al., 2008). Possible explanations for the discrepancies between these studies include the
type of anxiety (acutely experiment-produced or a chronic underlying diagnosis), whether
the cytokines measured were from induced lymphocyte production or systemically
circulating levels, and the sensitivity of the assay used to detect the cytokines. Using
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Multiplex assay analysis with the Luminex® system (Austin, TX), Hoge and colleagues
were able to demonstrate elevations in serum levels of eighteen cytokines including pro
inflammatory

IL-1~,

IL-6, IL-8 and TNF-u as well as anti-inflammatory IL-10 in PD and

PTSD study participants (Hoge et al., 2009). However, these peripheral results do not
clarify ifthere is a central mechanism that links anxiety, inflammation and pain.
The data on central inflammation and anxiety is very limited. Similar to chronic
pain studies that examine peripheral and central cytokine patterns, anxiety research
exemplifies the same theme: Peripheral and central levels of cytokines do not appear to
agree in magnitude or direction in most investigations. According to Baker et al. (2001 ),
levels of IL-6 were found to be increased in the CSF but not increased in the serum of
PTSD participants. Clearly, there is opportunity to examine the relationship between
anxiety, commonly found with pain-related conditions, and the centrally mediated
response of inflammation.
Inflammation & Depression

The direct correlative relationship between depression and pain has been
thoroughly documented in the literature showing that both depressed patients exhibit at
least one painful symptom (Vaccarino, Sills, Evans, & Kalai, 2009) and chronic pain
patients frequently exhibit depression (Dworkin & Gitlin, 1991 ). In a study by the
American Pain Foundation, over half of the chronic pain sufferers surveyed reported that
pain impacted their overall enjoyment of life and over 75% reported feeling depressed
because of their pain (David Michaelson & Company, LLC, 2006). Thus pain and
depression warrant mutual inspection.
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Similar to the anxiety literature, the relationship between levels of pro- and anti
inflammatory cytokines and their neuroimmune relationship in the pathophysiology of
depression are not fully understood. Through a meta-analysis of 136 studies on serum
levels of cytokines in depressive patients, Dowlati and colleagues found both supportive
and contradictory results supporting the role of peripherally measured inflammatory
cytokines and depression. They were only able to report a significant increase in IL-6
and TNF-u in depressed subjects when compared to control subjects (Dowlati et al.,
2010), and it is unclear to what degree peripheral levels of cytokines relate to depression
itself verses the chronic generalized stress depression causes.
Because some antidepressants work centrally and have been shown to reduce
levels of inflammatory cytokines (Basterzi et al., 2005; Janssen, Caniato, Verster, &
Baune, 2010), the patterns of CNS inflammatory cytokines in the depressed patient begs
for more extensive investigation. The evidence of central levels of pro- and anti
inflammatory cytokines and depression in humans is very limited but presently
underway. Cerebrospinal fluid levels of cytokines have been measured in unmedicated
depressed patients (Levine et al., 1999), suicidal populations (Lindqvist et al., 2009), and
chronic PTSD sufferers (Bonne et al., 2011) all with conflicting results. Clearly chronic
pain and depressive symptoms are usually experienced together, but there is no data
currently available exploring the role of central inflammation and the pathophysiology of
these co-existing symptoms. More data must be collected to ascertain the relationship of
central inflammation and depression, especially in the chronic pain population. This
study adds valuable data in its examination of the relationship of central inflammation
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and the depressive psychological component of chronic pain.
Evidence Snpporting Inflammatory Contributions to Sleep Deprivation

The complex relationship between pain and poor sleep quality is one that has been
extensively documented in the literature, but its causality not fully understood. Both
processes of pain causing poor sleep, and poor sleep causing pain are primary paradigms
in the bidirectional relationship between pain and sleep. From the protective sickness
behavior/sickness response theory, as previously described, sleep has been suggested as a
critical component in the restorative process of healing (Dantzer, 2001; Hart, 1988;
Watkins & Maier, 2000). Counterproductively, in the presence of chronic pain
pathophysiology, the restorative process is impaired by a lack of sleep: In a complex,
detrimental dynamic, pain itself causes sleep deprivation and sleep deprivation has been
shown to increase pain perception (Chiu et al., 2005; Lautenbacher, Kundermann, &
Krieg, 2006; Moldofsky, 2001; Smith & Haythornthwaite, 2004). Up to 53% of chronic
back pain patients and 88% of neuropathic pain patients report sleep disturbances
(Meyer-Rosberg et al., 2001; Tang, Wright, & Salkovskis, 2007). Furthermore, patients
with chronic lower back pain are 18 times more likely than normal control subjects to
experience clinical insomnia (Tang et al., 2007). Thus, literature supports that sleep and
pain do interact with one another, the abnormalities of sleep are frequently reported by
the chronic pain population, and the effects are not benign: The effects of sleep
disturbances have been linked with poor physical and psychological outcomes, absence
from work, decreased performance, difficulty with personal relationships, accidents and
cognitive decline (Fulda & Schulz, 2001 ). Even in healthy individuals, sleep deprivation
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has been noted to cause spontaneous pain (Smith, Edwards, McCann, &
Haythornthwaite, 2007). Clearly a holistic approach to treating these patients must
involve attention of both the sleep and pain symptomatologies. The causes or common
mechanisms between poor sleep and pain are just starting to develop and warrant
investigation for treatment of these patients. Interestingly, one of the foremost emerging
theories on the link between pain and sleep deprivation include circulating inflammatory
cytokines.
Inflammation & Sleep

Historic, seminal studies on sleep have demonstrated repeatedly that there is a
centrally produced mechanism or substrate for sleep. At the turn of the century, Ishimori
demonstrated that upon injecting rested animals with the CSF of sleep deprived animals,
the rested animals fell into a deep sleep (Ishimori, 1909). Pappenheimer and colleagues
reported similar findings, demonstrating that when the CSF of sleep-deprived animals
was injected into rested rodents, a decrease in activity and an increase in sleep was
observed (Pappenheimer, Miller, & Goodrich, 1967). Later when it was found that
muramyl peptide induced synthesis and secretion ofIL-1 by astrocytes, a biological basis
for sleep alteration by a centrally mediated mechanism was confirmed (Fontana,
Kristensen, Dubs, Gemsa, & Weber, 1982). Repeated animal studies have shown that
upon central administration of IL-1 to both rabbits and rats, the result is an increase in
various aspects of sleep (Krueger, Walter, Dinarello, Wolff, & Chedid, 1984; Tobler,
Borbely, Schwyzer, & Fontana, 1984) independent of, but similar to the somnogenic
effects ofTNF-u (Shoham, Davenne, Cady, Dinarello, & Krueger, 1987; Kapas et al.,
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1992). The concentrations of inflammatory cytokine required to influence sleep, either
positively or negatively, is variable in the literature. In one study, Opp and colleagues
found that low doses of intracerebroventricular doses of a pro-inflammatory cytokine did
not affect rapid eye movement sleep (REMS) while higher doses did impair both non
rapid eye movement sleep (NREMS) and REMS (Opp, Oba!, & Krueger, 1991). Thus,
there is not only evidence that central inflammatory cytokines influence sleep, but the
amount of the inflammatory cytokine circulating influences the quality and type of sleep
as well.
Unfortunately, monitoring of central inflammatory cytokines in human sleep
studies has been very lacking thus far, and those studies that have monitored peripheral
concentrations of inflammation have yielded conflicting results. Peripherally monitored
cytokines have been measured in humans, but on a limited basis and have focused on IL
1, IL-6 and TNF-u. Prior human studies have found that peripherally circulating levels of
IL-6 have been correlated with decreases in slow wave sleep (Hong, Mills, Loredo,
Adler, & Dimsdale, 2005) and increased REMS (Irwin et al., 2004) (both of which are
associated with poor sleep quality). However, V gontzas and colleagues found that levels
ofIL-6 were associated with decreased REMS (Vgontzas et al., 2003) (a result that points
to more restful sleep). Patients with excessive daytime sleepiness disorder have been
found to express increased plasma IL-6 levels (Motivala, Sarfatti, Olmos, & Irwin, 2005)
and TNF- a levels (V gontzas et al., 1997). Thus it seems that an increase in peripherally
circulating inflammatory cytokines is present when there is poor sleep or in conditions of
chronic sleep deprivation, but there is conflicting experimental data. Further studies must
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describe the means to scaffold concrete treatment options for these patients.
Similar to animal studies that illustrate the pertinent role of inflammatory
cytokine concentration on either sleep promotion or sleep disturbance, human plasma
studies have also yielded similar results: Peripheral pro-inflammatory cytokine
concentrations seem to peek after sleep onset and have higher circulating levels at night
(Bauer et al., 1994; Redwine, Hauger, Gillin, & Irwin, 2000). However, when there is
poor sleep quality and/or sleep deprivation, higher peripheral levels of pro-inflammatory
cytokines are common (Haack, Sanchez, & Mullington, 2007; Moldofsky, Lue,
Davidson, & Gorczynski, 1989). These studies beg the question that at what
concentration do inflammatory cytokines stop being sleep promoting and begin to be part
of the cycle of sleep deprivation? Perhaps the measured peripheral levels of cytokines
are not sensitive enough to detect the intricacies of the inflammatory cytokine sleep
cycle. Perhaps the central cytokine levels are predominantly the cause of sleep
deprivation. Unfortunately none of these studies examined central levels of
inflammatory cytokines related to sleep quality, regardless of the seminal sleep literature
that suggests central levels of cytokines are sonmogenic.
Pain, Inflammation & Sleep

In human pain populations there exists almost a complete deficiency of data
comparing inflammatory markers, sleep and pain. A study by Heffner and colleagues,
substantiates that patients with chronic lower back pain were found to have higher levels
of plasma IL-6 than healthy control subjects. In the chronic pain population studied, poor
sleep quality was found to be associated with greater pain on the following morning
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(Heffner, France, Trost, Ng, & Pigeon, 2011). Thus there is scant data to support the
theory that inflammatory cytokines may contribute to the poor sleep quality endured by
the chronic pain population, and central levels have not been examined even with the
knowledge that there is a CNS component to sleep. Human data is requisite and
developing presently. With a better understanding of central inflammatory cytokines
associated with chronic pain and poor sleep quality, further discussion can be instigated
to encompass a more holistic approach to treating the entire experience of the pain
patient. This study offers a novel and exciting exploration of previously unexamined
interactions between three critical physiological phenomena: pain, sleep, and the central
inflammatory cytokine responses.
Implications for Future Knowledge Development
Because there is a scarcity of human evidence supporting the link between
chronic pain, anxiety, depression and sleep deprivation and central inflammation, this
study hopes to provide supportive evidence of this relationship. If this study, and future
human studies illustrate the same association that preclinical models show, the
implications for chronic pain treatment in our patient population are tremendous.
Hutchinson and colleagues' preclinical study demonstrated that by blocking the pro
inflammatory cytokine IL-1, the length of time of intrathecal opioid analgesia was
doubled and the time of systemic opioid analgesia increased by over one-and-a-half
times. The study also demonstrated an approximate seven-and-a-half -fold increase in
analgesic efficacy with morphine was possible by co-administrating the opioid with a
receptor blocker ofIL-1. These results were not just limited to morphine, Hutchinson's
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study also produced similar results with methadone as well (Hutchinson et al., 2008). In
another preclinical study, Johnston and colleagues indicated that by blocking IL-1 in the
CNS, the analgesia of an intrathecally administered opioid was enhanced, opioid
tolerance was blunted and both newly developed and established allodynia and
hyperalgesia were reduced (Johnston et al., 2004). Because newly marketed
antidepressants have elicited central responses through changes in inflammatory cytokine
levels (Basterzi et al., 2005; Janssen et al., 2010), the central patterns of these cytokines
must be examined in the depressed pain patient.
With supportive evidence that there is a relationship between chronic pain,
anxiety, depression and sleep deprivation and central inflammation in humans, the
responsible cytokines can be isolated and targeted. With further human evidence that
inflammatory cytokines are part of the physiologic and psychological chronic pain cycle,
there is a potential to treat chronic pain patients with opioids that would have a longer
duration of action and increased efficacy. With further human evidence there is a
potential to blunt opioid tolerance that develops over time, and reduce the allodynia and
hyperalgesia chronic pain populations experience. With more advanced neurologies that
pharmacologically target central inflammation, perhaps anxious and depressive
symptoms can be better mitigated. Finally, with further human understanding of the
psychoneuroimmunologic aspect of chronic pain, the complete patient will find relief in
therapy that addresses all facets of the disease.
Conclusion

Animal models show in repeated studies that chronic pain states, opioid tolerance,
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hyperalgesia, allodynia, anxiety, depression and sleep deprivation can be linked to
aberrant levels of inflammation. By blocking pro-inflammatory cytokines, animal studies
have shown that analgesia time and efficacy can be dramatically increased, opioid
tolerance can be decreased and hyperalgesia and allodynia can be resolved. Similar
advancements in inhibition of inflammation in the treatment of anxiety and depression
are just now showing similar results. Because our current treatment techniques for
chronic pain are restrictive and ineffective for certain sufferers, corroborative human
evidence needs to be accumulated to illustrate the link between inflammation and chronic
pain. If the same relationship that exists in rodent models can be shown in humans, new
and innovative treatment modalities can be developed to treat intractable chronic pain and
the psychological attributes that accompany this disease. One cannot continue to treat
patients with medications and procedures that provide minimal relief for a short duration
of time. With new avenues and pathways to target chronic pain, anxiety, depression and
sleep deprivation, inflammatory cytokines certainly provide an exciting possibility in the
future of chronic pain therapy.
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Chapter 3: METHODOLOGY
Design
This was a cross-sectional, correlational study with a convenience sample of
approximately eight chronic pain patients recruited from the Pain Management Center at
the University of California, Los Angeles (UCLA). One-time collections of
cerebrospinal fluid (CSF) samples were analyzed and compared to 30 control CSF
samples to allow for testing of the first and second hypothesis. Psychological tool
analysis of study participants allowed for testing of the third and fourth hypothesis.
Demographic analysis allowed for testing of the fifth and sixth hypothesis.
Sample and Sample Size Calculation
Study Participants
Approximately eight patients with the diagnosis and symptomatology of chronic
pain who were eligible for, and medically recommended treatment with an intrathecal
opioid infusion pain pump (the Medtronic SynchroMed® II Pain Pump) were enrolled in
this study after informed consent (Appendix A) was obtained. Potential participants
were recruited from the Pain Management Center at UCLA. Inclusion criteria for this
study melded both surgical and experimental criteria; examples of such criteria include
the participant's age (the surgical eligibility for an implant of an intrathecal opioid
infusion pain pump is 18 years of age) and duration of diagnosis (this study required
subjects have a chronic pain diagnosis greater than 6 months duration to be considered
"chronic"). Diagnosis of chronic pain was made on standard clinical criteria, as
suggested by the International Association for the Study of Pain (IASP). Exclusion
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criteria also incorporated a combination of surgical and experimental criteria; surgical
criteria that would exclude a patient from obtaining an implanted intrathecal opioid
infusion pain pump included meningitis, active upper respiratory infection/flu or febrile
nature, acute medical or psychiatric disorders, acute psychological or physiologic
danger/instability, altered mental status, pregnancy and the inability to communicate in
English. Experimental exclusion criteria included a diagnosis of cancer, human
immunodeficiency virus (HIV), recent epidural injections for treatment of chronic pain
(within six months), drug abuse, meningitis or history of meningitis, history of blood
transfusion(s) and palliative pain treatment. The inclusion and exclusion criteria were
confirmed using standard clinical and laboratory methods of analysis, not above or
beyond the standard of care, or at any additional burden to study participants. All study
participants were instructed to continue all of their medications and therapies without
making any changes prior to, or during study involvement.
Control Samples

Control samples ofCSF were obtained from the California NeuroAIDS Tissue
Network. Thirty random, individual control samples of 1-2 milliliters (mL) ofCSF,
collected through the HIV Neurobehavioral Research Center between the years 2005
2012, were utilized from this tissue bank as a means to compare levels of central
inflammatory cytokines. The CSF samples obtained from this tissue bank were
supported by the HIV Neurobehavioral Research Center (HNRC) P30 MH62512
(Principle Investigator: Robert K. Heaton, PhD) and supplied by Scott Letendre, MD
through a collaboration with the University of California, San Diego (UCSD). The
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control samples of CSF were selected randomly to include seronegative HIV and
hepatitis C virus (HCV) donors, with no history of recreational drug use, no diagnosis of
cancer and an approximate equal distribution of men and women donors. No other
information pertinent to the control sample donors was provided to the research team
except the date of collection.
Sample Size Calculation

In order to estimate the sample size needed to yield statistically significant results
in the testing of the difference between two means (the CSF cytokine levels between
healthy and chronic pain participants), the effect size was estimated using Cohen's d.
Using this power analysis to estimate the sample size and reduce the risk of a Type II
statistical error, aided in estimating the sample size when the population effect size was
not known. Human chronic pain CSF studies are just beginning to be explored and as
such, this novel new research is not advanced enough to lend proven effect sizes. This
could be because the average chronic pain CSF study incorporates small sample sizes
(usually 10-40 participants) (Bjurstrom, Giron, & Griffis, 2014) due in part to the
invasiveness of collecting CSF, participant burden and risk, and the expense of analyzing
cytokines. There are approximately 19 studies to date that have been published on the
analysis of CSF cytokines in chronic pain populations. Only two of these studies utilize
Multiplex assay analysis (McCarthy et al., 2013; Rijsdijk et al, 2013). Thus, a sample
size calculation for this study was necessary.
Given the significance level was set at 0.05 (to reduced the risk of a Type I
statistical error) and the power was set at 0.80 for this study, the effect size was estimated
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using results from similar studies that explored CSF levels of cytokines in chronic pain
and healthy controls. Rather than estimate the effect size based on the expectations of a
small, medium or large effect, Cohen's d was calculated for each cytokine analyzed by
several prior studies that analyzed chronic pain patients' levels of cytokines (see Table 1).

Table 1

Summary ofCohen's d Score for Similar Chronic Pain Studies
Author

Kadetoff et
al., 2012
Lundborg et
al., 2010
Backonja et
al., 2008
Ohtori et al.,
2011
Alexander et
al., 2007
Nagashima
et al., 2009
Rozen &
Swidan,
2007
Ludwig et
al., 2008
Alexander et
al., 2005
Aver~e

IL-1
Cohen's
d
0.84

IL-6
Cohen's
d
NIM

IL-8
Cohen's
d
2.37

IL-10
Cohen's
d
NIM

TNF- a
Cohen's
d
NIM

0.69

0.27

0.85

NID

0.52

1.06

0.68

0.33

0.97

NID

NIM

1.35

NIM

NIM

NIM

NIM

0.67

0.47

0.02

NIM

1.69

1.16

NIM

NIM

NID

NIM

NIM

NIM

NIM

0.36

NIM

0.52

NIM

NIM

0.55

0.73

1.08

NIM

NIM

0.18

1.00

0.82

1.01

0.50

0.40

Note. NIM denotes that the study did not measure this variable. NID denotes that the
variable was not detectable.
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Referring to Polit and Beck's sample size estimates (Polit & Beck, 2012, p. 424),
given the a of0.05 and a power of0.8, the approximate sample sizes were obtained from
the average Cohen's d (see Table 2).

Table 2

Estimated Sample Sizes Based on Effect Size Averages ofPrior Studies

IL-1

Average Cohen's d
from Table 1
_{_Effect Siz~
0.96

Estimated Sample
Size from Polit and
Beck a
<25

IL-6

0.76

25-33

IL-8

1.49

<25

IL-10

0.92

<25

TNF-a

0.43

40-62

Cytokine

Note.· Values taken from Table 17.6 in Polit & Beck, 2012, p.424.

The planned number of study participants was set at approximately 30, given the
amount of time and the budget for the study, based on this power analysis. The amount
of healthy CSF samples obtained from the California NeuroAIDS Tissue Network was
30, allowing for a total

n~60.

According to the Cohen's d calculation, this sample size

would be large enough to detect significance in the majority of inflammatory cytokines
tested. Approximately 36 study recruits would be solicited to account for up to 20%
attrition.
The actual number of study participants recruited from April 2013 to December
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2014 was eight. Potential factors that contributed to the lower than anticipated study
participant recruitment included changes in the personnel of the UCLA Pain Management
Office, a decrease in the number of physicians performing the intrathecal opioid infusion
pain pump procedures, an increase in the number of intrathecal neurostimulator
placement procedures and hence, lower than anticipated intrathecal opioid infusion pain
pump placement procedures. Only one patient who was solicited to participate in this
study refused, making the actual attrition rate approximately 11 %.

Setting
The UCLA Pain Management Center was the primary location of subject
recruitment, consent and psychological testing. Subjects recruited from the UCLA Pain
Management Center had CSF collected in an operative procedure performed at UCLA
Santa Monica Orthopedic Hospital Outpatient Surgery Center. The UCLA Cousins
Center for Psychoneuroimmunology Inflammatory Biology Laboratory served as the
specimen processing, storage and analysis site of this study.

Instrumentation
Multiplexing Assays
To analyze the patterns of inflammatory markers in both chronic pain and control
samples of CSF, Luminex Performance Human High Sensitivity Cytokine Panel (R&D
Systems, Minneapolis, MN) and the Bio-Plex 200 instrument (Luminex®) with Bio-Plex
Manager software version 5.0 were utilized for the precise and highly sensitive
measurement of inflammatory cytokines. Multiplex assays were chosen over high
sensitivity enzyme-linked immunosorbant assays (ELISAs) to analyze the CSF samples
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because of the minimal amount of sample needed to perform the analysis, the decreased
time to analyze the samples for inflammatory cytokines (analytes ), the decreased cost of
analyzing multiple analytes, and because of its novel new laboratory analysis technique.
Multiplex assays utilize fluorescence and spectral analysis as a reporter system instead of
the enzyme amplification of antibody-antigen "sandwiches" utilized by ELIS As.
Specifically, the Luminex® multi-analyte profiling system uses digital processing to
analyze polystyrene beads for up to 500 different analytes at one time (Andreasson,
Protelius, Pannee, Zetterberg & Blennow, 2012). It implements a two-laser instrument
that detects three-color fluorescence; two colors are used for analyte classification and the
third color is used to detect the intensity or amount of analyte. Because of the spherical
medium and the use of spectral identification with fluoroscene, multiple analytes can be
analyzed simultaneously (Elshal & McCoy, 2006).
Precision, accuracy and error. When assessing measurement tools of biophysical

samples, such as a new laboratory technique like Multiplex assays, the precision and
accuracy of the tool must be reviewed, and the potential error surrounding the tool
identified. According to Ryan-Wenger, precision is similar to the concept of reliability; it
is not a characteristic of the tool but rather how the tool is utilized by the researcher.
Precision reflects the tool's sensitivity, or tool's ability to reflect a change in value if
there is a corresponding change in the value being measured (Ryan-Wenger, 2010, p.
373 ). Accuracy is similar to the concept of validity; it is the extent to which the
measured values are in agreement with true scores elicited from a gold standard (Ryan
Wenger, 2010, p. 374). Thus, for the purpose of critiquing Multiplex assays, the
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precision of the tool reflects the consistency across the measurements, and the accuracy
reflects the agreement with the gold standard.
Precision. To assess the consistency across measurements, or precision of Multiplexing

in measuring human biological samples, studies were examined that reported on greater
than two Multiplex assay analysis on the same biologic sample or control sample. To
measure the repeatability or precision of the Luminex® Multiplex tool, the coefficient of
variation (%CV) was inspected in several studies. The %CV was examined for
Multiplexing as a statistic to relay the error in precision given that tools that have high
%CVs are considered to have a high error in their precision, and therefore are not
consistent in their measurement.
In a 2013 study examining the validation of three Mulitplex kits utilizing the
Luminex® platform, Belabani et al. reports that the intra-assay %CV between three
Multiplex kits inspected was less than 25% with the exception of one cytokine in one of
the Multiplex kits. For the lower limit of quantification, the %CV was less than 30% for
all cytokines in all kits with the exception of two cytokines in two kits (Belabani,
Rajasekharan, Poupon, Johnson, & Bar-Oh, 2013). DuPont's study shows the inter-assay
%CV for two Luminex® Multiplex kits as less than 25%, except for one cytokine in one
of the kits. The intra-assay %CV for both kits was less than 25%, except for one
cytokine in the aforementioned kit (duPont, Wang, Wadhwa, Culhane, & Nelson, 2005).
These studies illustrate the specific nature of this testing modality: Not all kits are
appropriate for testing all biomarkers. Manufacturer recommendations should be
followed explicitly when selecting a kit for the specific biomarkers to be measured.
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Chowdhury's 2009 piece illustrates that the Luminex® Multiplex intra-assay
%CV was less than 25%. The mean inter-assay %CV when measuring high
concentrations of cytokines was 25%; for low concentrations of cytokines %CV was 30%
(Chowdhury, Williams & Johnson, 2009). This exemplifies again the importance of
proper kit selection given the expected concentration of analyte. Not all Multiplex kits
can measure all ranges ofbiomarker values.
Kang and colleagues demonstrated intra-laboratory precision values (reported as
%CV) for Luminex® Multiplexing between 5.3%-10.8% for the three cytokines
analyzed. The inter-laboratory %CV for Multiplexing ranged from 13.1 %- 17.9%,
demonstrating the importance of developing protocol standards in laboratory techniques
for maximizing precision in Multiplexing (Kang, Vanderstichele, Trojanowski & Shaw,
2012).
If precision of a measurement is not a characteristic of the tool, but how the tool is

utilized by the researcher, the aforementioned studies illustrate this definition of precision
for Multiplexing: Proper kit selection, strict adherence to manufacturer recommendations
and standardization of protocols all influence the %CV or precision of this specific tool.
Given that the %CV is consistently less than 30% across all studies, precision for the
Luminex® Multiplexing assay seems adequate for the analysis of human biologic
samples. It is stressed however, that continued validation of the tool must be ongoing
and collaborative between laboratories is essential to develop standards for this new
assay.
Accuracy. To assess the accuracy of Multiplexing in measuring human biologics,
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studies were examined that reported the values of the Luminex® Multiplex tool
compared to the gold standard of ELISA analysis. This was done by analyzing the
correlations of Multiplexing to ELISA either reported as r or r' (correlation or regression
coefficients of various statistical analysis). Table 3 (adapted from Elshal & McCoy,
2006) summarizes the correlations of various Multiplex assays to the gold standard
ELISA from a variety of studies.

Table 3
Correlations Between Multiplexing and ELISAs
Cytokines

Keller & de Jager
Douglass, et al.,
2003
2003

Chen et al., Prabhakar Richens
1999
et al., 2002 et al.,
2010

DuPont et
al., 2005

IL-1~

0.964

0.96-0.98

0.838

IL-6

0.847

0.98

0.903

0.946

0.92-0.96

IL-8

0.999

IL-10
TNF-a

0.998

Correlation r
Calculation

0.926

1.0

0.911

0.97

0.96

r2

r

r2

0.9816
0.9859
0.820
0.938
r2

r

Note. Table 3 is adapted from Elshal & McCoy, 2006, p.321 with data from Richens,
Urbanowicz, Metcalf, Corne, O'Shea, & Fairclough, 2010.

Unfortunately, limitations of these correlations across the different studies include
different methodological approaches, poorly described statistical analysis, utilization of
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different Multiplex kits and variation in kit manufacturers. However, from the high
degree of correlation detailed in the literature it can be deduced that Multiplexing is
appropriate in the analysis of biologic analytes measured by ELISAs. However,
throughout the literature, it is stressed that the values elicited from ELIS As and
Multiplexing are not interchangeable. Trends or patterns in biomarkers correlate well
between ELIS As and Multiplexing, but future comparisons of specific values should note
that ELISAs and Multiplex assays do not yield the same values.
Error or bias. Using classic test theory for the evaluation of Multiplexing as a tool to

measure cytokines in biologics, it is postulated that the observed value ofbiomarkers (0)
is equal to the true value ofbiomarkers (T) plus error.
0

~

T +error

Error diminishes the extent to which the measured biomarker values serve as
adequate representations of the values trying to be measured. Because error in precision
and accuracy is cumulative, the extent of the error or bias must be identified and
prevented a priori, controlled for, and accounted for the in the research design (Ryan
Wenger, 2010, p.371).
Multiplexing was also assessed for its capacity to analyze biological samples for
the presence and amount of biomarkers. However, the error or bias that can occur and
convolute the final values involves all parts of the experimental process: from the
collection of the sample, through the storage, to the handling of the specimens, through
the Multiplex assay process and analysis, and documentation of the results, error can
occur. Some of the potential errors with analyzing biological specimens (specifically
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CSF) using Multiplexing has been identified by Kang and colleagues. When the error
can temporally occur in the experiment, the source of the error and suggestions for
correcting the error is presented in Table 4 (Kang et al., 2012). These sources of error
cited by Kang and colleagues helped scaffold the methodological approach of this study,
as all precautions were taken to avoid these potential sources of error.
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Table 4

Potential Error in Multiplexing
Phase of Experiment Source of Error iu
Procedure
Preanalytical Phase

Lumbar Puncture

Means to Correct Error

Training and Standardization
Use of Polypropylene
Collection Tubes
Avoid Blood Contamination
ofCSF
CSF Collection in Morning
Fasting

CSF Handling and Storage

Immediate Freezing ofCSF
Samples
Use of Polypropylene
Storage Tubes
Limited Dead Volume in
Tubes
Limit Freeze-Thaw Cycles

Reagent Handling

Standardized Procedures
Follow Manufacturers
Instructions

Analytical Phase

Quality Control Procedures

Predefined Run-Acceptance
Criteria
Use of Aqueous QC Samples
and CSF Pools to Assess
Within-Run and BetweenRun Analytical Performance
Use of Samples for Lot-toLot Consistency
SOP for Calibration Curve
Performance of Analysts
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Proficiency Panel to Qualify
Performance of Analysts
Sample Thawing

Standardization of Sample
Thawing Procedure (Temp
and Time) Before Testing

Microbead Preparation

Follow Manufacturer's
Instructions

Vacuum Pressure

Standardization of Vacuum
Pressure and Equipment

Shaking of Reagents

Use Orbital-Type Shaker

Centrifugation of CSF

Standardization of
Centrifugation or No
Centrifugation Before
Testing

Pipetting

Standardized Approach
Use of Polypropylene Tips
Avoid Up and Down
Pipetting

Post-Analytical
Phase

Inherent to the Kit

Equipment

Standardized Regular
Validation and Maintenance

Assay

SOP for Testing

Type of Curve-Fit
Algorithm

Use of Nonlinear Logistic
Curve-Fit

Run Validation

Predefined Run Acceptance
Criteria

Lot-to-Lot Variability

Efforts to Minimize the
Variation by Kit
Manufacturer
Lab Establishes Criteria for
Acceptable Variability
Limits
Commit to Collaborative
Efforts Between Kit Vendors
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and Labs
Documentation

Detailed Standard Operating
Procedure
Identify Possible Sources of
Error and Provide
Troubleshooting Guidelines

Note. QC denotes quality control. SOP denotes standard operating procedures. Table 4
is adapted from Kang, Vanderstichele, Trojanowski, & Shaw, 2012, p.487.

With a review of validation studies of Multiplex assays, the precision and
accuracy of this measurement tool was explored. From the literature, the precision and
reproducibility of Multiplex values were found to be good both intra- and inter-assay.
The correlations of various biomarkers were assessed between Multiplexing and the gold
standard ELISA, and found to be relevant and acceptable. Multiplexing therefore was
chosen to measure biomarkers in this study's biological specimens with the
understanding that further validation reports should be reported with this research. The
individual analytes, or cytokines, that the Multiplex analysis can detect are summarized
in Table 5 along with the sensitivity of each assay.
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Table 5

Summary ofthe Luminex!EJ Performance Human High Sensitivity Cytokine Panel for
Laboratory Analysis
Analytes

Sensitivity (pg/mL)

High Standard Value
(pg/mL)

IL-lB

0.18

1,500

IL-2

0.28

2,450

IL-4

2.54

7,000

IL-5

0.12

1,600

IL-6

0.31

4,050

IL-8

0.07

3,200

IL-10

0.24

2,100

IL-12

2.96

24,500

GM-CSF (GranulocyteMacrophage Colony
Stirnulati11£._F acto!l_
IFN-g (Interferon Gamma)

0.13

1,575

0.08

1,350

TNF-alpha

0.54

3,350

VEGF (Vascular
Endothelial Growth Factor)

1.35

2,000

Note. Adapted from manufacturer's website,
http://www.rndsystems.com/Products/FCST09, R & D Systems, Inc ..

Psychological Instruments

To measure the psychological variables within chronic pain, several tools were
selected for this study and are discussed in detail. These psychological tools were
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selected for their internal consistency and reliability (reflected in Table 6 as the
Cronbach's us ), their ease of completion and their use in previous chronic pain
inflammatory studies. They were used to measure the study participants' level of pain
perception, anxiety, depression, and sleep quality.
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Table 6

Summary ofPsychological Tools Utilized
Behavioral
Measures
Pain

Measurement

Scale

Cronbach's a

Scores for the questionnaire can "0.73-0.89
b0.96
range from 0 to 45 on the Pain
Rating Index, from 0 to 5 on the
Present Pain Intensity, and from
0 to 10 centimeters on the
Visual Analog Scale. No
established scoring noted by
authors
'0.89
Anxiety
The Hamilton
A total anxiety score of< 17
indicates mild anxiety levels; 18
Anxiety Rating
Scale
to 24 mild-moderate anxiety
levels; and 25 to 30 indicates
(HAM-A)
moderate-severe anxie!Y_levels
Depression The Beck
0-13: minimal depression; 14 °0.91
Depression
19: mild depression; 20-28:
Inventory-II
moderate depression; and 29
(BDI-II)
63: severe depression
Sleep
The Pittsburgh
Nineteen components that yield '0.83
Quality
Sleep Quality
a global score of0-21, with a
total of< 5 associated with
Index
(PSQI)
good sleep quality and < 5
associated with poor sleep
_g_uali!Y_
a
b
Note. Taken from Burckhardt & Jones, 2003. Reported as an Intraclass Correlation
The Short FormMcGill Pain
Questionnaire
(SF-MPQ)

Coefficient for total pain score by Grafton, Foster, & Wright, 2005. c Taken from
Kummer, Cardoso, & Teixeira, 2010.d Reported as a Coefficient Alpha by Beck, Steer,
Ball, & Ranieri, 1996. 'Reported by Buysse, Reynolds, Monk, Berman, & Kupfer, 1989.

Measure of pain perception. The Short Form McGill Pain Questionnaire (SF-MPQ) is

a self-reported survey that consists of fifteen descriptors known as the Pain Rating Index
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(PRI); eleven sensory descriptors and four that are affective in nature. Each descriptor is
rated on a scale of 0-3: 0 (none) to 3 (severe). It also includes a Present Pain Intensity
(PPI) index and a Visual Analogue Scale (VAS). Scores for the questionnaire can range
from 0 to 45 on the PRI, from 0 to 5 on the PPI, and from 0 to 10 centimeters on the
VAS. (Melzack, 1975; Melzack, 1987). This tool can be found in Appendix B.
Measure of anxiety. The Hamilton Anxiety Rating Scale (HAM-A) is a survey

completed by the researcher and measures the severity of a patient's anxiety. Based on
14 parameters, each survey item is given a 5-point score - 0 (not present) to 4 (severe)
and includes anxious mood, tension, fears, insomnia, intellectual impairment, depression,
somatic complaints, autonomic symptoms, physiologic symptoms and behavior at the
interview. A total anxiety score of <17 indicates mild anxiety levels; 18 to 24 mild
moderate anxiety levels; and 25 to 30 indicates moderate-severe anxiety levels
(Hamilton, 1959). This tool can be found in Appendix C.
Measure of depression. The Beck Depression Inventory-II (BDI-II) is a self-reported

survey that assesses and score levels of depression. The BDI-II contains 21 questions,
each answer being scored on a scale value ofO to 3. The cutoffs values used will be: 0
13: minimal depression; 14-19: mild depression; 20-28: moderate depression; and 29
63: severe depression. Higher total scores indicate more severe depressive symptoms
(Beck, Ward, Mendeson, Mock, & Arbough, 1961). This tool can be found in Appendix
D.

Measure of sleep quality. The Pittsburgh Sleep Quality Index (PSQI) is a self-reported

survey that is composed of nineteen components that yield scores on subjective sleep
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quality, sleep latency, sleep duration, habitual sleep efficacy, sleep disturbance, use of
sleeping medication and daytime dysfunction. These seven components are scored from
0-3 and yield a total score of0-21. Higher scores indicate worse sleep quality, with a
total of :S 5 associated with good sleep quality and > 5 associated with poor sleep quality
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). This tool can be found in
Appendix E.

Data Collection Protocol
Approximately eight patients with the diagnosis and symptomatology of chronic
pain who were eligible for, and medically recommended treatment with an intrathecal
opioid infusion pain pump (the Medtronic SynchroMed® II Pain Pump) were enrolled in
this study. Potential participants were recruited from the Pain Management Center at
UCLA. After informed consent was obtained using Institutional Review Board (IRB)
approved forms (Appendix A), subjects completed the psychological instruments to
measure their pain perception, depression and sleep deprivation (Appendices B, D, E).
The anxiety tool (Appendix C) was completed by the practitioner collecting the
demographic clinical data (Appendix G) and consent for study involvement. Participants
underwent a structured interview to compile their demographic information (Appendix F)
and results were number coded to ensure participant anonymity. All psychological study
results and demographic information were number coded for anonymous participant
identification and entered into a password-protected spreadsheet for analysis. Upon
completion of the questionnaires, study participants were given a $25 Visa gift certificate
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for their participation in the study. Participants were also reimbursed for their parking
fees upon enrollment of the study for the date for the trial operation.
Approximately one month after the preclinical office visit, the study participant
underwent a surgical outpatient operation called an intrathecal opioid infusion pain pump
trial. This operative surgical procedure and study procedure of collecting intraoperative
CSF samples was performed in the operating suite at UCLA Santa Monica Orthopedic
Hospital Outpatient Surgery Center. Three mL of CSF were collected from the eight
study participants undergoing intrathecal opioid infusion pain pump trials for the
treatment of their pain. Standard preoperative preparation and evaluation took place in
the preoperative suite of UCLA Santa Monica Orthopedic Hospital Outpatient Surgery
Center. A qualified member of the preoperative evaluation team started peripheral
intravenous fluids in the preoperative suite and preoperative vital signs were recorded.
The patient participant was then brought to the operating room and positioned per
surgeon preference, and standard monitors (electrocardiogram, noninvasive blood
pressure cuff, pulse oximeter) were applied. Patient participants were given 2-4 L/min
nasal cannula oxygen and a combination of intravenous versed and fentanyl was titrated
for comfort by a qualified operating room nurse at the surgeon's direction. Strict,
standard sterile surgical protocol was followed per the regulations and policies of UCLA
Santa Monica Orthopedic Hospital guidelines. Intrathecal access was performed with or
without the use offluoroscopy per the surgeon's discretion. All samples of CSF were
collected intraoperatively before 1300 in appropriate polypropylene specimen collection
tubes, properly labeled with a number code for anonymous participant identification and
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placed on ice in UCLA approved specimen transportation boxes. A member of the
research team then transported the specimens from UCLA Santa Monica Orthopedic
Hospital to the UCLA Cousins Center for Psychoneuroimmunology Inflammatory
Biology Laboratory in the 300 Medical Plaza building of the UCLA Westwood campus
via car, with an estimated transportation time of30 minutes. Upon receipt of the
specimens, the UCLA Cousins Center for Psychoneuroimmunology Inflammatory
Biology Laboratory centrifuged the samples at 2000G for 10 minutes at 4°C, and
partitioned the 3 mL samples into 0.25 mL aliquots with appropriately labeled
anonymous participant identification. The aliquots were then stored at -80°C until batch
analysis was performed.
After collection of 3 mL of CSF in a specimen collection tube, the surgeon
administered a dose of opioid through an intrathecal trial catheter. The catheter was
secured and dressed in a sterile fashion and the patient participant was taken to the
postoperative suite for recovery. The patient participant was then monitored for side
effects and complications arising from the administration of the intrathecal opioid.
During the postoperative stay, the participants' hemodynamic stability and vital signs
were continually assessed by a member of the pain management team and/or
postoperative nursing staff. Once a member of the pain management team determined
that the patient participant had not incurred any serious side effects from the
administration of an intrathecal opioid, the participant was then eligible to have a
permanent opioid infusion pain pump. The catheter was removed, a sterile dressing
placed over the operative site and the participant was discharged home with instructions
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and emergency contact information.
Control samples ofCSF were analyzed from the California NeuroAIDS Tissue
Network obtained from Dr. Scott Letendre at the University of California, San Diego
(UCSD). Thirty samples of 1-2 mL ofCSF were utilized from this tissue bank as a
means to compare levels of central inflammatory cytokines. Samples of 1-2 mL were
obtained in specimen collection tubes and placed on ice in the appropriate biological
hazard transport container. The specimens were shipped from UCSD to the UCLA
Cousins Center for Psychoneuroimmunology Inflammatory Biology Laboratory in Los
Angeles. Upon receipt of the specimens, the UCLA Cousins Center for
Psychoneuroimmunology Inflammatory Biology Laboratory centrifuged at 2000G for 10
minutes at 4°C, and partitioned the 1-2 mL individual samples into 0.25 mL aliquots with
appropriately labeled identification. The aliquots were then be stored at -80°C until batch
analysis could be performed. Figure 3 depicts the complete cross-sectional study process
integrated into the intrathecal opioid pain catheter trial experience.
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Figure 3. Data collection for cross-sectional study of Psychoneuroimmunology and
Chronic Pain.

Cerebrospinal fluid levels of IL-1, IL-6, IL-8, TNF- a and IL-10 were determined
using the Luminex® Performance Human High Sensitivity Cytokine Panel (R&D
Systems, Minneapolis, MN). All assays were performed in duplicate per manufacturers
recommendations. Cerebrospinal fluid samples were diluted 1:2, following the protocol
recommended for serum and plasma. All analyses were run in duplicate per the
manufacturer's recommendation. Samples with o/<£V > 20 % between duplicates were
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evaluated on a case-by-case basis for repeat assays and/or modified data analysis. The
cytokine levels for all of the samples obtained, both from UCLA and UCSD are reported
as picograms'milliliter (pg/ml). The data analysis plan and potential dissemiuation of
study findings are outlined in Figure 4.
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Figure 4. Data analysis plan for cross-sectional study of Psychoneuroimmunology and
Chronic Pain.

Statistical Analysis
Descriptive statistics were calculated for all variables in the study and examined
for responses. Multiple approaches were used to analyze the data and the level of
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significance was set at p < 0.05 for all statistical testing. To test the first and second
hypothesis, CSF levels of inflammatory cytokines in study participants were compared to
controls using parametric statistics for normally distributed variables to include
multivariate analysis of variance (MANOVA) followed up with analysis of variance
(ANOV A) (non-parametric testing using Mann-Whitney U analysis would be
implemented for non-normally-distributed variables). To test the third through the sixth
hypothesis, correlations were calculated to explore relationships between psychological
instrument measures, potential cofactors (demographics), pretreatment critical cofactors
and biomarkers using Pearson's r, Spearman's Rho or non-parametric correlations for
non-normally distributed data. Multivariate analysis of variance and ANOV A was used
to examine differences between gender, diagnosis and types of medications. Calculations
were accomplished with SPSS software version 22 (SPSS, IBM Inc., Armonk, NY).
The planned analysis was primarily exploratory given the small study population
size, and designed to answer the question: Are there significant relationships between
such psychological variables as pain perception, anxiety, depression or sleep deprivation
and levels of inflammatory mediators in the CSF of the chronic pain patient?
Compliance Plans
Data and Safety Monitoring Plan

Data and safety monitoring for this study proceeded in an exacting manner and
met all UCLA and University of San Diego (USD) IRB requirements. The data collected
from paperwork, including but not limited to, the psychological tests administered, were
entered into a spreadsheet database that was password-protected, and all paper copies
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stored in a locked cabinet at the UCLA Pain Management Center. No electronic data was
anticipated to be stored on servers, but in the event that electronic data storage was
necessary, UCLA protected servers that are in compliance with Good Clinical Practice
(GCP) and Health Insurance Portability and Accountability Act (HIPP A) regulations
would have been utilized.
Throughout the study there was a review of data to carefully ensure that there
were no adverse effects to study participants. The study was reviewed and all adverse
effects would have been reported to the UCLA and USD IRBs by the Principal
Investigator (PI) of the study. The Co-Investigators provided a second level of review as
the study proceeded. Data was entered on an ongoing basis and weekly reports detailing
health events, study progress, data accuracy and completeness was generated for review
by the PI and Co-Investigators. Quality assurance activities were supervised by the PI.
Statement of Assumptions and Protection of Human Subjects
Informed Consent

This study protocol was reviewed and approved by the IRBs (Human Subjects
Protection Committee) of UCLA and USD. All participants received a California
Experimental Subject's Bill of Rights and voluntarily signed an informed consent,
specific to the study protocol, prior to study participation in a private setting. All study
participants were asked to read and ask questions, and complete consent forms prior to
study participation. Risks of study participation were carefully detailed in the consent
form. Participants had the option to withdraw consent at any time without prejudice to
their future medical care at UCLA Medical Center.
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Risks of Study Participation
This study analyzed CSF collected during the surgical procedure necessary for
determining chronic pain patients' eligibility to receive a surgically implanted, Food and
Drug Administration-approved device for the treatment of their chronic pain symptoms.
Patients received this device regardless of their participation in this study, this device did
not sponsor this study, the device was not paid for by the study and in no way was being
tested by this study. The surgical risks of performing the trial catheter insertion were
known risks to the surgical procedure and were consented for by the patient, but did not
represent additional patient burden for those participating in this study. Participants were
assured via the consent process that they could discontinue their study participation at
any time if they decided not to undergo the intrathecal opioid infusion pain pump trial.
Minimal adverse effects have been reported with intrathecal opioid infusion pain pump
trials. The UCLA Pain Management Center medical doctors that performed the
intrathecal opioid infusion pain pump trials in this study have done so in hundreds of past
patients with no adverse events related to surgical placement of the intrathecal catheter or
pain pump. Additional risks posed to the patient study group above and beyond the
surgical risks are listed here.
Cerebrospinal fluid sampling. Study participants were scheduled for a surgical
procedure called an intrathecal opioid infusion pain pump trial and CSF drainage is a
known and accepted component of performing this surgical technique. Cerebrospinal
fluid was available for collection with the same risks and benefits as the surgical
procedure for which the participants were consented for with no expected increase in
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participant burden. Potential additional risks to the study participants (above the surgical
risks) were minimal; a spinal headache is the most common side effect of CSF volume
depletion. Because the majority of CSF volume collected was minimized and not
anticipated to be greater than what would normally be lost intraoperatively, the risk of the
study participant developing a spinal headache was no greater than the surgical risk of
developing a spinal headache. The CSF sample represents a minimal amount of CSF
present in the adult central nervous system (CNS): Approximately 150 mL of CSF is
present in the CNS of the average adult. Cerebrospinal fluid is manufactured and
replaced every eight hours, hence the adult body produces around 500 mL of CSF per day
(Marieb, 2001). Given the amount ofCSF in the CNS and the rapid production of this
fluid, the 3 mL sample of CSF necessary for study analysis represented a small but
noteworthy participant burden. The risk of developing a spinal headache from 3 mL of
CSF sampled was a small, but serious risk to the study participant. The literature
supports that spinal headaches occur after approximately 20 mL of CSF is drained from
the CNS (Wolff, 1948). While the risk is low, a spinal headache is a serious side effect to
monitor for. Throughout the intrathecal opioid pain pump trial, and for approximately 8
10 hours postoperatively, vital signs were continuously monitored and staff was available
to talk to participants about any discomforts or side effects they experienced. In
accordance with UCLA IRB requirements, and operating room protocols, an Advanced
Cardiovascular Life Support (ACLS)-certified study physician was immediately available
during all procedures. This was fully explained in the consent form.
Infection. During the surgical procedure where study samples of CSF were
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collected, there was a risk of infection to the participant. This risk of infection was the
same as the surgical risk of infection and did not represent any additional subject burden
above and beyond the surgical risk. An infection after a surgical intrathecal needle stick
is rare, but represented a potential risk to the participant. Should an infection occur,
treatment including antibiotics or additional surgery may have been necessary.
Bleeding. It is possible, though unusual, to experience an excessive bleeding

episode through an intrathecal needle stick. The risk of developing a bleeding episode
where an intervention would be necessary was no greater than the surgical risk to study
participants. Should bleeding occur, it may require emergency treatment to drain
accumulated blood called a hematoma. This was fully disclosed to study participants
upon enrollment in the study and fully explained within the consent.
Scarring. In rare cases, scarring from an intrathecal needle stick may result. This

represented a small risk to study participants, but not above and beyond the surgical risk
of scarring. This was fully disclosed to study participants upon enrollment in the study
and fully explained within the consent.
Confidentiality

All records will be kept strictly confidential. No person except the research team
will know the subjects were in a research study. Data forms for the collection of health
and study data was coded with an anonymous identification number. No data form
identified the participants by name. Data forms were kept in a locked cabinet at the
UCLA Pain Management Center. No presentation or publication of the results of this
study refer to the individual participants or present information that would identify any
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participant.
Potential Benefits
The potential benefits for both the participants and broader segments of society
include improved understanding of the psychoneuroimmunologic consequences of pain,
anxiety, depression and sleep disturbances leading to more effective therapies and
prevention. However, participants were informed that no change in their chronic pain
treatment or direct benefit was expected to accrue to them from participation in the study.
Subject Reimbursement
Study participants were reimbursed for the parking visit needed for the trial
operative day visit. Upon completion of the psychometric tools and after study
enrollment, patients were given a $25 Visa gift certificate.
Inclusion of Women
The chronic pain population of the UCLA Pain Management Center is
approximately evenly divided with respect to gender, and women were recruited as part
of the study sample. Pregnant women were excluded from this study as it is surgically
contraindicated in the intrathecal pain pump trial and permanent pump insertion.
Inclusion of Minorities
The chronic pain population of the UCLA Pain Management Center is extremely
ethnically diverse. Recruitment efforts were equally directed toward members of all
racial and ethnic groups.
Inclusion of Children
Subjects who are 18-20 years of age (defined as "children" by the National
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Institutes of Health) were eligible for recruitment from the UCLA Pain Management
Center. Children below the age of 18 would have been excluded as the experience of
pain in the pediatric population differs from that of adults (McGrath & Brigham, 1992).
Further, the imposition of surgical intrathecal pain pump trials and permanent pump
insertions on children below the age of 18 is usually surgically contraindicated.
Safety Precautions and Emergency Protocols
Trained medical and nursing personnel were in attendance during all surgical
procedures. Any adverse event related to CSF sampling was immediately evaluated by
the study physician. If injury occurred and deemed minor, treatment would have been
administered on-site and the participant followed on an outpatient basis. In the extremely
unlikely event of a significant injury, the subject would have been referred to the
appropriate UCLA service for treatment and follow-up care. The UCLA and USD IRB
would have been informed by telephone within 24 hours by the investigators of any
serious adverse event, and a written report would follow within three days.
Description of the System for Maintenance of Records
Upon consent and enrollment in the study, the subject's name, address, email,
phone number(s), medical record number, enrollment date, intrathecal catheter trail date
and demographic data (including the patient's age) was all recorded on a single
spreadsheet representing that specific study subject. All identifying information was
removed from all subsequent research paperwork, psychological tools and CSF samples,
and alphanumerically coded to maintain anonymity. The study anticipated approximately
thirty study subjects to participate in this study and alphanumerically coded each study
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participant in random assignment of study enrollment. Study subjects enrolled were
alphanumerically assigned a code from SGPOO 1 to SGP030. Additional numbers could
have been added ifthere were additional study recruits. The paper copies of the
aforementioned information and copies of psychological surveys completed by the study
subjects (identifiable only by the subjects alphanumeric code) were stored in a locked
cabinet at the UCLA Pain Management Center. A key or legend linking the study
subject's information to their alphanumeric identifier was kept in a locked file cabinet at
the UCLA Pain Management Center. The key or legend included the assigned
alphanumeric code (i.e. SGPOOl) and the patient's last name and first initial. The laptop
computer used to create the study subjects spreadsheet and code list was password
protected, utilized only secure Internet connections and was maintained only for study
purposes. Sarah Giron was the sole user of this laptop computer.
Cerebrospinal fluid samples from patients were stored in deep freeze storage at
the UCLA Cousins Center for Psychoneuroimmunology Inflammatory Biology
Laboratory with only the alphanumeric code identifier. Samples were stored with
anonymous identification in deep freeze storage until batch analysis was performed per
manufacturers recommendations. Throughout the laboratory analysis of the samples,
only the alphanumeric code was available to lab personnel for identification of samples.
Limitations
Because of the cross-sectional, correlational nature of this study's design,
causality of chronic pain and the causal relationships between levels of pro- or antiinflammatory cytokines, chronic pain, anxiety, depression and sleep deprivation were not
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determined. The study design itselflimits the findings of this study to simply providing
support for prior studies and serving as a basis for developing future studies. Given the
specific criteria and study population of this cross-sectional study, this study design also
limited the ability to generalize the results.
The small sample size also limited study findings: Even though a power analysis
was performed and determined that the sample size was adequately powerful enough to
determine significant changes between three of the five cytokines analyzed, the sample
size would have been possibly too small to detect changes with IL-10 and TNF-u. The
sample size necessary to detect changes in IL-10 and TNF-u would have been 64-99
participants, but given the budget and time available for this study, this sample size was
unrealistic. Nevertheless, because IL-10 and TNF-u are cytokines analyzed on the same
Multiplex assay as the other three cytokines, they were still explored with minimal
increase in cost or time.
Obtaining the control samples from an outside source was also a limitation of this
study. While obtaining these samples confirmed that 30 healthy CSF samples could be
obtained and it decreased the time to acquire the CSF samples, lessened the participant
burden and cost of recruiting participants to obtain these samples, these control CSF
samples only came with a limited description and external assurance. The control
samples may not adequately represent the CSF of healthy participants in the general
public.
The unequal number of participants between the chronic pain and control CSF
samples, as well as the small sample size, may limit the reliability of statistical analysis
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of this study. Likewise, because psychological testing was not performed on the control
subjects from whom the control CSF came, statistical analysis between inflammatory
cytokines and psychological instrument data will only be possible in chronic pain
participants.
Three of the four psychometric tests utilized by this study were from direct
participant report, while the Hamilton Anxiety Scale was completed by the practitioner
consenting and obtaining demographic information from study participants. While this
study tried to limit the number of practitioners completing the scales on the participants,
to limit inter-reporter variability, a total of four practitioners ultimately completed the
Hamilton Anxiety Scale for this study. This number of practitioners may have skewed
the results for this psychological variable.
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Abstract
Chronic pain is a devastating amalgam of symptoms that affects millions of
Americans at a tremendous cost to our healthcare system and, more importantly, to
patients' quality oflife. Literature and research demonstrate that neuroimmune cells
called glia are not only responsible for initiating and maintaining part of the chronic pain
disease process, but also release inflammatory molecules responsible for decreasing the
efficacy of one of the most prominent treatments for pain, opioid analgesia. This article
describes chronic pain as a disease process that has ineffective treatment modalities;
explores the mechanisms of glial cell activation and inflammatory responses that lead to
chronic pain and decreased opioid treatment efficacy; and hypothesizes novel chronic
pain treatment modalities based on the glial cell inactivation and anti-inflammatory
pathways.

Keywords: Inflammation, Chronic Pain, Cytokines, Opioids, Glia
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Chronic pain is a serious health concern of tremendous scope that spans
socioeconomic boundaries, educational levels, and cultural, gender, and age
demographics (Pleis, Ward & Lucas, 2009). An estimated 116 million Americans suffer
and are disabled by this chronic condition (Tsang et al., 2008), with a cost of $630 billion
in lost work revenue, sick time, health care costs (Gaskin & Richard, 2011 ), and, most
importantly, at the cost of patients' quality of life. Patients report not only a wide
spectrum of painful symptoms and psychological effects, but also suffer from different
types of pain in various anatomical locations. Current modalities utilized to treat these
patients are limited in scope, and often ineffective for a large portion of the chronic pain
population with a host of dangerous or self-limiting side effects. This raises the question
of what more can be done for a patient population larger than all diabetic, coronary heart
disease, stroke and cancer patients combined (Tsang et al., 2008)?
For decades, pain research focused on neuronal opioid receptors as the mainstays
of pain physiology and management. Isolated from opium in the 1800's, morphine has
become a mainstay of pain therapy (Ahlbeck, 2011; Mehendale, Goldman, Mehendale, &
Rana, 2013), and clinicians eventually developed an array of powerful synthetic opioids
for pain relief. Yet, despite the useful addition of variably efficacious anti-depressive and
anti-convulsant drugs, which decrease neuropathic pain symptomatology (Vranken,
2009), consistently effective treatment of chronic pain eludes the medical community.
Fortunately, recent scientific discoveries have started to unmask various chronic pain
neuroimmune pathways, which could lead to more effective treatment of this epidemic.
One of the new directions for inquiry highlights central nervous system (CNS)
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inflammatory mechanisms that are believed to exacerbate and prolong neuropathic pain
states via positive feedback mechanisms (Griffis, 2011 ). Recent pain literature suggests
that the inflammatory mechanisms responsible for the initiation and prolongation of
chronic pain are perpetuated by opioid therapy (Raghavendra, Rutkowski, & DeLeo,
2002; Tai et al., 2006). Given the widespread use of opioids in the anesthetic or pain
management of patients with chronic pain, it is imperative for nursing and medical
practitioners to understand the underlying mechanism of neuroimmune-mediated CNS
inflammation, its hypothesized role in chronic pain, and the possibilities for novel pain
management modalities if these inflammatory mechanisms are targeted.
Acute Pain Verses Chronic Pain

Pain is an elegant physiologic mechanism that functions as a protective measure
to preserve cellular function and life. The International Association for the Study of Pain
(IASP) defines pain as "an unpleasant sensory and emotional experience associated with
actual or potential tissue damage, or described in terms of such damage" (Merskey &
Bogduk, 1994, p. 213). However there are instances when pain ceases to be protective
and begins to be destructive. The neuroimmune-mediated CNS inflammatory
mechanisms described here offer one possible way to differentiate between these two
very different pain states.
Acute Pain

When pain pathways work as intended to detect tissue damage or trauma, painsensing receptors known as nociceptors detect chemical, mechanical, or thermal stimuli.
Nociceptive detection is then converted and transduced as neural electrical impulses. Ao
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and C primary afferent nerve fibers transmit these nociceptive signals to synapse at
Rexed' s Laminae II (located in the substantial gelatinosa) of the dorsal horn of the spinal
cord (Todd, 2012). Via ascending spinothalamic tracts in the spinal cord, these
nociceptive neural signals are transmitted to the thalamus where the pain sensation is
relayed to higher cortical regions for processing. The basal ganglia, anterior cingulate
cortex, amygdala, periaqueductal grey region, hypothalamus, prefrontal cortex and rostral
ventromedial medulla are all areas of the higher cortex that process ascending
nociception. As nociception proceeds, descending pain modulatory systems may be
activated, resulting in increases and decreases in pain perception by the host. All of the
higher cortical regions except the basal ganglia participate in descending pain
modulation. Figure 1 depicts the acute pain process as described (Garland, 2012).
Through a complex series of peripherally and centrally mediated neuro-cellular
interactions, and reflex and cognitive actions, sensing and responding to acute
nociceptive pain helps the host remove itself from danger. Thus, pain, the proper
perception of pain, and the proper withdrawal reaction to painful stimuli has aided in our
species' survival.
Chronic Pain

Unfortunately, there are many conditions in which individuals' nociception and
reaction to painful stimuli have developed into chronic pain states that provide no
survival or protective benefit. Chronic pain, a term loosely and inconsistently defined in
the literature, can be classified as any pain that endures beyond the expected healing
phase following an injury or in the absence of injury, or pain that lasts longer than three
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months (Ruetsch et al., 2013). Common attributes of chronic pain, include hyperalgesia,
an increased sensitivity to painful stimuli, and allodynia, a sensation of pain in response
to stimuli not normally responsible for pain. A barrage of sustained pain signaling via
afferent pathways contributes to the maintenance of the chronic pain state and has been
described in the literature as central sensitization (Millin & Kerr, 2013; Woolf, 2011),
however this paper will focus on the contributions of neuroinflammation to chronic pain
syndromes as well as resistance to opioid analgesic therapy.
Glial activation. Glia are neuroimmune cells located in the brain and spinal cord

and comprise approximately 70% of all cells in the CNS. Though there are multiple glial
cells responsible for the proposed inflammation-driven chronic pain pathways; in
accordance with most of the experimental investigations of the phenomenon, this
discussion will focus on two innate immune cell types known as microglia and astrocytes.
Historically, glia were thought to contribute exclusively to the structure and
nourishment of neurons, until research using a rodent model of sciatic nerve injury
identified a positive correlation between astrocyte activity and the level of hyperalgesia
observed after an experimentally-induced nerve injury (Garrison, Doughterty, Kajander,
& Carlton, 1991). Over a decade later, multiple pre-clinical investigations consistently

support what Garrison et al. 's study initially suggested: glial functions comprise much
more than nourishment, protection, and structural support of neurons. Glial cells are
involved in the development and formation of the blood brain barrier and myelin sheath
(Watkins, Hutchinson, Johnston, & Maier, 2005; Watkins et al., 2007) and are activated
following tissue injury, illness, or inflammation (Tsuda, Inoue, & Salter, 2005; Watkins
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& Maier, 2000). Once activated by peripheral or central stimuli, glial cells in the brain

and spinal cord have been shown to release a cascade of molecules, including pro
inflammatory cytokines, contributing to CNS plasticity in pain responses (Mika,
Rojewska, Makuch, & Przewlocka, 2010; Wei, Guo, Zou, Ren, & Dubner, 2008). Studies
have also suggested that glial cells may represent some of the fundamental components
for nociception, and neural detection of pain (Watkins & Maier, 2003; Wieseler-Frank,
Maier, & Watkins, 2004). Figure 2 depicts a possible mechanism by which activated glia
contribute to increased pain perception through increased neuronal firing via the
ascending spinothalamic tract.
Subsequent research among glia cells has delineated a specific order of cellular
activation that is fundamental to the genesis of chronic pain states. These data suggest
that microglia may initiate the chronic pain cycle, as they are the first glial cells activated
by excessive sensory afferent neural signaling, and may play a role in astrocyte
activation. Astrocytes may be implicated in the persistence of chronic pain, remaining
activated long after microglial activation has ceased (Fleming et al., 2006; Ledeboer,
Hutchinson, Watkins, & Johnson, 2007; Romero-Sandoval, Chai, Nutile-McMenemy, &
DeLeo, 2008). Published reports propose that in chronic pain scenarios microglia cells
undergo a transformation from a resting, homeostatic state, to an activated state in the
dorsal horn minutes to hours after nerve damage or injury, followed by astrocyte cellular
activation 24 hours to several days later. The activated microglia remain activated for
several months, and astrocyte activation persists after microglial activation has subsided,
sometimes for months to years (Fleming et al., 2006; Ledeboer et al., 2005; Romero
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Sandoval et al., 2008). Figure 3 illustrates the temporal nature of glial cell activation in
chronic pain. The exact characteristics of neural signaling stimuli that initially cause
microglia to activate and begin the chronic pain cascade, as well as the molecular signals
that transmit the message from activated microglia to initiate astrocyte activation remain
unclear, though fractalkine (a neuron-bound chemoattractant molecule) may play a role in
neuron-to-glia signaling (Chapman et al., 2000; Milligan et al., 2004; Milligan, Sloane, &
Watkins, 2008). What is more certain from research is that there may be a specific order
of cellular activation among these glial cells that is necessary for chronic pain to be
initiated and then maintained (Fleming et al., 2006; Ledeboer at al., 2007; Ledeboer et al.,
2005; Romero-Sandoval et al., 2008).
Acute pain models demonstrate, and may be associated with a lack of microglial
cellular activation. With stimuli that results in acute pain, microglia are not activated,
astrocyte activation occurs immediately (rather than the delayed response in chronic
pathways) and then subsides after several days (rather than months to years in the chronic
pain process) (Romero-Sandoval et al., 2008). Figure 4 illustrates the temporal nature of
acute pain glial activation. Thus, without the activation of microglia to initiate the
chronic pain process, acute pain models currently demonstrate that microglia and
astrocyte activation is a specific and necessary component to chronic pain physiology.
However, because there is evidence indicating glial activation can occur within one week
of injury (Winkelstein, Rutkowski, Sweitzer, Pahl, & DeLeo, 2001 ), the possibility that
microglial activation contributes to acute pain responses cannot be ruled out.
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Inflammatory response from glia. Once activated in the chronic pain model,

glial cells release inflammatory mediator molecules including cytokines; more
specifically these cells release pro-inflammatory interleukins (ILs) and tumor necrosis
factor-alpha (TNF-u). Research suggests that pro-inflammatory cytokines can increase
pain transmission in dorsal horn neurons (Reeve, Patel, Fox, Walker, & Urban, 2000),
and increase the release of neurotransmitters from peripheral nociceptive sensory afferent
nerves (Inoue et al., 1999; Morioka et al., 2002). These pro-inflammatory cytokines may
also enhance pain via upregulation of AMPA (2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4
yl) propanoic acid) and NMDA (N-Methyl-D-aspartate) receptor expression and activity
(Beattie et al., 2002; Viviani et al., 2003; Wang et al., 2005). The pain-enhancing effects
of pro-inflammatory ILs and TNF- a have been implicated in both pre-clinical (Dubovy,
Jancalek, Klusakova, Svizenska, & Pejchalova, 2006; Sacerdote et al., 2008; Sung et al.,
2004; Zelenka, Schafers, & Sommer, 2005) and human studies (Backonja, Coe, Muller,
& Schell, 2008; Kadetoff, Lampa, Westman, Andersson, & Kosek, 2012; Zin, Nissen,

O'Callaghan, Moore, & Smith, 2010) of chronic pain syndromes. All of these
investigations indicate that where there is chronic pain, there are excessive levels of CNS
pro-inflammatory cytokines. Thus, the literature supports the theory that through the
intricate activation sequence of neuroglial cells, followed by the production and release
of inflammatory molecules, chronic pain is initiated and maintained.
Chronic Pain Treatment

To date, the most common form of treatment for the chronic pain patient is opioid
analgesics. Approximately 3% of adults in the U.S. receive long-term opioid therapy for
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treatment in chronic non-cancer pain, with close to six million hospital visits per year
directed at obtaining opioid prescriptions (Boudreau et al., 2009; Caudill-Slosberg,
Schwartz, & Woloshin, 2004). A study of over 70,000 chronic pain patients' healthcare
utilization patterns found that prescriptive costs to treat the pain increase dramatically
after a second year of treatment. Remarkably all of the chronic pain patients in this study
realized a rise in their prescriptive costs, often exceeding $5,100 per year (Ruetsch et al.,
2013). The rising costs indicate what many practitioners treating chronic pain already
know: As the pain continues, so does the use of increasing doses of medications to
control the pain. As these drugs are used over time, tolerance (the need for increasing
dosages to control pain) develops. Interestingly-glial activation and pro-inflammatory
cytokines, known to be present in and contribute to chronic pain syndromes, may offer an
explanation for the decrease in opioid efficacy.
Opioid-Gila Interactions

As previously described, studies have repeatedly shown that glial cell activation
contributes to increased nociception following injury, and in the initiation and
maintenance of chronic pain states. Recently, multiple preclinical studies have shown
that the administration of long-term opioids also results in an increase in CNS glial
activity (Eidson & Murphy, 2013; Hutchinson et al., 2011). This phenomenon could be
mediated in part, by microglial kappa- and mu-opioid receptors (Chao et al., 1996), as
well as toll-like receptors on glial cells (TLRs) that bind opioid molecules (Chao, Hu,
Sheng, Gekker, & Peterson, 1997). Opioid molecules binding to both types of receptors
initiate microglial activation with subsequent production and release of pro-inflammatory
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cytokines (Woller & Hook, 2013). Astrocytes have also been found to have mu-, delta
and kappa-opioid receptors, and respond similarly to opioid agonist effects (Dobrenis,
Makman, & Stefano, 1995; Eriksson, Hansson, & Riinnbiich, 1990). Figure 5 depicts how
opioid administration increases nociception via activated glia and the pro-inflammatory
response.
Thus, based upon this, theories hypothesizing glia as neuroimmune cells that
contribute solely to structure and function of neuronal cells are incorrect. Pre-clinical
studies of chronic opioid administration in the absence of chronic pain syndromes
demonstrate that this glial-induced increase in CNS cytokine activity contributes to both
opioid tolerance and pain enhancement in opioid withdrawal (Eidson & Murphy, 2013;
Johnston et al., 2004; Raghavendra, Tanga, & DeLeo, 2004). These investigations suggest
that not only are glia partially responsible for the maintenance of chronic pain, but they
are also responsible for decreasing the efficacy of opioid drugs, and thus, one of the most
common treatments of pain. It is hypothesized that tolerance results when opioid
activated immune cell pro-inflammatory cytokine production leads to up-regulation of
CNS nociceptive neurons, increasing pain perception and severity (Raghavendra et al.,
2002; Raghavendra et al., 2004; Song & Zhao, 2001). Thus, when treating chronic pain
with opioids, over time the very treatment prescribed to relieve the pain will become part
of a self propagating cascade of events responsible for perpetuating the pain, increasing
the level of pain, decreasing the effectiveness of treatment (through opioid tolerance), and
contributing to allodynia.
Glial Inhibition in Chronic Pain Treatment
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Inhibiting glial cells is not currently an option in treatment of chronic pain
patients because the health implications to the host are still being explored. Multiple
investigations using pre-clinical neuropathic pain models have shown that arresting glial
cell function in vivo using fluorocitrate, a glial metabolic inhibitor, attenuates neuropathic
pain in these animals (Lan et al., 2007; Nakagawa et al., 2007). Fluorocitrate has also
been shown to enhance morphine analgesia (Song & Zhao, 2001). Minocycline, a
microglia inhibitor and tetracycline derivative, may prevent glial hyperactivation, but it
cannot be used in cases of established neuropathic pain unless it is given prior to the
injury and is continued after the injury (Mika et al., 2010). This may be due, in part, to
the fact that minocycline suppresses microglia but not astrocytes (Yoon, Patel, &
Dougherty, 2012) which are believed responsible for perpetuating chronic pain once
established. Intrathecal or peripheral administration of minocycline has, however,
demonstrated the ability to reduce the symptoms of allodynia and hyperalgesia (Ledeboer
et al., 2005; Mika, Osikowicz, Makuch, & Przewlocka, 2007), and has also demonstrated
neuroprotective properties in neurodegenerative disease associated with glial activation
(Tikka, Fiebich, Goldsteins, Keinanen, & Koistinaho, 2001 ). Not surprisingly
minocycline has also been shown to reduce tolerance to morphine in a dose-dependent
manner when administered intrathecally (Cui et al., 2008).
Inflammatory Mediator Inhibition in Chronic Pain Treatment

A new direction for research in chronic pain treatment involves targeting the proinflammatory mediators released by glia. Two methods to alter the activity of pro
inflammatory cytokines are commonly cited in pain studies: inhibiting the production of
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the cytokine (Genevay, Stingelin, & Gabay, 2004; Iwatsuki et al., 2013; Ohtori et al.,
2012b) or blocking the cytokine's receptor binding site (Hutchinson et al., 2008; Shavit,
Wolf, Goshen, Livshits, & Yirmiya, 2005; Wolf, Gabay, Tai, Yirmiya, & Shavit, 2006).
The results of animal model studies targeting cytokines are compelling: Several studies
have suggested that morphine tolerance can be slowed or reversed by genetically
inactivating the pro-inflammatory cytokine interleukin-I (IL-1) or by blocking IL-1 with
a receptor antagonist (Hutchinson et al., 2008; Shavit et al., 2005). As predicted from the
theoretical discussion above, the analgesic time and efficacy of both morphine and
methadone were found to increase when IL-1 was blocked with a receptor antagonist
(Hutchinson et al., 2008). Hence, receptor antagonists may offer one approach to improve
opioid pharmacology in the chronic pain population where opioid tolerance and analgesic
efficacy must be ameliorated.
Ibudilast, a phosphodiesterase inhibitor, selectively targets the synthesis of pro
inflammatory cytokines by microglia and has been globally used as a treatment for
asthma, a disease often associated with inflammation of the respiratory system (Rolan,
Hutchinson, & Johnson, 2009). Given that pro-inflammatory cytokines have also been
implicated in the initiation and maintenance of chronic pain, it is encouraging to see this
drug has been effective in blocking neuropathic pain symptoms in animal models
(Ledeboer et al., 2007). In addition, ibudilast has also been shown to enhance morphine
and oxycodone analgesia, further supporting the possibility that opioid management of
chronic pain patients could benefit by using this type of pharmacotherapy (Hutchinson et
al., 2009).
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The possible effects of using these approaches to treat chronic pain, delay opioid
tolerance in humans, and their potential side effects remain unknown. It should be
emphasized, however, that inhibition of pro-inflammatory cytokines does not appear to
interfere with the neural basis of the acute pain process (Milligan et al., 2001; Sweitzer,
Martin, & De Leo, 2001 ). This treatment could potentially offer a possible treatment for
chronic pain without interfering with acute, protective pain physiology. Thus, the
literature suggests that there are several modalities that could be explored for future
treatment of chronic pain involving direct manipulation of glial cells or the inflammatory
markers they release, but additional studies are needed. Figure 6 provides a synopsis of
glial-mediated inflammation inhibition and the agents used to block the neuroimmune
effects (Thomas & Hutchinson, 2012).
Implications for Future Treatment of Chronic Pain
If future human-based studies can illustrate the same link that preclinical studies

show between glial activation, inflammatory mediator release, chronic pain persistence
and decreased opioid efficacy, the implications for treatment in the chronic pain patient
population are far-reaching. Research demonstrates that by blocking a pro-inflammatory
cytokine in rodents, the effective analgesic duration of an intrathecally-administered
opioid can be doubled, and the analgesic duration of systemically administered opioids
can be increased more than one-and-a-halftimes. The same study also demonstrated an
approximately seven-and-a-half-fold increase in analgesic efficacy with morphine by
administrating the opioid in combination with a receptor blocker of IL-1. These results
were found with both morphine and methadone (Hutchinson et al., 2008).
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Similar investigations demonstrate that drugs which block a pro-inflammatory
cytokine in the CNS enhance intrathecally-administered opioid analgesia, blunt opioid
tolerance, and reduce both newly developed and established allodynia and hyperalgesia
(Johnston et al., 2004). Ibudilast has been shown to increase the analgesic potency of
morphine and oxycodone by three to five times the average potency when administered
concurrently with the opioid (Hutchinson et al., 2009). The same class of drugs targeting
TNF-a has been used successfully in autoimmune disease therapy for rheumatoid

arthritis, psoriasis, and enteritis (all of which have inflammatory etiologies) (Sfikakis,
2010), and has also been shown to decrease neuropathic pain when administered
intrathecally in a pre-clinical trial (Marchand et al., 2009). In addition, drugs in this class
are being investigated for use in the treatment of sciatica (a painful nerve compression
condition) (Genevay et al., 2004).
Similarly, anti-interleukin receptor monoclonal antibody therapy has been shown
to reduce pain in patients with lumbar spinal stenosis (Ohtori et al., 2012a) and in
rheumatoid arthritis (a painful inflammatory disorder of the joints) (Burmester et al.,
2011 ). In many of these studies, therapy targeting interleukins improved symptoms for
weeks with little to no side effects noted except serious infection in one study (Burmester
et al., 2011). Pre-clinical investigators noted that anti-interleukin treatment was only
effective against mechanical allodynia if given at the time of injury; delayed
administration of the TNF-a blocker demonstrated no clinical improvement in
mechanical allodynia (Marchand et al., 2009).
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Thus, further progress and understanding of safe interruption of glial cell and
cytokine participation is necessary for future chronic pain treatment. Research suggests
that chronic pain could be treated with opioids that would have a longer duration of
action and increased efficacy. With additional understanding, opioid tolerance could be
curbed, and the allodynia and hyperalgesia chronic pain patients experience may be
reduced.
Conclusion

Animal models show that chronic pain states, opioid tolerance, hyperalgesia, and
allodynia can be linked to glial activation and increased levels of pro-inflammatory
cytokines. By blocking the pro-inflammatory cytokines or the glial cells which produce
them, studies have shown that analgesia time and efficacy can be dramatically increased,
opioid tolerance can be improved, and hyperalgesia and allodynia can be diminished.
Advancements in inflammatory inhibition of other diseases are showing similar results.
Because our current treatment techniques for chronic pain are restrictive and ineffective
for many chronic pain patients, additional human evidence needs to be accumulated to
illustrate the link between glia, cytokines, and chronic pain. An in depth understanding
of these complex relationships will hopefully lead to innovative therapies that can safely
interrupt the devastating consequences of the self-perpetuated cycle of
neuroinflammation underlying chronic pain syndromes and scaffold highly effective
opioid therapy.
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I. Title
Psychoneuroimmunology and Chronic Pain
II. Specific Aims

Chronic pain is a serious health concern of tremendous scope. An estimated 116
million Americans suffer and are disabled by this diagnosis (Tsang et al., 2008) at a cost
of $630 billion in lost work revenue, sick time, health care costs (Gaskin & Richard,
201 l) and most importantly, at the cost of the patient's quality of life. Patients report not
only a wide spectrum of painful symptoms, but also suffer from the psychological
devastation pain can accompany. Current modalities utilized to treat these patients both
physically and psychologically are limited, and often ineffective for a large portion of the
chronic pain population. Recent investigations of the underlying causes of chronic pain
have revealed a new direction for advancement: Central inflammatory mechanisms that
are believed to exacerbate and prolong neuropathic pain states (Kreutzberg, 1996; Reeve,
Patel, Fox, Walker, & Urban, 2000; Samad, Wang, Broom, & Woolf, 2004; Watkins &
Maier, 2003; Watkins, Milligan, & Maier, 2001) as well as sleep deprivation (Dauvilliers
et al., 2014), anxiety (Baker et al., 2001) and depression (Bonne et al., 201 l; Levine et
al., 1999; Lindqvist et al., 2009). Though preclinical data is accumulating, there remains
a dearth of human data in this rapidly developing correlation between central
inflammation, chronic pain and the psychology of pain.
This study will investigate the emerging relationships between chronic pain
syndromes and the role of central inflammation, as measured by cerebrospinal fluid
(CSF) patterns of inflammatory mediator molecules. More specifically, this study will
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investigate ifthe same central pro- and anti-inflammatory cytokines found in chronic
pain-induced animal models (Inoue et al., 1999; Morioka et al., 2002; Raghavendra,
Tanga, & DeLeo 2004; Song & Zhao, 2001) are found in human chronic pain patients.
This study will also explore the psychological responses to chronic pain as evidenced by
scores on the Pittsburgh Sleep Quality Index, Beck Depression Inventory and the
Hamilton Anxiety Scale, as well as chronic pain patients' perception and experience of
pain as measured by the McGill Pain Questionnaire. Relationships between the
psychological responses to pain and the pain experience will be made and then correlated
to CSF levels of inflammatory markers. Because there is a scarcity of human evidence
supporting the link between physical and psychological pain and central levels of
inflammatory mediator molecules associated with these constructs, this study hopes to
provide supportive evidence of this multimodal relationship.

Specific Aim #1: This study will examine and characterize the relationships between
chronic pain and pro- and anti-inflammatory mediator molecules.
Hypothesis: Patients with chronic pain syndromes will have elevated CSF levels
ofproinflammatory cytokines IL-1, IL-6, IL-8 and TNF-u and decreased levels ofanti
inflammatory IL-10 as detected on high sensitivity enzyme-linked immunosorbent assay
(ELISA) when compared to control samples ofCSF.

Specific Aim #2: To explore the relationship between the psychological responses to
chronic pain and the concentration of pro- and anti-inflammatory cytokines in the CSF.
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Hypothesis: There will be a positive correlation between the severity of chronic
pain as measured by the Short Form McGill Pain Questionnaire (SF-MPQ), degrees of
depression as measured by the Beck Depression Index (BD I-II), sleep disturbance as
measured by the Pittsburgh Sleep Quality Index, and anxiety as measured by scores on
the Hamilton Anxiety Scale (HAM-A), and the levels ofproinflammatory cytokines in
the CSF. There will be an inverse correlation between the severity of symptoms and the
anti-inflammatory IL-10.
By gaining knowledge of the relationship between the psychoneuroimmune
responses to prolonged pain states propagated by central inflammatory mechanisms, we
can acquire the information pertinent to more effective analgesic and psychological
treatment of these patients. It is the goal of this study to explore the psychoneuroimmune
relationship of central inflammation, chronic pain, sleep deprivation, anxiety and
depression in the chronic pain population.
III. Research Strategy
A. Significance

Evidence Supporting Central Inflammatory Contributions to Chronic Pain
A myriad of mechanisms have been hypothesized to contribute to the
maintenance of chronic pain states, but one of the most promising new constructs
described in the literature is via glial cell activity. Recent literature has shown that glia
are neuroimmune cells that are activated following tissue injury, illness or inflammation
(Tsuda, Inoue, & Salter, 2005; Watkins & Maier, 2000). Once activated, they release a
cascade of molecules, predominantly inflammatory cytokines, which have been shown to
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upregulate pain transmission and experience centrally (Kreutzberg, 1996; Watkins,
Milligan, & Maier, 2001 ), thus they are a fundamental component for enhanced pain
perception (Watkins & Maier, 2003 ). These pro inflammatory cytokines sensitize dorsal
horn neurons in pain transmission (Reeve, Patel, Fox, Walker, & Urban, 2000; Samad,
Wang, Broom, & Woolf, 2004), stimulate the release of neurotransmitters from sensory
afferent nerves responsible for pain perception (Inoue et al., 1999; Morioka et al., 2002)
and may enhance pain via upregulation of excitatory amino acids systems (i.e., AMP A
(2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4-yl)propanoic acid) and NMDA (N-Methyl-D
aspartate) receptor expression and activity) (Beattie et al., 2002; Samad, Wang, Broom,
& Woolf, 2004; Viviani et al., 2003; Wang, et al., 2005).

Clinical research on central inflammatory cytokines in humans with chronic pain
is very limited and developing now. Prior human studies have focused on measuring
inflammatory cytokines through serum analysis secondary to the decreased invasiveness
and ease of collection. However, there is evidence that these peripheral markers of
inflammation may not reflect levels in the central nervous system (CNS), which are those
most relevant to the proposed work. Levels of cytokines found to be high in CSF were
found to be low or undetectable in the serum (Backonja, Coe, Muller, & Schell, 2008;
Lundborg, Hahn-Zoric, Biber, & Hansson, 2010; Zin, Nissen, Moore, & Smith, 2010).
While glia are uniformly distributed throughout the CNS, it has been reflected in the
literature that only glia in the spinal cord are activated following nerve injury (Zhang et
al., 2008). Therefore to assess the inflammatory markers related to neuropathic pain,
specimens drawn closest to the glia that release the markers would be most accurate in
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assessing the types and amounts of markers responsible for this type of inflammatory
nociception. This study will focus on CSF analysis because of the central location of glia
and cytokines, rather than serum, as a means of supportive analysis for developing
literature on the role of central neuroimmune responses and chronic pain.
Prior evidence supporting the use of CSF in the examination of cytokine patterns
in chronic pain subjects has focused on patients with Complex Regional Pain Syndrome
(Alexander, Perreault, Reichenberger, & Schwartzman, 2005; Alexander et al., 2007;
Backonja et al., 2008; Munts et al., 2008); lumbar radiculopathy (Ohtori et al., 2011 );
chronic pain patients receiving intrathecal opioid infusions for pain management (Zin et
al., 2010); persistent headache (Rozen & Swidan, 2007); chronic migraine (Peres et al.,
2004); neuropathic pain related to previous spinal surgery (Capelle et al., 2009) and
chronic osteoarthritis pain (Lundborg et al., 2010). Various inflammatory cytokines have
been found to be elevated in the CSF of human pain study participants including
interleukin-I (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8) and soluble TNFa receptor
(TNFa). Other studies have shown a decrease in anti-inflammatory cytokine interleukin
10 (IL-10).

Evidence Supporting Inflammatory Contributions to Anxiety, Depression and Sleep
Deprivation
Part of the psychoneuroimmunologic component to pain is the interaction
between cytokines and the behavioral complex known as sickness behavior. Feelings of
sickness can be characterized by fatigue, decrease appetite, fever, lack of mobility, sleep
disturbances, depression and inability to concentrate (Dantzer, 2001; Hart, 1988; Watkins
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& Maier, 2000). Though the neuroimmune-mediated sickness behavior may promote

unsavory feelings, this natural response to illness is paramount in healing and is usually
short-lived with resolution of the offending illness. However, like chronic pain, when the
mechanism of the sickness behavior goes awry, feelings of depression and anxiety, and
sleep disturbances can be perpetuated longer than the illness or stress. If the effects of
anxiety, depression and sleep deprivation are related to the illness or stress of pain, the
mechanism is still unclear. Inflammatory cytokines offer one possible explanatory link
between all of the psychoneuroimmune responses and pain, but central levels of
cytokines in humans have been relatively unstudied thus far.
Peripheral levels of inflammatory cytokines have been examined with conflicting
results in human studies related to anxiety disorders (Hoge et al., 2009; Koh & Lee, 2004;
van Duinen et al., 2008). However, these peripheral results do not clarify ifthere is a
central mechanism that links anxiety, inflammation and pain. The data on central
inflammation and anxiety is very limited. Similar to chronic pain studies that examine
peripheral and central cytokine patterns, anxiety research exemplifies the same theme:
Peripheral levels of cytokines do not always exemplify what is found centrally. Baker
and colleagues discovered increased IL-6 levels in CSF but not in serum when they
analyzed PTSD patients (Baker et al., 2001 ). Clearly, more studies are necessary to
examine the relationship between anxiety, commonly found with pain-related conditions,
and the centrally mediated response of inflammation.
The direct correlative relationship between depression and pain has been
thoroughly documented in the literature showing that both depressed patients exhibit at
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least one painful symptom (Vaccarino, Sills, Evans, & Kalai, 2009) and chronic pain
patients frequently exhibit depression (Dworkin & Gitlin, 1991 ). Similar to the anxiety
literature, the relationship between levels of pro- and anti-inflammatory cytokines and
their contribution to the pathophysiology of depression are not fully understood. Because
antidepressants work centrally and have been shown to reduce levels of inflammatory
cytokines (Basterzi et al., 2005; Janssen, Caniato, Verster, & Baune, 2010), the central
pro- and anti-inflammatory patterns of these cytokines must be examined in the depressed
patient. Cerebrospinal fluid levels of cytokines have been measured in unmedicated
depressed patients (Levine et al., 1999), attempted suicide patients (Lindqvist et al.,
2009), and chronic PTSD sufferers (Bonne et al., 2011) all with conflicting results.
Clearly chronic pain and depressive symptoms are usually experienced together, but there
is no data currently available exploring the role of central inflammation and the
pathophysiology of these co-existing symptoms. More data is necessary to ascertain the
relationship of central inflammation and depression, especially in the chronic pain
population.
The complex relationship between pain and poor sleep quality is one that has been
extensively documented in the literature, but its causality not fully understood. Up to
53% of chronic back pain patients (Tang, Wright, & Salkovskis, 2007) and 88% of
neuropathic pain patients (Meyer-Rosberg et al., 2001) report sleep disturbances. Thus
the literature supports that sleep and pain do interact with one another, sleep
abnormalities are frequently reported by the chronic pain population, and the effects are
not benign (Fulda & Schulz, 2001). Unfortunately, monitoring of central inflammatory
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cytokines in human sleep studies has been very lacking thus far, and those studies that
have monitored peripheral concentrations of inflammation have yielded conflicting
results. Peripherally monitored cytokines have been measured in humans, but on a
limited basis and have focused on IL-I, IL-6 and TNFa with conflicting results (Heffner
et al., 2011; Hong, Mills, Loredo, Adler, & Dimsdale, 2005; Irwin et al., 2004; Vgontzas
et al., 2003 ). There is scant data to support that pro inflammatory cytokines may
contribute to the poor sleep quality endured by chronic pain patients, but central levels
have not been examined even with the knowledge from prior animal models that central
levels of cytokines do scaffold involvement with sleep (Kapas et al., 1992; Oba!, &
Krueger, 1991; Shoham, Davenne, Cady, Dinarello, & Krueger, 1987; Tobler, Borbely,
Schwyzer, & Fontana, 1984). More data is crucial to discovering the role of central
inflammation on sleep deprivation in the chronic pain patient.
B. Innovation

Review of the current literature on central inflammatory cytokine patterns reveals
new relationships among chronic pain, sleep deprivation, anxiety and depression.
Though the evidence indicates chronic pain, sleep deprivation, anxiety and depression are
associated with central inflammatory changes, the mechanisms responsible require
further description. Confirmatory studies are needed to clarify the pathways that have
been tentatively identified as new relationships emerge. Thus, the proposed study is
justified, in that it will further describe the pathophysiology of pain pathways, as well as
explore novel relationships between the psychological responses to chronic pain and
inflammatory mediator release.
141

If this study and future human-based studies can replicate prior findings, the

implications for physical and psychological chronic pain treatment in our patient
population are highly significant: Prior animal studies have demonstrated that by
blocking the release of the proinflammatory IL-1, the length of analgesic effect of an
opioid can double, there is an approximate seven and a half-fold increase in analgesic
efficacy, opioid tolerance is blunted and both newly developed and established allodynia
and hyperalgesia, both of which are common in chronic pain states, can be reduced
(Hutchinson et al., 2008; Johnston et al., 2004). Through antagonism of the
proinflammatory molecule TNFa, the same agent that was shown to decrease both pain
and hyperalgesia in animals has also preliminarily been shown to decrease depression,
pain and inflammation in human subjects (Alldred, 2001; Sommer, Schiifers, Marziniak,
& Toyka, 2001; Tyring et al., 2006). Clearly human studies are paramount in progressing

towards integrating comprehension of chronic pain pathways with treatment of the entire
patient pain experience.
The proposed project will investigate the role of inflammation in the CNS and the
psychological impact of chronic pain. This study utilizes a rare opportunity to collect
CSF from patients prior to and while undergoing a trial of an intrathecal opiate drug
delivery system for treatment of chronic pain. An interdisciplinary team of nurse
anesthetist researchers, pain management clinicians and psychoneuroimmunology (PNI)
researchers will collaborate to measure CSF levels of inflammatory mediator molecules
and evaluate the psychological status as each patient prepares for and then undergoes an
intrathecal opioid catheter trial.
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This study is a novel and unique approach to bridge chronic pain and PNI
research. Additionally, collaboration among nurse anesthetist researchers, the physicians
at the University of California, Los Angeles (UCLA) Pain Management Clinic and PNI
researchers in the area of chronic pain would be instrumental in developing future clinical
studies in the field of chronic pain. This study clearly has translational potential, as it
may lead to targeted neuroimmunologic therapies for chronic pain, identification of
treatment disparities within this patient population, and scaffold a better understanding of
the psychological components of chronic pain. Given the impact chronic pain has on
society, the healthcare system and the economy, any discoveries that would allow for
improved treatments for chronic pain would be of vital importance.
C. Approach
Design

This will be a cross-sectional, descriptive study with a convenience sample of
approximately 30 chronic pain patients recruited from the Pain Management Clinic at
UCLA. One time CSF draws will be analyzed and compared to control samples of CSF
to allow for testing of the first hypothesis. Psychometric analysis of study participants
will allow for testing of the second hypothesis.
Sample

Approximately thirty patients with the diagnosis and symptomatology of chronic
pain who are eligible for and medically recommended treatment with a Food and Drug
Administration (FDA)-approved intrathecal opioid infusion pain pump (the Medtronic
SynchroMed® II Pain Pump) will be enrolled in this study after informed consent is
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obtained. Potential participants will be recruited from the Pain Management Clinic at
UCLA. Inclusion criteria include the patient being older than 18 years of age and have a
chronic pain diagnosis greater than 6 months duration. Diagnosis will be made on
standard clinical criteria, as suggested by the International Association for the Study of
Pain (IASP). Exclusion criteria will include acute medical or psychiatric disorders,
cancer, HIV, prior epidural injections for treatment of chronic pain, drug abuse, non
English speaking, meningitis or history of meningitis, active upper respiratory
infection/flu or febrile nature, history of blood transfusion, acute psychological or
physiologic danger/instability, altered mental status, palliative treatment, and pregnancy.
The inclusion and exclusion criteria will be confirmed using standard clinical and
laboratory methods of analysis and all patients will be instructed to continue all of their
medications and therapies without making any changes prior to study involvement.
Measures
Beck Depression Inventory II. The Beck Depression Inventory II (BDI-II) will

be obtained from each patient before collection of CSF to assess and score levels of
depression. The BDI-II contains 21 questions, each answer being scored on a scale value
ofO to 3. The cutoffs used will be: 0-13: minimal depression; 14-19: mild depression;
20-28: moderate depression; and 29-63: severe depression. Higher total scores indicate

more severe depressive symptoms (Beck, Ward, Mendeson, Mock & Arbough, 1961).
Hamilton Anxiety Scale. The Hamilton Anxiety Scale (HAM-A) measures the

severity of a patient's anxiety, based on 14 parameters, each item given a 5-point score - 0
(not present) to 4 (severe) and includes anxious mood, tension, fears, insomnia,
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intellectual impairment, depression, somatic complaints, autonomic symptoms,
physiologic symptoms and behavior at the interview. A total anxiety score of <17
indicates mild anxiety levels; 18 to 24 moderate anxiety levels; and 25 to 30 indicates
severe anxiety levels (Hamilton, 1959).
Short Form McGill Pain Questionnaire. The Short Form McGill Pain

Questionnaire (SF-MPQ) consists of fifteen descriptors, eleven sensory descriptors and
four that are affective in nature. Each descriptor is rated on a scale of 0-3: 0 (none) to 3
(severe). It also includes a Present Pain Intensity (PPI) index and a Visual Analogue
Scale (VAS) (Melzack, 1975; Melzack, 1987).
The Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index is

composed of nineteen components that yield scores on subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficacy, sleep disturbance, use of sleeping
medication and daytime dysfunction. These seven components are scored from 0-3 and
yield a total score of0-21. Higher scores indicate worse sleep quality (Buysse et
al., 1989).
Procedures

Approximately thirty patients with the diagnosis and symptomatology of chronic
pain who are eligible for and medically recommended treatment with an FDA-approved
intrathecal opioid infusion pain pump (the Medtronic SynchroMed® II Pain Pump) will
be enrolled in this study. Potential participants will be recruited from the Pain
Management Clinic at UCLA. After informed consent is obtained using Institutional
Review Board (IRB)-approved forms, subjects will complete the psychometric
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instruments to measure sleep deprivation, depression, anxiety and pain experience.
Patients will undergo a structured interview to compile their demographic information
and results will be number coded to ensure anonymity. Upon completion of the
psychological questionnaires, study participants will be given a twenty-five dollar Visa
gift certificate for their participation in the study. Participants will also be reimbursed for
their parking fees upon enrollment of the study for the preclinical office visit date and the
date forthe trial operation (a total of two parking fees per study participant).
Approximately one month after the preclinical office visit, the study participant will be
scheduled to undergo a surgical outpatient operation called an intrathecal opioid infusion
pain pump trial. This operative surgical procedure and study procedure of collecting
intraoperative CSF samples will be performed in the operating suite at UCLA Santa
Monica Orthopedic Hospital. Three milliliters (mL) of CSF will be collected from the
approximate 30 patient study participants undergoing intrathecal opioid infusion pain
pump trials for the treatment of their pain. Standard preoperative preparation and
evaluation will take place in the preoperative suite of UCLA Santa Monica Orthopedic
Hospital. A qualified member of the preoperative evaluation team will start peripheral
intravenous fluids in the preoperative suite and preoperative vital signs will be recorded.
The patient will be brought to the operating room and positioned per surgeon preference,
and standard monitors (electrocardiogram, noninvasive blood pressure cuff, pulse
oximeter) will be applied. Patients will be given 2-4 liters/minute nasal cannula oxygen
and a combination of intravenous versed and fentanyl will be titrated for patient comfort
by a qualified operating room nurse at the surgeon's direction. Strict, standard sterile
146

surgical protocol will be followed per the regulations and policies of UCLA Santa
Monica Orthopedic Hospital guidelines. Intrathecal access will be accessed with or
without the use offluoroscopy per the surgeon's discretion. All samples of CSF will be
collected intraoperatively during daylight hours in appropriate polypropylene specimen
collection tubes, properly labeled with a number code for anonymous identification and
placed on ice in UCLA approved specimen transportation boxes. A member of the
research team will then transport specimens from UCLA Santa Monica Orthopedic
Hospital to the UCLA Cousin's Institute Inflammatory Biology Laboratory in the 300
Medical Plaza building of the UCLA Westwood campus via car, with an estimated
transportation time of thirty minutes. Upon receipt of the specimens, the UCLA Cousin's
Institute Inflammatory Biology Laboratory will centrifuge and partition the 3 mL samples
into 0.5-1 mL aliquots with appropriately labeled anonymous identification. The aliquots
will then be stored at -80°C until batch analysis can be performed.
After collection of 3 mL of CSF in a specimen collection tube, the surgeon will
place an intrathecal opioid infusion pain catheter and administer of a dose of intrathecal
opioid. The catheter will be secured and dressed in a sterile fashion and the patient will
be taken to the postoperative suite for recovery. The patient is then monitored for eight
to ten hours for side effects and complications arising from the administration of an
intrathecal opioid. The patients' hemodynamic stability and vital signs are also
continually assessed during this eight to ten hour postoperative stay by a member of the
pain management team and/or postoperative nursing staff. Once a member of the pain
management team has determined that the patient has not incurred any serious side
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effects from the administration of an intrathecal opioid, the patient is then eligible to have
a permanent opioid infusion pain pump. The catheter is removed, a sterile dressing is
placed over the operative site and the patient is discharged home with instructions and
emergency contact information.
Control samples ofCSF will be analyzed from the California NeuroAIDS Tissue
Network obtained from Dr. Scott Letendre at the University of California, San Diego
(UCSD). Thirty random, individual samples of 1-2 mL ofCSF, collected from 2005
2012, will be utilized from this tissue bank as a means to compare levels of central
inflammatory cytokines. Samples of 1-2 mL will be obtained in specimen collection
tubes and placed on ice in the appropriate biological hazard container. The specimens
will be shipped from UCSD to the UCLA Cousin's Institute Inflammatory Biology
Laboratory in Los Angeles with an estimated travel time of two and half hours. Upon
receipt of the specimens, the UCLA Cousin's Institute Inflammatory Biology Laboratory
will centrifuge and partition the 1-2 mL individual samples into 0.5-1 mL aliquots with
appropriately labeled identification. The aliquots will then be stored at -80°C until batch
analysis can be performed.
Control and study participant CSF levels ofIL-1, IL-6, IL-8, TNFa and IL-10
will be determined using high sensitivity enzyme linked immunosorbant assay (ELISA)
(R&D Systems, Minneapolis, MN) or similar. All assays will be performed in duplicate
per manufacturers recommendations. The cytokine levels for all of the samples
obtained, both from UCLA and UCSD will be reported as picograrns/milliliter (pg/ml).
Variables
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Independent Variable: Diagnosis of Chronic Pain (as defined by the International
Association for the Study of Pain) greater than 6 months in duration.

Dependent Variables: Proinflammatory Cytokines (IL-1, IL-6, IL-8, TNFa);
Anti-inflammatory Cytokine (IL-1 O); Depression (as measured by Beck Depression
Inventory II (BDI-II)); Anxiety (as measured by the Hamilton Anxiety Scale (HAM-A));
Pain (as measured by the McGill Pain Questionnaire).

Categorical Covariate Variables: Age; Gender; Cause of Chronic Pain; Length of time
from initial diagnosis; Type of medication used to treat chronic pain; Length of time
taking medication; Race; Education Level; Income/Socioeconomic Status; Level of
Activity; Body Mass Index.

Possible Exclusion Criteria: Cancer; HIV; Prior epidural injections for treatment of
chronic pain; Drug Abuse; Non-English Speaking; Meningitis or history of meningitis;
Active URI/flu or febrile nature; History of blood transfusion; Acute psychological or
physiologic danger/instability; Altered mental status; Palliative treatment; Pregnancy.
Analysis Plan

Descriptive statistics will be utilized to evaluate study CSF cytokine patterns and
participant demographics. Statistically significant differences between patient and
control group cytokine levels will be evaluated using multivariate statistical analysis; ttests and chi-square tests for parametric data. To determine the relationship of cytokine
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patterns on sleep deprivation, anxiety, depression and self-reported pain in the study
participants, analysis of variance (ANOV A) at one/two-tailed p < 0.05 for parametric
data will be performed. For non-parametric data Mann-Whitney U statistical analysis
may be selected as the appropriate statistical tool to test the second hypothesis.
Calculations will be accomplished with the aid of the statistical software SPSS version
v.19 or newer (SPSS, IBM Inc., Armonk, NY).
The planned analysis at this time is primarily exploratory, and designed to answer
the questions: Are there significant relationships between such psychological variables
as sleep deprivation, depression, anxiety, or pain intensity and levels of inflammatory
mediators in the CSF of the chronic pain patient? Is there a significant difference in the
central levels of inflammatory cytokines of chronic pain patients and control samples of
CSF? Following literature review, other analyses may be devised using a triangulation
approach with the qualitative data obtained during the demographic interview.

D. Investigators

The principal investigator, Sarah E. Giron, CRNA, MS, is currently a Doctoral
Student at University of San Diego (USD) Hahn School of Nursing and Health Science's
PhD Program. Her prior research experience includes work at the San Diego Veterans
Affairs Hospital for which she received the UCSD Undergraduate Excellence in Research
Award. Ms. Giron has participated in data collection at UCLA's Department of
Integrative Biology and Physiology, as well as a private gastroenterology office, La Jolla
Gastroenterology. She has participated in Phase Three clinical trials of Sugammadex at
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UCLA's Jules Stein Eye Institute and was awarded the 2012 American Association of
Nurse Anesthetists (AANA) Baxter Research Doctoral Fellowship. Ms. Giron will be
responsible for managing study operations, coordinating communication amongst team
members and patients, and facilitating data collection logistical arrangements.
Co-Investigator Charles Griffis CRNA, PhD, Associate Professor, UCLA
Department of Anesthesiology and School of Nursing, is a well-accomplished nurse
anesthesia expert in inflammation/chronic pain research. As a highly respected member
of the nurse anesthesia academic and UCLA research community, Dr. Griffis was
awarded the AANA Researcher of the Year Award in 2010. His numerous publications
in a wide array of multi-disciplinary peer-reviewed journals also affirm his expertise in
academic research writing. Dr. Griffis will provide faculty support at UCLA, project
oversight pertaining to the protocol development and project details at UCLA and
provide mentorship to Ms. Giron in academic writing and manuscript publication.
Co-Investigator Joseph Burkard, CRNA, DNSc, Associate Professor, USD Hahn
School of Nursing and Health Science, is also a well-accomplished nurse anesthesia
educator and researcher. Dr. Burkard has been awarded Instructor of the Year by both
the Navy and Kaiser Permanente Programs of Nurse Anesthesia and has been funded by
USD and Military Grants for his ongoing research in Simulation and Emergence
Delirium. Dr. Burkard will be providing faculty support at USD, oversight for
procedures at USD, grant subcontract coordination between UCLA and USD, guidance
with statistical analysis and manuscript writing.
E. Environment
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The UCLA Santa Monica Orthopedic Hospital and UCLA Cousin's Inflammatory
Biology Laboratory will serve as the data collection and analysis site of this study, which
will be primarily based at the USD Hahn School of Nursing and Health Science, PhD
Program. The study will serve as the dissertation project for USD Doctoral Student,
Sarah Giron CRNA, MS. Charles Griffis, CRNA, PhD and Joseph Burkard, CRNA,
DNSc will provide academic oversight of the dissertation process. Ms. Giron will be the
principal investigator for the project, responsible for developing, managing and
collaborating with team members to ensure an ethical and comprehensive research
strategy.
The UCLA Department of Anesthesiology, Pain Management Clinic would seem
to be an ideal setting for the participant recruitment necessary for this study. Andrea
Nicol, MD, Assistant Clinical Professor and Director of Research for UCLA Pain
Management Center and Michael Ferrante, MD, Director of UCLA Pain Management
Center and Team, UCLA Department of Anesthesiology, have confirmed that once IRB
approval is obtained, the patients could be recruited into the study in the clinic setting.
The psychological instruments can be administered in the preoperative timeframe. The
CSF sample collection can be accomplished at the time of an intrathecal catheter trial,
and would not seem to require any escalation in care, nor present any increased risk to the
patient. The UCLA Norman Cousins PNI Institute will provide support for the PNI
theory aspects of the study through collaboration with Michael Irwin, MD, Professor and
Director, an internationally recognized expert in this area. Additionally, Elizabeth Breen,
PhD, a research immunologist with extensive experience in cytokine and inflammatory
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molecule analysis will provide oversight of the immune analyses. Dr. Breen is the
Director of the Inflammatory Biology Laboratory, which is a fully equipped research
laboratory, located within the Cousins Center, and will be used for study sample analysis.
IV. Biographical Sketch of Key Researchers

Sarah Giron, CRNA, MS-USD Doctoral Student, Study Principal Investigator, AANA
Baxter Research Doctoral Fellowship Grant Recipient
J. Burkard, CRNA, DNSc-Associate Professor, USD Faculty Support and Oversight

C. Griffis CRNA, PhD-Associate Professor, UCLA Faculty Support and Oversight
V. References

See Word Attachment
VI. Timeline

See Word Attachment
VII. Budget

See Attachment
VII. Appendices

Please see the following attachments:
Sarah Giron's CV
Picture of Sarah Giron
Biographical Sketch of Sarah Giron
Dr. Charles Griffis' CV
Dr. Joseph Burkard's CV
Letter to Foundation Addressing IRB Application and Study Progress
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High Sensitivity ELISA Instructions for
a. ELISAHSlOOC
b. ELISA hs600b
c. ELISA hslbOOc
d. ELISA HSTAOOD
e. ELISA MEAOOl

Psychological Instruments
a. The Short Form McGill Pain Questionnaire (SF-MPQ)
b. Beck Depression Inventory II (BDI-II)
c. The Hamilton Anxiety Scale (HAM-A)
d. The Pittsburgh Sleep Quality Index
Letters of Support
a. Dr. Andrea Nicol
b. Dr. Elizabeth Breen
c. Dr. Charles Griffis
d. Dr. Joseph Burkard
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IV. Biographical Sketch of Key Researchers
Sarah Giron, CRNA, PhD(c), is a Clinical Instructor of Anesthesiology at the
University of Southern California (USC) where she is a full-time Faculty Nurse
Anesthetist at the Keck Hospital of USC. She is currently enrolled as a PhD Doctoral
Candidate at the University of San Diego's Hahn School of Nursing and Health Science,
and is an active Committee Chair and Editor for her state nurse anesthetist association,
the California Association of Nurse Anesthetists. She has authored several chapters in
nurse anesthesia textbooks and will be featured as the guest speaker for the 2013
graduating USC Program of Nurse Anesthesia Commencement Ceremony. Her most
recent funded research endeavors focus on the role of inflammation in the psychology
and physiology of chronic pain.
Joseph Burkard, CRNA, DNSc, Associate Professor, USD Hahn School of Nursing and
Health Science, is a well-accomplished nurse anesthesia educator and researcher. Dr.
Burkard has been awarded Instructor of the Year by both the Navy and Kaiser
Permanente Programs of Nurse Anesthesia and has been funded by USD and Military
Grants for his ongoing research in Simulation and Emergence Delirium.
Charles Griffis CRNA, PhD, Associate Professor, UCLA Department of
Anesthesiology and School of Nursing, is a well-accomplished nurse anesthesia expert in
inflammation/chronic pain research. As a highly respected member of the nurse
anesthesia academic and UCLA research community, Dr. Griffis was awarded the AANA
Researcher of the Year Award in 2010. His numerous publications in a wide array of
multi-disciplinary peer-reviewed journals affirm his expertise in academic research
writing.
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Budget Justification for Psychoneuroimmunology and Chronic Pain Cross-Sectional
Study

Dr. Elizabeth Breen, PhD is an active Co-Investigator in this study and Director for the
UCLA Cousins Inflammatory Biology Laboratory where all CSF samples will be
analyzed. Her expertise in cytokine analysis and methodological experience with these
studies is critical for successful development and completion of this study. Because of
her academic appointment and position at the UCLA Cousins Institute of
Psychoneuroimmunology Dr. Breen will need 5% salary and benefits to justify her
participation in this study. One of her lab assistants, C. Perez, is skilled in handling and
performing ELISAs on CSF samples and will be utilized from the Cousins Inflammatory
Biology Laboratory as part of this study. This budget reflects the salary and benefits of
both Dr. Breen and C. Perez.
All CSF samples will be analyzed with a high-sensitivity ELISA assay to assess for
cytokines IL-1, IL-6, IL-8, IL-10 and TNFu. From previous literature, CSF levels of
these cytokines are not detectable using a regular ELISA, thus a high-sensitivity is
necessary to detect levels. The rates quoted in this budget represent consumables, assay
plates, storage test tubes, pipettes, and other lab equipment necessary for analysis.
Upon receiving the CSF samples, the Cousins laboratory will be centrifuging the
specimens to separate any precipitate, and making 0.5-lmL aliquots for deep freeze
storage. This budget covers the labor of centrifugation and aliquots, and the test tube
labeling for correct identification of study samples.
Once centrifuged and the aliquots of CSF samples are made, the specimens need to be
preserved at -80°C until all specimens are available for duplicate analysis. This form of
batch analysis decreases the rate of discrepancies if assays were performed as CSF
samples arrived. Freezer space and handling are included in this budget.
CSF will need to be collected from the patients and transported to the lab in an
appropriate container. Per previous studies, polypropylene specimen tubes are
appropriate and will not alter the specimens for analysis. Because 2-3 mL of CSF will be
collected, 4 mL polypropylene specimens tubes were selected from Fisher Scientific
www.fishersci.com. The cost of the polypropylene specimen tubes are included in this
budget.
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Psychological Instruments
Found in Appendices of Dissertation
Letters of Support

• Dr. Andrea Nicol
• Dr. Elizabeth Breen
• Dr. Charles Griffis
• Dr. Joseph Burkard
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Sarah Elizabeth Giron, CRNA, MS

Education:
High School
University
University
Graduate School

Whitney M. Young, Chicago, Illinois, Illinois State Scholar, Honor
Roll, 1997
University of California San Diego, La Jolla, California, BS
(Biochemistry and Cellular Biology), 2001
Columbia University, New York, New York, BS (Nursing), Dean's
List, 2002
Columbia University, New York, New York, MS (Nurse
Anesthesia), Dean's List, 2005
University of San Diego, San Diego, California, PhD (Nursing),
Anticipated Commencement 2014

Honors and Awards

•The AANA Doctoral Research Baxter Fellowship Award, San
Francisco, 2012
•Eight and Forty Scholarship, The American Legion, New York,
2005,
2011, 2012
•Award for Excellence, Sigma Theta Tau, Graduate
Commencement, New
York, 2005
•Excellence in Research, UCSD Faculty Mentorship Program,
Undergraduate Symposium, La Jolla, 2000

Board Certification
Other

Registered Nurse, 2002-present
Certified Registered Nurse Anesthetist, 2005-present
BLS and ACLS 2005-present

Professional Background:
Clinical Administrative Appointments
•Clinical Instructor of Anesthesiology, University of Southern California, Los Angeles,
California, 2009-present
•Faculty Nurse Anesthetist, University of Southern California, Los Angeles, California,
2009
present
•Senior Certified Registered Nurse Anesthetist, University of California Los Angeles,
Los
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Angeles, California, 2006-2009
•Certified Registered Nurse Anesthetist, University of California Los Angeles, Los
Angeles,
California, 2005-2006
•Burn Intensive Care Unit Registered Nurse, New York-Presbyterian Cornell Weill
Medical
Center, New York, New York, 2002-2004
Specific Teaching Responsibilities
•Clinical Preceptor and Didactic Faculty Member, Keck School of Medicine Program of
Nurse
Anesthesia, 2009-present
•Clinical Preceptor, Kaiser Permanente and USC Student Nurse Anesthetist out-patient
clinical
rotations at UCLA, 2006-2009
•Undergraduate Clinical Coordinator, Fresno State University student Registered Nurse
clinical
observation and volunteer rotation at UCLA, 2007-2008
Other
Editor in Chief, California Association of Nurse Anesthetists E-Journal, 2010-present
Editor, California Association of Nurse Anesthetists Newsletter, 2009-present

Society Memberships:
Distinguished
Sigma Theta Tau International, 2002-present
Professional
American Association of Nurse Anesthetists, 2003-present
California Association of Nurse Anesthetists, 2005-present
Service:
Professional Organizations
Editorial Committee Member, California Association of Nurse Anesthetists, 2011-present
Membership Engagement/Information Technology Committee Chairperson, California
Association of Nurse Anesthetists, 2009-present
Committee Member, Information Technology Committee, California Association of
Nurse Anesthetists, 2008-2009
University/Other Committees
University of Southern California/Keck School of Medicine Program of Nurse
Anesthesia Webmaster, University of Southern California, Los Angeles, California,
2010- present
Faculty Development Chairperson, University of Southern California, Los Angeles,
California, 2009-present
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LEAP Scholarship Foundation Vice President, Keck School of Medicine Program of
Nurse Anesthesia, Los Angeles, California, 2011-present
LEAP Scholarship Foundation Secretary, Keck School of Medicine Program of Nurse
Anesthesia, Los Angeles, California, 2010-2011
Quality Assurance Committee, University of California Los Angeles, Los Angeles,
California, 2007-2009
Research Activities:
Major Areas ofResearch Interest
Psychoneuroimmunology, Chronic Pain, Pharmacology
Past Clinical Research
Sugammadex phase 3 clinical trials, University of California, Los Angeles, 2008-2009
Invited Lectures:
Distinguished
"Pain, Opioids and Inflammation: Update on Physiology." CANA Spring 2009
Conference, California Association of Nurse Anesthetists, Rancho Mirage, California,
February 2009.
"Sugammadex and a Return to the Land of Neuromuscular Blockade." Winter 2008
Educational Conference, Kaiser Permanente Nurse Anesthetist Association, Anaheim,
California, January 2008.
Other
"Sugammadex (Organon 25969) Update." Faculty Development Meeting, University of
Southern California, Los Angeles, California, February 2011.
"Ethical Decision Making in Anesthesia." Co-Lecturer, USC School of Nurse
Anesthesia, Los Angeles, California, November 2010, 2011.
"Anesthesia for Out-Patient Surgery." Lecturer, USC School of Nurse Anesthesia, Los
Angeles, California, September 2010, 2011.
"Opioid Physiology and Pharmacology." Guest Lecturer, Samuel Merritt University,
Oakland, California, August 2009, July 2012.
"Opioid and Neuroglial Interactions--What Happens When Opioids Aren't Enough?"
Guest Lecturer, Samuel Merritt University, Oakland, California, August 2009, July 2012.
"Opioid Physiology and Pharmacology." Lecturer, USC School of Nurse Anesthesia, Los
Angeles, California, June 2009, 2010, 2011, 2012.
"Opioid and Neuroglial Interactions--What Happens When Opioids Aren't Enough?"
Lecturer, USC School of Nurse Anesthesia, Los Angeles, California, June 2009, 2010,
2011, 2012.
"Opioids and Benzodiazepines: A Physiology and Pharmacology Review." Continuing
Education Series, UCLA Healthcare Registered Nurses, Los Angeles, California, April
2009.
"Sugammadex (Organon 25969) Update." Journal Club Continuing Education, UCLA
Healthcare Nurse Anesthetists, Los Angeles, California, September 2006.
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BIOGRAPHICAL SKETCH
Provide the following 1nformat1on for the Senior/key personnel and other s1gnif1cant contnbutors 1n the order listed on Form Page 2
Follow this format for each person DO NOT EXCEED FOUR PAGES.

NAME

POSITION TITLE

Giron, Sarah Elizabeth

Clinical Instructor of Anesthesiology

eRA COMMONS USER NAME (credential, e g, agency login)

EDUCATION/TRAIN ING

with baccalaureate or other 1mt1al professional education, such as nursmg, mclude postdoctoral trammg and

residency trammg 1f app/1cab1:.J...

INSTITUTION AND LOCATION

DEGREE
(1f appl!Cable)

University of California, San Diego (La Jolla, CA)
Columbia University (New York, New York)
Columbia University (New York, New York)

B.S.
B.S.
M.S.

University of San Diego (San Diego, CA)

PhD

MMNY

05/2001
08/2002
08/2005
Currently
Enrolled

FIELD OF STUDY

Biochem. &Cellular Bio.
Nursing
Nurse Anesthesia
Nursing

NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions
below.
A.

Personal Statement

Within the medical and nursing community it is imperative that advanced practice nurses take a more
prominent role in research. Attaining a previous bachelor's degree in Biochemistry & Cellular Biology and
experience with several undergraduate and postgraduate research projects, science has been a staple of my
past and will continue to be a necessity for my future. I look forward to continuing research in the field of
psychoneuimmunology with accurate, clinically significant studies that focus on the central inflammatory
process and psychological implications of chronic pain. Such studies should help define pain pathways and
clarify more effective pain modality treatments both analgesically and psychologically.

B.

Positions and Honors

Positions and Employment
1999
Undergraduate Research Assistant, Neurology Dept., University of California, Los Angeles,
Los Angeles, CA
2000

Hepatitis C Lookback Coordinator/Undergraduate Research Assistant, Veterans Affairs, La
Jolla, CA

1998-2001

Lab Technician, La Jolla Gastroenterology, La Jolla, CA

2002-2004

Burn Intensive Care Unit staff Nurse, New York-Presbyterian Cornell Weill Medical Center,
New York, New York
Certified Registered Nurse Anesthetist, University of California, Los Angeles, Los Angeles, CA

2005-2006
2006-2009
2009-present

Senior Certified Registered Nurse Anesthetist, University of California, Los Angeles, Los
Angeles, CA
Faculty Nurse Anesthetist, University of Southern California, Los Angeles, CA
Clinical Instructor of Anesthesiology, University of Southern California, Los Angeles, CA

Other Experience and Professional Memberships
2002-Present Sigma I heta I au International IVlember
2003-Present

American Association of Nurse Anesthetists Member

2005-Present

California Association of Nurse Anesthetists Member
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CURRICULUM VITAE (04/2011)
CHARLES ALAN GRIFFIS, CRNA, Ph.D.

Date of Birth

August 25, 1951

Education
Fall 2005
Doctor of Philosophy
School of Nursing, Graduate Division
University of California at Los Angeles
Los Angeles, California
Fall 1985 - 1987

Ed.Psych, Doctoral Student (36 hrs course work)
College of Education
Learning and Instruction
University of California at Los Angeles
Los Angeles, California

1979 - 1981

Master of Science in Nurse Anesthesia
Program of Nurse Anesthesia
College of Medicine
UCLA
Los Angeles, CA

1976

Bachelor of Science in Nursing (Magna cum
Laude)
College of Nursing
University of South Florida
Tampa, Florida

1974

Associate of Science in Nursing
(Magna cum Laude)
Hillsborough Community College
Tampa, Florida

Academic Appointments
9/11 - present

Associate Professor
Research and Didactic Instruction
UCLA School of Nursing

7/10 - present

Associate Clinical Professor
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Department of Anesthesiology
UCLA School of Medicine
Los Angeles, CA

8/89 - 7/2010

Assistant Clinical Professor
Department of Anesthesiology
UCLA School of Medicine
UCLA School of Nursing (secondary)
Los Angeles, CA

9/84 - 3/87

Adjunct Assistant Professor
Department of Anesthesiology
UCLA School of Medicine
Los Angeles, CA

1995-Present

Visiting Faculty
University of Southern California Program of Nurse

Anesthesia
Kaiser Permanente Program of Nurse Anesthesia
Professional Employment
Sept. 2011-present

Per Diem Staff Nurse Anesthetist and Clinical Instructor
Greater Los Angeles VA Healthcare System
Department of Anesthesia
Los Angeles, CA

Sept. 2009
Education

Professional

2006-Present

Principal Nurse Anesthetist
Assistant Administrative Director, Nurse Anesthesia
Clinical Educator, Educational Director
UCLA Department of Anesthesiology

5/87 - 2006

Staff Senior Nurse Anesthetist and Instructor
UCLA Department of Anesthesiology
Los Angeles, CA

3/92 - 12/98

Staff Nurse Anesthetist
Clinical Instructor
West Los Angeles Veteran's Administration

Lecturer,

Institute

for

Post-Graduate
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Medical Center
Department of Anesthesia
Los Angeles, CA
6/89 - 8/89

Staff Nurse Anesthetist (Part-time)
Sepulveda Veterans Admin Medical Center
Sepulveda, CA

1/85 - 5/87

Director
UCLA Program of Nurse Anesthesia
UCLA Department of Anesthesiology
School of Medicine
Los Angeles, CA

6/81 - 1/85

Staff Nurse Anesthetist
Clinical Instructor
UCLA Department of Anesthesiology
Los Angeles, CA

6/81 - 1/85

Private Anesthesia Practice (Part-time)
Plastic Surgery Offices
Los Angeles, CA

1974 - 1979

Registered Professional Critical Care Nurse
Tampa, Florida
Emergency Department
Staff Nurse
St. Joseph Hospital
Intensive Care Unit
Staff and Charge Nurse
Tampa General Hospital
Coronary Care Unit
Staff and Charge Nurse
St. Joseph Hospital
Cardiac Surgery Intensive Care Unit
Staff and Charge Nurse
Tampa, Florida
Surgical Intensive Care unit
Veteran's Administration Hospital
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Tampa, Florida
Societies
California Association of Nurse Anesthetists
American Association of Nurse Anesthetists
International Association for the Study of Pain
International Anesthesia Research Society
CPR Certification
American Heart Association
Basic Life Support, biannual recertification
1974 - present
Advanced Cardiac Life Support, bi.an.recert
1978 - present
ACLS Instructor, volunteer with UCLA Dept of PreHospital Care
2008-2009
Educational Certification
Approved Continuing Education Provider #CEP 14381
California Board of Registered Nursing
Conference Presentations
UCLA Department of Anesthesiology Clinical Case Conference
"Syncope During Local Anesthesia", Feb 1983
"Cardiac Depression Following V ancomycin", Oct 1983
"Anaphylaxis Following Ancef', May 1984
"Tension Pneumothorax in the Recovery Room", June 1984
"The Effects ofNaloxone on the Exercise Hyperpnea", August 1984
"HIV Chemoprophylaxis", May 2001
West Los Angeles VA Medical Center, Department of Anesthesia
Grand Rounds
"Propofol and Alfentanil for Sedation", August 1993
"HIV Disease and Anesthesia", April 1996
"Update on HIV and Anesthesia", November 1997
"HIV/AIDS Drugs: Anesthetic Implications", July 1997

Federation of American Societies for Experimental Biology, Annual Meeting April 1984.
"The Influence of the Endogenous Opiate System on the Control of the Exercise
Hyperpnea in Man"
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Harbor-UCLA Medical Center, Division of Respiratory Physiology and Medicine
Research Conference, June 1984. "The Effects ofNaloxone on the Exercise Hyperpnea"
American Association of Nurse Anesthetists Annual Meeting, August 1984. "The Effect
ofNaloxone on the Exercise Hyperpnea"
Malignant Hyperthermia Association of the United States Annual Meeting, September,
1984. "Monitoring Techniques in the Operating Room"
American Association of Nurse Anesthetists Annual Meeting, August 1985. "End-Tidal
C02 Monitoring"
California Association of Nurse Anesthetists, May, 1986. "Cardiovascular Implications
of PAR Nursing Care"
American Society of Plastic and Reconstructive Nurses, October, 1986.
Hyperthermia"

"Malignant

California Association of Nurse Anesthetists, February, 1987. "The Future of Nurse
Anesthesia Education"
California Association of Nurse Anesthetists, October, 1988. "Clinical Implications of
the Harvard Standards for Monitoring"
California Association of Nurse Anesthetists, October, 1989. "The Use of Alfentanil for
Sedation in Ophthalmologic Outpatient Surgery"
California Association of Nurse Anesthetists, February, 1992. "Propofol and Alfentanil
in Outpatient Anesthesia"
American Association of Nurse Anesthetists Annual Meeting, August, 1993. "Use of
Propofol/Alfentanil Bolus and Infusion for Monitored Anesthesia"
California Association of Nurse Anesthetists, May 1996 Annual Meeting. "HIV and
AIDS - An Update for the Anesthesia Provider"
American Association of Nurse Anesthetists Annual Meeting, August, 1997.
"Perioperative Management:
Anesthesia for the Ambulatory Patient" and "Risk
Management in the Ambulatory Setting"
California Association of Nurse Anesthetists, Fall Meeting, October, 1997 - "Update on
the AIDS Epidemic and Chemoprophylaxis for Occupational Exposure to HIV"
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American Association of Nurse Anesthetists
"HIV/AIDS Drugs: Anesthesia Implications"

Annual

Meeting,

August,

1998.

California Association of Nurse Anesthetists, May 1999 Annual Meeting, "Anesthetic
Implications of HIVI AIDS Drugs"
24th Annual Gastrointestinal Nurses Seminar, March, 2000 - "Conscious Sedation: Do's
and Don'ts"
California Association of Nurse Anesthetists, May 2000 Annual Meeting, "Risk
Management in Anesthesia Practice"
American Association of Nurse Anesthetists, August 2006 Annual Meeting, Research
Forum, "The Effect of Pain on Proinflammatory Cytokines and Leukocyte Cellular
Adhesion Molecules"
UCLA Department of Anesthesiology, Mortality and Morbidity Conference, September
2006, "Anesthesia, Pain, Stress, and Immune System Responses"
UCLA Cousin's Center for Psychoneuroimmunology, Psychoneuroimmunology Seminar,
November, 2006, "Review of Stephen Maier and Linda Watkins Papers: Pain and
Cytokine Responses"
West Los Angeles Veteran's Administration Medical Center, Dept. of Anesthesia
Morbidity and Mortality Conference, March, 07, 2007, "Implications of Perioperative
Stress to Immune Function"
California Association of Nurse Anesthetists, April 2007, Annual Meeting, "Implications
of Anesthesia and Surgical Stress to Perioperative Immune Function"
Kaiser Permanente Nurse Anesthetists
Anesthesia: Issues and Update"

Association,

January,

2008, "Outpatient

UCLA Ronald Reagan Medical Center, Emergency Department Pediatric Conference,
Los Angeles Country Emergency Department Approved for Pediatrics (EDAP)
requirement, November 2008, "Pediatric Sedation in the Emergency Room; Acute
Pediatric Pain Management"
California Association of Nurse Anesthetists, February 2009, Spring Meeting, "Pain,
Opioids and Neuroinflammation" (2 hours); "Risk Management: Error Prevention" (I
hour)
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UCLA Nursing Practice Research Council, April 2009, "Pain and Inflammatory
Mediators: A Research Review"
UCLA Department of Anesthesiology, Weekly Morbidity and Mortality Conference,
June 2009, "The Contribution ofNeuroimmune Activation to Chronic Pain"
American Association of Nurse Anesthetists, Annual Meeting, San Diego, California,
Research Forum, Oral Poster Presentation, "Preliminary Data: Pain and
Neuroinflammatory Mediators"
Nebraska Association of Nurse Anesthetists, October, 2009, "Chronic Pain and
Neuroinflammation; Outpatient Anesthesia-Update on Issues; Anesthesia for Out of the
OR Settings"
California Association of Nurse Anesthetists, February 2010, Spring Meeting, "OPSU
Issues and Update" (1 hour)
American Association of Nurse Anesthetists, Assembly of School Faculty, February,
2011, Research Report of the John F. Garde Researcher of the Year, "Pain, Cellular
Adhesion Molecules, and Inflammatory Mediator Production"
California Association of Nurse Anesthetists, March, 2012, Spring Meeting, "Policy
Governance and CANA"
American Association of Nurse Anesthetists, August 2012, Annual Meeting, "Anesthetic
Management of the Patient with Implanted Cardiac Devices"; "Anesthesia for Out of OR
Cases"

Invited Lectures
Medical Media Associated, Inc., Continuing Education Lecture Series for Professional
Nurses, October 1984. "Airway Management in the Anesthetized Patient"
UCLA Allied Health Program, Center for the Health Sciences. December 1984 
"Anesthesia, A Nursing and Medical Specialty"; June 1985 - "UCLA Nurse Anesthesia
Program"; October 1985 - "Nurse Anesthesia at UCLA Medical Center"
Post Anesthesia Recovery Nurses, UCLA, Continuing Education Lectures. July 1985 
"Anesthetic Agents"; January 1986 - "The Choice of General Vs. Regional Anesthesia;
August 1986 - "Post Anesthesia Care of the Trauma Patient"
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UCLA Operating Room Postgraduate Nursing Program: "The Role of the OR Nurse in
Anesthesia Care" and "Anesthesia and Emergency Drugs" - 1985, 1986, 1987, 1988,
1989, 1990
Professional Symposiums, Inc. Continuing Education Lecture Series for Professional
Nurses, February, 1986. "Anesthesia and Perioperative Nursing Care"
CRNA Staff and Faculty, UCLA, May, 1986. "Motivation Theory and Nurse Anesthesia
Education"
UCLA Operating Room Nurses Continuing Education Conference, August 1986.
"Anesthesia and Perioperative Nursing Care"
CRNA Staff and Faculty, UCLA December, 1986.
Approaches to Nurse Anesthesia Education"

"Cognitive Psychological

UCLA Operating Room Nurses Weekly Teaching Conference, UCLA, August, 1988.
"Malignant Hyperthermia"
UCLA Department of Anesthesiology, Educational Lecture Series for Stuart
Pharmaceutical Sales Representatives. August - October 1988
"Monitoring in
Anesthesia"; "Preoperative and Postoperative Assessment and the Ambulatory Surgery
Unit"
UCLA Post Anesthesia Care Unit, UCLA, August, 1988. "Malignant Hyperthermia"
Jules Stein Operating Room Nurses, December, 1989. "The Pharmacology of Alfentanil
and Its Applications to Ophthalmologic Anesthesia"
UCLA Surgery Center Perioperative Nurses, June - September, 1990. Lecture Series
entitled: "Continuing Education on Anesthesia Care for the OR Nurse", composed of 10
two to four hour lecture-discussion classes.
UCLA Surgery Center Operating Room Nurses, February, 1991. "Review of Commonly
Used Anesthetic Techniques and Drugs"
September, 1995; August 1996; February 1997 UCLA Perioperative Nurses,
"Preoperative Anesthesia Evaluation for the Perioperative Nurse"(24 hours lecture)
UCLA Surgery Center Operating Room Nurses, April 1996. "Monitoring and Sedating
Patients in the OR"
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UCLA Surgery Center Operating Room Nurses, Perioperative Evaluation Suite Nurses,
and Pheresis Unit Nurses, Fall, 1996. "Chemoprophylaxis for Occupational HIV
Exposure"
Association of Operating Room Nurses, San Fernando Valley Chapter, March 1997.
"HIV and AIDS - Implications for Perioperative Nursing Care"
UCLA Surgery Center Operating Room Nurses, March, 1997; April, 1997, May, 1997 
"Anesthesia Equipment, Cart, Drugs, and Machine - A Hands-on Workshop"
September, 1997 UCLA Perioperative Nurses, "Review of Preoperative Evaluation and
Conscious Sedation"
UCLA Surgery Center Operating Room Nurses, October, 1997 - "Review of Cardiac
Arrest Procedures and Crash Cart in the OR"
UCLA Surgery Center Operating Room Nurses, November, 1997 - "Malignant
Hyperthermia"
November, 1997 West Los Angeles Veteran's Administration Medical Center
Perioperative Nurses, "Update on HIV Epidemic and Chemoprophylaxis for
Occupational Exposure"; Educational Workshop Organizer and Coordinator.
UCLA Surgery Center Operating Room Nurses, March, 1998 - "Sedation and Airway
Management for OR Nurses"
March, 1998 UCLA Perioperative Nurses, "Conscious Sedation"
March, 1998 UCLA Perioperative Nurses, "Perioperative Assessment for Anesthesia
Care At UCLA Surgery Center"
Jules Stein Eye Institute Perioperative Nurses, Fall, 1998 - "Discharge Criteria for
General Anesthesia and Monitored Anesthetic Care Patients"
October, 1998 UCLA Perioperative Evaluation Suite Nurses, "Perioperative
Preanesthesia Evaluation for the Perioperative Nurse" (24hrs of lecture; proctored and
tutored Angela Jackson, RN, BSN in assisting with class instruction)
UCLA Surgery Center Operating Room Nurses, January, 1999 - "Local Anesthetics:
Clinical Use and Pharmacology; Treatment of Adverse Reactions"
UCLA Surgery Center Operating Room Nurses, March, 1999 - "Review and
Demonstration of Defibrillator/Pacemaker and Crash Cart"
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UCLA Surgery Center Operating Room Nurses, September, 1999 -"Review of
Anesthesia and Sedation Equipment and Drugs"
November, 1999 UCLA Ambulatory Surgery Center Anesthesia Technicians, "Part 1
Introduction to Theory and Practice of Anesthesia - An Overview"; continuing through
Nov 2000, 15 one-hour lectures
Dept of Anesthesiology, Kaiser Harbor City Medical Center, March, 2000 - "Implications
of HIV Disease to Peri operative Care"
Medical Procedures Unit Nurses, UCLA Medical Plaza, May, 2000 - "Pre-Sedation
Assessment"
Procedure and Treatment Unit Nurses, UCLA Operating Room, May, 2000 - "Review of
Pre- and Post-Anesthesia Assessment and Care"
UCLA Ambulatory Surgery Center OR Nurses, May, 2000 - "Review of Crash Cart and
Cardiac Arrest in OR"
PACU Nurses, UCLA Operating Room, July 2000 - "Review of Anesthesia Techniques
and Drugs"
UCLA Ambulatory Surgery Center PACU Nurses, November 2000 Management"

"Airway

PACU Nurses, UCLA Operating Room, November 2000 - "Preoperative Assessment 
Implications for Postoperative Care"
Procedure and Treatment Unit Nurses, UCLA Medical Center, November 2000 
"Implications of Pain Drugs and Antiemetic Drugs to Outpatient Treatment and
Discharge"
Jules Stein Eye Institute OR Nurses, May 2001, "HIV Chemoprophylaxis"
August, 2001 UCLA Peri operative Nurses, "Pre-anesthesia Evaluation"
Procedure and Treatment Unit Nurses, UCLA Medical Center, September 2001 
"Perioperative Geriatric Care"
June, 2002 UCLA Perioperative Nurses, "Preanesthesia Assessment"

192

September 2005 UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses,
"Coagulation Pathways and Implications for PACU Care"
October 2005 UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses,
"Principles of Outpatient Surgery Nursing Care"
November 2005 UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses,
"Propofol: Pharmacology and Anesthesia Use"
Jules Stein Perioperative Nurses, January 2006, "Intravenous Therapy"
February 2006 UCLA Main OR Nurses, "Conscious Sedation Part l"
Journal Club Leader, UCLA CRNA Group, March, 2006, "Complications of Ophthalmic
Regional Anesthesia"
April 2006 UCLA Procedure and Treatment Unit and Post-Anesthesia Care Unit Nurses,
"Ophthalmic Surgery Postop Care"
UCLA Healthcare Enterprise Westwood Perianesthesia Nurses, April 2006, "Phase 1
Care, Post Anesthesia Care Unit"
UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses, May, 2006,
"Outpatient PACU Care and Discharge Criteria"
May 2006, UCLA Westwood MOR Nurses, "Conscious Sedation Part 2"
June, 2006, UCLA Westwood MOR Nurses, "Conscious Sedation Part 3:
UCLA Jules Stein Eye Institute Perianesthesia Nurses, July, 2006, "Jules Stein PACU
Care"

UCLA Santa Monica Perianesthesia Nurses, August, 2006, "Hemodynamic Monitoring
Principles"
UCLA Westwood MOR Nurses, August, 2006, "Conscious Sedation, Part 4"
UCLA Medical Procedures Unit Nurses, September, 2006, "Sedation Patient Assessment
and Preparation"
UCLA Medical Procedures Unit Nurses, October 4, 2006, "Combining Sedatives"
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UCLA Radiology Services Nurses, October 20, 2006, "Pharmacology and Physiology of
Sedation"
UCLA Medical Procedures Unit Nurses, October 25, 2006, "Difficult Sedation"
UCLA Radiology Services Nurses, October 27, 2006, "NPO Status, Propofol, and
Emergency Sedation"
UCLA Medical Procedures Unit Nurses, November 1, 2006, "NPO Status, Propofol,
Assessment and Emergency Sedation"
UCLA Medical Procedures Unit Nurses, November 22, 2006,, "Obstructive Sleep Apnea
and Sedation"
UCLA Medical Procedures Unit Nurses, December 6, 2006, "Vasopressors, Reversal
Drugs and Sedation"
UCLA Emergency Department Nurses, April, 2007, "Sedation in the ER and ETC02
Monitoring"
Santa Monica UCLA Medical Center, ICU Nurses, May 21, May 27, July 3, August 28,
2007, "P ACU Care for the ICU RN"
Jules Stein Operating Room Nurses, June 2007, July 2007, "Pre-Anesthesia Evaluation"
UCLA Radiology Nurses, August, 2007, "Vasopressor Infusions"
Santa Monica UCLA Medical Center, OR/Procedure Unit Nurses, September 29, 2007,
"Moderate Sedation"
Jules Stein Perioperative Nurses, October, 2007, "Malignant Hyperthermia"
UCLA Radiology Nurses, November, 2007, "Avoiding Oversedation"
UCLA Radiology Nurses, February, 2008, "Treating Delirium During Sedation"
Western University, Pomona California, Nurse Practitioner Program, March 2008,
"Peri operative Stressors and Preoperative Preparation of the Patient by the Primary Care
Nurse Practitioner"
Santa Monica UCLA Medical Center, OR Unit Nurses, May, July 2008, "Basic
Conscious Sedation-Introduction; Part 2, Part 3"
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Jules Stein Perioperative Nurses, June, 2008, "Perioperative Cardiac Arrest and
Resuscitation"
Santa Monica UCLA Medical Center, OR Unit Nurses, August/September 2008,
"Arrhytlunia Interpretation", Parts 1 - 4, one-hour lectures
UCLA Ronald Reagan Medical Center, Emergency Department Nursing, October 2008,
December 2008, "Sedation in the Emergency Room"
Santa Monica UCLA Medical Center, OR Unit Nurses, Medical Procedures Unit Nurses,
October 2008, "Arrhytlunia Interpretation"
Santa Monica UCLA Medical Center, Medical Procedures Unit Nurses, December 2008,
"ECG Interpretation"
UCLA Ronald Reagan Medical Center, Ambulatory Nursing, March, 2009, "Pediatric
Sedation"
UCLA Ronald Reagan Medical Center, Ambulatory Nursing, March 2009, "Adult
Sedation"
Western University, Pomona California, Nurse Practitioner Program, March 2009,
"Peri operative Stressors and Preoperative Preparation of the Patient by the Primary Care
Nurse Practitioner"
UCLA Ronald Reagan Medical Center, Emergency Department Nursing, May, 2009,
"Pediatric Sedation"
UCLA Ronald Reagan Medical Center, Radiology-Cardiac Catheterization Nurse Group,
July, August, 2009, "Adult Sedation"
Jules Stein Eye
H yperthermia"

Institute,

OR Nursing

Group,

September 2009,

"Malignant

Santa Monica/UCLA PACU Nurses, January, 2010 "PACU Phase 1and2"
UCLA Ambulatory Surgery Center, OR Nurse Group, July, 2010, "Update on Anesthesia
Drugs, Techniques, and SCIP Requirements"
California Student Nurse Association, "Nurse Anesthesia as an Advanced Nursing Career
Choice", October, 2010
UCLA Medical Procedures Unit RNs, "Adult Sedation", January, 2011
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Research Activities
1. Thesis Research Project: "The Effects of Naloxone on the Exercise Hyperpnea".
Human laboratory study.
2. Independent Research: "The Use of Alfentanil in Outpatient Ophthalmologic
Surgery": a clinical investigation of the use of the short-acting narcotic alfentanil in 26
patients for monitored anesthetic care at the Jules Stein Eye Institute, UCLA Medical
Center, May-August, 1989.
3. Doctoral Dissertation Research Project: "The Effect of Pain on Leukocyte Cellular
Adhesion Molecules" (human subjects). UCLA IRB Approval January 05, 2004.
Dissertation Defense 12-02-05.
Grant Support:
UCLA School of Nursing, Intramural Grant Award, $10,000, January,
2004
UCLA General Clinical Research Center, NIH/NCRR Grant #M01RR00865,
$10,000, January 2004-August 2005
American Association of Nurse Anesthetists Research Foundation General
Research Grant, $13,625, March 2004 - August 2005
4. Post-doctoral Research Project, begins 08-04-06, UCLA General Clinical Research
Center
Grant Support: National Institute of Nursing Research, "The Effect of Pain on
Leukocyte CAMs", Grant #1 R0-3 NR009106-01Al, August 2005
UCLA General Clinical Research Center, NIH/NCRR Grant, #M01RR00865,
April 2006
American Association of Nurse Anesthetists Research Foundation, Post-doctoral
Fellowship Grant, May, 2006
5. Research Rotation for USC Program of Nurse Anesthesia students, practicum portion
of ANST 512, Research Integration: Capstone Experience. Students attended 3 hours of
theory lecture on research methodology and project theoretical framework; assisted with
data collection and entry; chose a topic related to project and wrote a review paper, Sept
2007-May 2008.
6. Intramural Grant Award, UCLA Claude D. Pepper Older Americans Independence
Center,
$10,000. December 22, 2008 - June 30, 2009. Project Title: "Nuclear Factor Kappa-B
Activation and Pain.
7. American Association of Nurse Anesthetists "State of the Science" Poster and Oral
Session August 2009, "The effect of pain on leukocyte cellular adhesion molecules and
inflammatory mediators".
8. National Institutes of Health, Grant # 1 R21 DA027558-0l, "Pain Opioids and Pro
Inflammatory Immune Responses", September, 2010. Co-Investigator.
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9. General Research Grant, American Association of Nurse Anesthetists Foundation,
"Pain Opioids and Pro-Inflammatory Immune Responses", January, 2011. Co
Investigator.
10. American Association of Nurse Anesthetists "State of the Science" Poster and Oral
Session August 2012, "Acute painful stress and inflammatory mediator production."

Publications
RESEARCH PAPERS

1. Thesis - "The Effects ofNaloxone on the Exercise Hyperpnea"
Program of Anesthesiology for Registered Nurses
Department of Anesthesiology, School of Medicine
University of California at Los Angeles
Los Angeles, CA
2. Griffis, C.A., S.A. Ward and R.D. Kaufman. "Naloxone and the ventilatory
European Journal of Applied
response
to exercise in man."
Physiology 55: 624-629, 1986.
3. Griffis, C.A. "Monitored anesthetic care for outpatient cataract surgery with
alfentanil" Nurse Anesthesia 1(2): 71-78, 1990.
4. Dissertation. Griffis, C. "The effect of pain on proinflammatory cytokines and
leukocyte cellular adhesion molecules"
School of Nursing, Graduate Division
University of California at Los Angeles
Los Angeles, California
December 05, 2005
5. Griffis, C., Irwin, M.R., Martinez, 0., Doering, L., Nyamathi, A., Kaufman,
R.D., Elashoff, D., Aziz, N., Compton, P. "Pain-related activation of leukocyte
cellular adhesion molecules: preliminary findings". Neuroimmunomodulation 14:
224-228, 2007.
6. Griffis, C., et al., "Acute painful stress and inflammatory mediator production".
Submitted 91512012.
BOOKS
BOOK CHAPTERS
Elisha, S.M. (ed.), Case Studies in Anesthesia, "Ruptured Globe", author C.Griffis & E.
McCall, Jones & Bartlett: Sudbury, MA, 2010, pp. 373-382.
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Joyce, J. & Oullette, R. (ed. 's), Pharmacology for the Nurse Anesthetist, "Implications of
the Immune System to Pain", author C. Griffis, Jones & Bartlett: Sudbury, MA, 2011, pp.
437-444
REVIEW ARTICLES
Griffis, C.A. "Anesthetic implications ofvasovagal syncope", CANA Newsbulletin 40(1):
5-10, October, 1985.
Griffis, C.A. "Anesthetic implications of essential hypertension", CANA Newsbulletin
41(1): 10 - 17, October, 1986.
Griffis, C.A. "The future of nurse anesthesia education: curricular design, purpose and
evaluation" CRNAForum 2(4): 11-12, 1986.
Griffis, C.A. "End-tidal C02 Monitoring", AANA Journal 54( 4): 312 - 318, 1986.
Griffis, C.A., Gerbasi, R., Samph, T., Stoll, D. "The impact of present day trends in
testing on the certification process for nurse anesthetists" AANA Journal 55(3): 198-201,
1987.
Griffis, CA., Kelley, J. "The future of nurse anesthesia education", CANA Newsbulletin
41(2): 20-21, 1987.
Griffis, C.A. "Nurse Anesthesia: An Awakening Specialty" California Nursing Review
10(2): 32 - 35, 1988.
Griffis, C.A.
"Implications of recent antiviral pharmacology to prevention of
occupational HIV transmission in anesthesia clinical practice"AANA Journal 64(6): 525
527, 1996.
Griffis, C.A. "Anesthetic Implications of Human Immunodeficiency Virus" Nurse
Anesthetist Forum 1(3): 3,11-12, 1998.
Griffis, C.A. "Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
related drug therapy: anesthetic implications. CRNA The Clinical Forum for Nurse
Anesthetists 10(3): 107-116, 1999.
Griffis, C.A. "Prevention of occupational transmission of bloodborne diseases in nurse
anesthesia practice" CRNA The Clinical Forum for Nurse Anesthetists 11(1): 2-7, 2000.
Griffis, C., Compton, M., Doering, L. "The effect of pain on leukocyte cellular adhesion
molecules". Biological Research for Nursing, 7(4): 297-312, 2006.
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Griffis, C., Page, G., Kremer, M., Yermal, S. "Implications of immune function to
anesthesia care". American Association ofNurse Anesthetists Journal, 76(6): 449-454,
2008.
Griffis, C. "Neuroimmune activation and chronic pain". American Association ofNurse
Anesthetists Journal, 79 (1):31-37, 2011.

CASE REPORTS
Griffis, C.A. "Case Report--Management of examination under anesthesia and
electroretinogram in a child with degenerative neurological disease", CANA Newsbulletin
Flowmeter Column 43(3), 1989
Griffis, C.A. "Case Report--Use of retrobulbar block during general anesthesia", CANA
Newsbulletin Flowmeter Column 44(2), 1990.
Rochin, M., Griffis, C., Kaufman, R. "The development of Mobitz 1 heart block under
general anesthesia following chronic beta-adrenergic receptor antagonism", CANA
Newsbulletin Flowmeter Column 44(3): 18-21, 1990.
Griffis, C., Austin, J., Ritter, J. "The use of propofol and nitrous oxide for inguinal hernia
repair" CANA Newsbulletin Flowmeter Column 45(1), 1990.
Griffis, C.A. "The effect of intraoperative retrobulbar block on anesthetic management of
enucleation under general anesthesia" Nurse Anesthesia 2(1): 28-32, 1991.
Griffis, C. "Acute postoperative pain management and malfunctioning epidural catheter"
Oncology Nursing Forum 30(2): 217-218, 2003.

LETTERS TO THE EDITOR
Griffis, C. "Expert witness testimony and CRNA practice". AANA Journal 72(5): 334,
2004.
EDITORIALS
Griffis, C. "The Flowmeter", an educational column originated and written by C. Griffis
in the California Association ofNurse Anesthetists Newsbulletin:
"Review of research methods and statistical analysis for the mystified and/or totally
disinterested" CANA New sbulleti n Flowmeter Column 41 (4), 1987
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"Isoflurane: an emergmg controversy" CANA Newsbulletin Flowmeter Column 42(1),
1988
"Review of the Harvard Standards for Patient Monitoring: implications for practice"
CANA Newsbulletin Flowmeter Column 42(3), 1988.
"The uses of lidocaine in anesthesia" CANA Newsbulletin Flowmeter Column 42( 4), 1988
"Clinical implications of respiratory physiology" CANA Newsbulletin Flow meter Column
43(2), 1989
"Cranial Nerve anatomy and physiology-clinical implications for the nurse anesthetist"
CANA Newsbulletin Flowmeter Column 44(1), 1989.
"Review of recent anesthesia-related incidents with medico-legal implications" CANA
Newsbulletin Flowmeter Column 45(1), 1990.
"HIV and AIDS--An update on the pandemic and some implications for anesthesia
providers" CANA Newsbulletin Flowmeter Column 50(2): 24-29, February, 1996.
"HIV and AIDS Part 2--New Drugs and Exposure Prophylaxis" CANA Newsbulletin
Flowmeter Column 51(1): 25-25, October, 1996.
"Pain and Leukocyte Cellular Adhesion Molecules: My Research Journey" AANA
Newsbulletin, Foundation and Research News 63( 4): 36, April 2009.

BOOK REVIEWS
Griffis, C.A. Book review of Regional Anesthesia: An Illustrated Procedural Guide by
Michael Mulroy, M.D. Boston: Little, Brown and Co., 1989, pp 1-289; appearing
in Nurse Anesthesia, 1(4): 231-236, 1990.
ABSTRACTS
1. Griffis, C.A., S.A. Ward and R.D. Kaufman "The influence of the endogenous
opiate system on the control of the exercise hyperpnea in man" Fed Proc 43(3):
634, 1984.

2. Griffis, C.A. "The exercise hyperpnea and the endorphin system: Abstracts of
the 5Jrst Annual Meeting of the American Association of Nurse Anesthetists,
August, 1984.
3. Griffis, C.A. "End-tidal C02 monitoring" Abstracts of the 52nd Annual
Meeting ofthe American Association ofNurse Anesthetists, 1985.
4. Griffis, C.A. "Monitored anesthesia care for surgery with propofol and
alfentanil" Poster Session Abstracts of the AANA Education and Research
Foundation, 57th Annual Meeting of the American Association of Nurse
Anesthetists, August, 1990.
200

5. Griffis, C.A. "Use of propofol/alfentanil bolus and infusion for anesthesia
care" Summaries ofProfessional Sessions, 6dh Annual Meeting of the American
Association ofNurse Anesthetists, August, 1993.
6. Griffis, C.A. "Perioperative management: anesthesia for the ambulatory
patient" Summaries of Professional Sessions, 64th Annual Meeting of the
American Association ofNurse Anesthetists, August, 1997.
7. Griffis, C.A. "Risk management in the ambulatory setting" Summaries of
Professional Sessions, 64th Annual Meeting ofthe American Association ofNurse
Anesthetists, August, 1997.
8. Griffis, C.A. "HIV/AIDS drugs: anesthesia implications" Summaries of
Professional Sessions. 65th Annual Meeting of the American Association of
Nurse Anesthetists, August, 1998.
9. Griffis, C. & Compton, P. "The effect of pain on cellular adhesion molecules"
Communicating Nursing Research Conference Proceedings. Western Institute of
Nursing Assembly, April, 2004.
10. Griffis, C., Compton, M., Irwin, M.R., Kaufman, R. "The effect of pain on
leukocyte cellular adhesion molecule expression" AANA Journal, 74(6): 468,
2006.
11. Griffis, C., Compton, M., Irwin, M. "The effect of pain on leukocyte cellular
adhesion molecules and inflammatory mediators" AANA Journal, 77(5):384,
2009.
12. Griffis, C., Breen, E., Irwin, M., Compton, M. "Acute painful stress and
inflammatory mediator production." AANA Annual Meeting 2012 Research
Abstracts, 2012.
C. Other Publications
'I. Griffis, C.A. Book review of Regional Anesthesia: An Illustrated Procedural
Guide by Michael Mulroy, M.D. Boston: Little, Brown and Co., 1989, pp 1-289;
appearing in Nurse Anesthesia, 1(4): 231-236, 1990.

Teaching
A. Classroom Instruction
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March 1983; 1984 UCLA Program of Nurse Anesthesia, "Anesthesia for Vascular and
Thoracic Surgery"
March 1983, 1984 UCLA Program of Nurse Anesthesia, "Anesthesia for Cardiac
Surgery"
October, 1983 UCLA Program of Nurse Anesthesia, "Anesthesia for the Asthmatic
Patient"
Fall, Spring, 1984, 85, 87 UCLA Program of Nurse Anesthesia, Lecture Series, Anes
220A, B, C
"Clinical Applications of Respiratory Physiology: (1 )Gas Transport (2)
Mechanics of Ventilation (3) Pulmonary Gas Exchange (4) Control of Ventilation",
Course Coordinator
Fall, 1984 UCLA Program of Nurse Anesthesia, Anes 221 "Overview of Cardiovascular
and Respiratory Physiology", Course Coordinator
Fall, Spring, 1985 UCLA Program of Nurse Anesthesia, Anes 221 "Clinical Applications
of Cardiovascular Physiology:
Anesthesia for the Patient (1) With Hypertension (2)
With Coronary Artery Disease (3) Anesthesia for the Patient in Shock"; Course
Coordinator
Fall 1985-87 UCLA Program of Nurse Anesthesia, "Orientation and Overview of Nurse
Anesthesia"
Fall 1986-87 UCLA Program of Nurse Anesthesia, "Review of Research Methods: (1)
Experimental Design (2) Statistics Review
Fall 1987-91 UCLA Program of Nurse Anesthesia, "Chemistry and Physics Review: (1)
States of Matter (2) Gas Laws (3) Fluids and Flows (4) Vaporization" (Course
coordinator for this lecture series)
Winter, 1989 UCLA Program of Nurse Anesthesia, "Overview of Pharmacology"
Winter, 1989 UCLA Program of Nurse Anesthesia, "Clinical Applications of Respiratory
Mechanics"
Spring, 1989-96 UCLA Program of Nurse Anesthesia, "Anesthesia for Ophthalmologic
Surgery"
Fall 1989-91 UCLA Program of Nurse Anesthesia, "Clinical Applications of Chemistry
to Nurse Anesthesia Practice: (1) General Chemistry (2) Pharmacology and Chemistry
(3) Organic Chemistry (4) Biochemistry" (Course coordinator for this lecture series)
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Winter, 1991-96 UCLA Program of Nurse Anesthesia, "Anesthesia for Outpatient
Surgery"
Fall, 1996 University of Southern California Program of Nurse Anesthesia, "Anesthesia
for Ophthalmologic Surgery"
July, 1997 Kaiser Permanente School of Nurse Anesthesia, Los Angeles, "Anesthesia for
the Patient With HIV Disease and Chemoprophylaxis for Occupational Exposure to HIV"
September, 1997 University of Southern California Program of Nurse Anesthesia,
"Anesthesia, Universal Precautions, and Infectious Diseases"
March 1998 Kaiser School of Nurse Anesthesia, Los Angeles,
"Care of the Patient with HIV/AIDS"
May, 1998 Kaiser School of Nurse Anesthesia, Los Angeles,
"Anesthesia for Off-site Cases"
September, 1998 USC Program of Nurse Anesthesia, Los Angeles,
"Implications of Asepsis and Infectious Disease Control to Anesthesia Practice"
November, 1999 USC Program of Nurse Anesthesia and Kaiser School of Nurse
Anesthesia, Los Angeles. "Implications of Asepsis and Infectious Disease Control to
Anesthesia Practice"
November, 2000-2005 University of Southern California and Kaiser Permanente
Programs of Nurse Anesthesia (combined), "Asepsis and Infectious Diseases 
Implications for Anesthesia Care"
January, 2003, 2004, 2005, 2006, 2007, 2008, 2009 UCLA School of Nursing, Nursing
230, Pathophysiology-"Introduction to the Immune System"
January 2004, UCLA School of Nursing, Nursing 264-Roles of the Advanced Practice
Nurse, "Issues in Nurse Anesthesia Practice"
April, 2004, Kaiser Permanente Program of Nurse Anesthesia, "Outpatient Anesthesia"
January 2005, UCLA School of Nursing, Nursing 264-Roles of the Advanced Practice
Nurse, "Issues in Nurse Anesthesia Practice"
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UCLA School of Nursing, Nursing 239- Nurse Practitioner Professional Practice,
Prescribing Schedule II Medications, January 2005, "Pain and Addiction
Neurophysiology, Mechanism of Opioid Effects"
April, 2005; April, 2006; June 2007; April 2008; April 2009 UCLA School of Nursing,
N206 Theory Development, "Development of My Theory into My Research Project"
January 2006, UCLA School of Nursing, Nursing 264-Roles of the Advanced Practice
Nurse, "Issues in Nurse Anesthesia Practice"
January 2006, 2007 UCLA School of Nursing, Nursing 239- Nurse Practitioner
Professional Practice, Prescribing Schedule II Medications, "Pain and Addiction
Neurophysiology, Mechanism of Opioid Effects"
September 2006, 2007, 2008, 2009, 2010 Kaiser Permanente School of Nurse Anesthesia,
"Principles of Asepsis and Prevention of Occupational Exposure to Infectious Diseases"
UCLA School of Nursing, Nursing 242-Nurse Practitioner Professional Practice,
Prescribing Schedule II Medications, January, 2007, "Pain and Addiction
Neurophysiology, Mechanism of Opioid Effects"
Kaiser Permanente School of Nurse Anesthesia, February 2007, February 2008, February
2009, March 2010 "Anesthesia for Off-Site Cases"
UCLA School of Nursing, Nursing 230, Pathophysiology, March, 2007, "Immune
System, Stress, and Psychoneuroimmunology"
USC Program of Nurse Anesthesia, Anst 503-Advanced Pharmacology, April 2007,
April 2008, April 2009; April 2010 "Anesthesia, Stress and Immune System Responses"
UCLA School of Nursing, Nursing 242-Nurse Practitioner Program, July 2007,
"Introduction to Psychoneuroimmunology"
UCLA School of Nursing, Nursing 262-MECN Program, August, 2007, "Overview of
Perioperative Nursing Care of the Patient for Surgery"
UCLA School of Nursing, Nursing 262-MECN Program, August, 2008, "Overview of
Perioperative Nursing Care of the Patient for Surgery"
Kaiser Permanente School of Nurse Anesthesia, Junior Class, November, 2008,
"Principles of Asepsis and Occupational Disease Prevention in Nurse Anesthesia
Practice"
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Kaiser Permanente School of Nurse Anesthesia, Junior Class, January 2009, March, 2010
"Anesthesia for Ophthalmology"
Kaiser Permanente School of Nurse Anesthesia, Junior Class, January 2009, "Anesthesia
for Bariatric Surgery"
Kaiser Permanente School of Nurse Anesthesia, Junior Class, March 2009, March, 2010
"Off-site Out of OR Anesthesia"
UCLA School of Nursing, N206, Doctoral Students, March 2009, "Theory Development
and the Dissertation Process"
UCLA School of Nursing, Nl62, Bachelor of Science Students April 2009, "The
Perioperative Nursing Process"
USC Program of Nurse Anesthesia, Junior Class, June 2009 , "Nociceptive and Chronic
Pain, Opioid Physiology, Tolerance and Neuroimmune Activation"
Samuel Merritt Certified Registered Nurse Anesthetist Program, Junior Class, August
2009, "Nociceptive and Chronic Pain, Opioid Physiology,Tolerance and Neuroimmune
Activation"
David Geffen School of Medicine at UCLA, Doctoring 3, Lecturing Faculty, September
2009 - May 2010
UCLA School of Nursing, N206, Doctoral Students, March 2010, "Theory Development
and the Dissertation Process"
UCLA School of Nursing, N270, MECN Students, January, 2011, "Ventilator
Management"

B. Clinical Instruction

1. 1981-1989: supervision and teaching of nurse anesthetist students for the UCLA
Program of Nurse Anesthesia at UCLA Medical Center Operating Rooms.
2. 1992 - 97: supervision and teaching of nurse anesthetist students (UCLA Program of
Nurse Anesthesia, now known as the University of Southern California Program of Nurse
Anesthesia) and medical students (UCLA School of Medicine) rotating through
Anesthesia Department, West Los Angeles Veterans Administration Medical Center, Los
Angeles.
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3. Simulation Laboratory: May 2004; May 2005; May 2006, May 2007; May 2008; May
2009; May 2010. UCLA School of Nursing, N439A Clinical Laboratory Series Acute
Care Nurse Practitioner students "Lumbar Puncture Workshop"
4. February 2005-0ctober 2005: Clinical Coordinator of UCLA nurse anesthetist
student rotation. Supervision of junior and senior nurse anesthetist students from Kaiser
School of Nurse Anesthesia during clinical anesthesia administration.
5. October 2005-Present: Senior consultant to clinical coordinators. Supervised and
instructed medical students and nurse anesthetist students from the Kaiser and USC
Programs of Nurse Anesthesia in the UCLA Operating Rooms.
6. April, 2006: supervised and instructed Jules Stein perioperative nurses in insertion of
intravenous catheters
7. Fall, 2007-2008: arranged and supervised Master's Entry-Level Clinical Nurse UCLA
School of Nursing students in OR visits for observational experiences (Dahianna Lopez
[dahianna@ucla.edu];
Evan
Jacobson;
Susan
Chapdelain;
Miriam
Wesley[mirmir37@ucla.edu]; April Bautista [aprill85@aol.com])
8. Simulation Laboratory: April & May 2009; March 2010. Supervision and instruction
of nurse anesthetist students in the Kaiser Program of Nurse Anesthesia Simulation
Training Facility
C. Mentoring
Certified Registered Nurse Anesthetists
1. Sarah Rozycki, CRNA, MSN: mentored for first conference presentation, January,
2008; mentored to supervise nursing student on observational rotation in the Department
of Anesthesiology, April 2008; mentored participation in second conference presentation
February 2009.
2. Erica Zima, CRNA, MSN: mentored for curriculum vitae preparation (2008); co
authorship of book chapter (2008); leadership guidance (2007-2009)
Registered Nurses
1. Bert B. Mekpongsatorn (bmekpongsatorn@mednet.ucla.edu), RN, BSN: 4/08
arranged supervised OR visit, counseled about nurse anesthetist school
Research Assistants
1. Fall 2007: trained 4 research assistants (AJ Freeman [d.free.06@gmail.com], DM
Verkade[dmverkade@mac.com], L Guerrero [lance.guerrero@gmail.com], and A Keyes
[annkeyesrn@yahoo.com]) to participate in post-doctoral project; also mentored these
RNs in their consideration of and application to schools of nurse anesthesia.
2. Summer, 2008: trained 2 research assistants (John Scott [jascott@mednet.ucla.edu];
Gregory Zweigle [gvbz@yahoo.com]) to participate in post-doctoral project; also
mentored for preparation to apply and attend school of nurse anesthesia.
Nursing Doctorate Students
1. Samira Moughrabi (smoughrabi@gmailcom), UCLA School of Nursing: consulted
and counseled on operationalization of doctoral study 4/22/08
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2. Julia Lassegard (roadrunl@sbcglobal.net) UCLA School of Nursing: consulted and
counseled on degree options, progress, and preparation for written qualifying
examination 3/08-6/08.
February 2009: Ms. Lassegard will participate in my research project "NFKappa
B and Pain" as a research assistant, and as part of Nursing 299 in the UCLA School of
Nursing Doctoral Program; I will supervise, train, and mentor her.

Committee Service (UCLA)
Department of Anesthesiology Committees
1. Program of Nurse Anesthesia, Curriculum Committee (Member)
1982-86.
2. Program of Nurse Anesthesia, Student Evaluation Committee (Member)
1981-1993.
3. Program of Nurse Anesthesia Program Advisory Committee (Chair) 1985-87
Program Evaluation Committee (Chair) 1985 - 87
4. Quality Assurance Committee (Visiting Member) 1997, 1998, 1999;
Full
Member 2000-2001
5. Task Force Perianesthesia Nursing Cross-training Project, UCLA Medical
Enterprise, Chairman, March 2006-Present
UCLA Medical Center
UCLA Committee on Interdisciplinary Practice (Member) 1985-87
Sedation Committee (Member) 2007-Present; (designated as Sedation Committee
Educator)
Research Thesis Committees, UCLA Graduate Division
1. Passani, C. Topic: Characteristics of Best Clinical Instructors, Thesis
approved, 1985.
2. Brown, D. Topic: The Effect of Lidocaine on Reflex
Bronchoconstriction, (Member August 1985-March 1987)
3. Grogan, D. Topic: Cardiovascular Interactions of Lidocaine and
Diltiazem Under Isoflurane Anesthesia, (Member) Thesis approved, 1986.
Committee Service Professional Societies
California Association of Nurse Anesthetists (CANA)
Program Committee (Member) 1984-85
Nominating Committee (Chairman) 1985-86
Public Relations Committee (Member) 1985-86
Government Relations Committee (Member) 1985-86; 90-92
Co-chairman, CANA Annual Meeting, May, 1986
CANA - CSA Liaison Committee (Member), 1986-87
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Founder, editor, and contributor continuing education column, "The
Flowmeter", CANA Newsbulletin 1987-97
Member, Peer Review Committee, 1988-89-90
Representative to California Board of Registered Nursing, 2008-2009
Board of Directors, Trustee (elected), 2009-Present
Bylaws Committee Chairman 2009-Present
Council on Certification of Nurse Anesthetists (National)
Member, 1986-87
Examination Committee (Chairman) 1987
Examination Committee (Member) 2007-2008-2009
National Board of Certification and Recertification of Nurse Anesthetists
Staff, Item Writer's Workshop, San Antonio, February, 2010
Examination Committee (Chairman) March, 2010-Feb, 2012

American Association of Nurse Anesthetists (AANA)
AANA Journal, Editorial Advisory Board, 1992-94; 2009-2012
Infection Control Taskforce, Chairman, 2009-present
AANA Foundation
Research Committee, 2009-present

Kaiser Permanente School of Nurse Anesthesia
Admissions Committee, February 2008
Admissions Committee, February 2009
Admissions Committee, February 2011
University of Southern California, Program of Nurse Anesthesia
Admissions Committee, March, 2009; March 2011
Honors and Awards
Phi Theta Kappa National Honor Fraternity (April 1970)
"Who's Who Among Students in American Junior Colleges",
Hillsborough Community College, Tampa, Florida (1973-74)
Phi Kappa Phi Honor Society, University of South Florida (April 1973)
Pi Lamba Theta National Honor and Professional Association in Education, UCLA
Graduate School of Education, 1986

"Who's Who in Professional Nursing" (1985-86)
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Best Didactic Instructor Award, UCLA Program of Nurse Anesthesia, 1988
Distinguished Faculty Award for academic and clinical excellence in nurse
anesthesia education, UCLA/LAC/Oliveview Program of Nurse Anesthesia, 1994
UCLA Department of Anesthesiology, UCLA School of Medicine, Incentive
Award Program, Team Award "For his many contributions to the Department
July 1, 1996, to June 30, 1997.
UCLA Department of Anesthesiology, UCLA School of Medicine,
Certificate of Achievement "For outstanding achievement in
Department of Anesthesiology" for the year of 1998, 1999.
UCLA Graduate Division Unrestricted Fellowship Award, 2001-2002 academic
year
Sigma Theta Tau International Honor Society of Nursing, Gamma Tau Chapter,
2003
Outstanding Research Presentation Award, "The Effect of Pain on Cellular
Adhesion Molecules", Nursing Research Symposium, UCLA School of Nursing,
March 2005
American Association of Nurse Anesthetists Research Foundation, Post-doctoral
Fellowship Award, August 2006
UCLA Medical Enterprise Employee Incentive Award, June, 2008
University of Southern California, Program of Nurse Anesthesia, Keynote
Commencement Speech, August, 2009
AAN A Foundation John F. Garde Researcher of the Year Award, 2010
Community Service
UCLA Health Fair Expo, volunteer in producing, 1985-86
AIDS Project Los Angeles: Completing of 52-hour training course for telephone
Hotline service in biology and pharmacology of HIV infection and treatment, and
in therapeutic communication techniques. Served as Hotline phone volunteer
from 1991-97
Assistant volunteer instructor for AIDS Hotline training course, Fall, 1992.
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California AIDS Ride (one week long bicycle non-profit event):
registered nurse in camp, 1995-96-97

volunteer
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Curriculum Vitae
Dr. Joseph F. Burkard, DNSc, CRNA
CDR(ret), NC, USN
Updated: 4 June 2012
Business Address:

Hahn School of Nursing
University of San Diego
5998 Alacala Park
San Diego, CA 92110-2492

Home Address:

Telephone:

Mobile:
Office:
Home:
e-mail:
e-Mail:
e-mail:

Present Position:

Associate Professor, University of San Diego DNP I PhD Program,
Clinical Researcher I Clinician University of California, San Diego

Immediate Past:

Clinical Coordinator I Department Head, NNCAP, San Diego
Clinical Research Director Naval School of Health Sciences
Vice-Chairman, Institutional Review Board
Program Director, Advanced Cardiac Life Support
Naval School of Health Sciences
34101 Farrenholdt Drive.
San Diego, CA 92134
Didactic Instructor,
Kaiser Permanente School of Nurse Anesthesia
100 South Los Robles Street
Pasadena, CA 91188
Assistant Professor, School of Nursing, Georgetown University
Medical Center: November 2005-2009
Assistant Professor in Nursing, Nurse Anesthesia Program,
Uniformed Services University of the Health Sciences: November
2005-2010

Nurse Anesthesia Scope I Responsibility I Function: Anesthetic management of patients to
be rendered unconscious or insensitive to pain and emotional stress during surgical,
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obstetrical, dental and certain medical procedures, including preoperative, intraoperative,
and postoperative monitoring, evaluation and treatment.
Professional Experience

October 2011-Present
February 2010-Present
August 2010-2011

Jonas Foundation Military Merit Fellow
Visiting Health Policy Professor Samuel
Merritt University, Oakland, CA
Fellow AACN "Leadership for Academic
Nursing Program"

January 2006-2008

Member, Council on Accreditation, American
Association of Nurse Anesthetists

October 2005-2007

Member, Public Relations Committee,
American Association of Nurse Anesthetists

October 2005-2008

Vice-Chair, Institutional Review Board,
Naval Medical Center, San Diego, CA

October 2004-2008

Chairman, Advanced Life Support I
Simulation Systems, Naval Medical Center,
San Diego, CA

August 2000-0ctober 2004

President, Board of Directors California
Association of Nurse Anesthetists
Practice Chair, Public Relations Committee

August 2000- May 2003

Clinical Instructor
Navy Nurse Corp Anesthesia Program
Naval School of Health Sciences
San Diego, CA 92134

January 1999- August 2000

Staff Nurse Anesthetist
Adjunct Clinical Instructor
Naval Medical Center
San Diego, CA

January 1997- 1999

Staff Nurse Anesthetist
Fleet Surgical Team Nine
USS BOXER LHD-4
Phibron Seven, USS BOXER
FPO AP 96601-5806

October 1994 - January 1997

Staff Nurse Anesthetist
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U.S. Naval Hospital
USS INDEPENDENCE CV-62
Yokosuka, Japan
August 1992 - September 1994

U.S. Navy Nurse Anesthesia Program
NSHS Bethesda, MD
George Washington University
NH San Diego, CA

January 1991 - July 1992

Staff Nurse, ICU
NH Camp Pendleton, CA
Clinical Instructor, ICU, PACU

August 1989 - December 1990

Staff Nurse, Med I Surg unit
NH Camp Pendleton, CA

August 1986 - May 1989

BSNProgram
Fairfax, Virginia
George Mason University

January 1986 - July 1986

Supervisor I Head, Lab Department
CVN-71
USS THEODORE ROOSEVELT
Norfolk, Virginia

October 1983 - December 1985

Medical Lab Tech, Research Assistant
Point Loma, CA
Naval Health Research Center

February 1977 - October 1983

Hospital Corpsman, EMT, Paramedic, Work
Center Supervisor
Various commands
Educational Experience

August 2010-2011

Fellow AACN "Leadership for Academic
Nursing Program"

July 2001- December 2003

DNSc Program- Acute Care/ Critical Care
Nursing, University of Tennessee

Dissertation: Bispectral Analysis and Motor Activity Assessment Scores in
Mechanically Ventilated Patients in the Intensive Care Unit.
August 1992 - September 1994

MS in Health Sciences (Nurse Anesthesia)
George Washington University
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August 1986 - May 1989

BSN
George Mason University
Fairfax, Virginia

January 1984 - January 1986

AA Medical Laboratory
Technology
George Washington University

Certifications
Basic Cardiac Life Support Provider (BCLS)
Basic Cardiac Life Support Instructor (BCLS-I)
Advanced Cardiac Life Support Provider (ACLS-P)
Advanced Cardiac Life Support Instructor (ACLS-I)
Director, Advanced Cardiac Life Support
Advanced Cardiac Life Support Affiliate Faculty I Program Director
Pediatric Advanced Life Support Provider (PALS-P)
Pediatric Advanced Life Support Instructor (PALS-I)
Neonatal Advanced Life Support Provider (NALS-I)
Certified Registered Nurse Anesthetist (CRNA)
Critical Care Registered Nurse (CCRN) Inactive
Medical Laboratory Technician (MLT) Inactive
Cooper Institute Health Promotion Director
Professional Membership
American Association of Nurse Anesthetists (AANA)
California Association of Nurse Anesthetists (CANA)
American Association of Critical Care Nurses (AACN)
Member Sigma Theta Tau 1989-Present

Professional Honors I Committees
October 2011 Faculty Appointment Jonas Foundation Military Merit Fellow
August 2011 Faculty Appointment Uniformed Services University of the Health Sciences
2011-Present
July 2011 Western Institute of Nursing Abstract Reviewer
2011 JOPANMary Hana Memorial Journalism Award
USD Senate 2009-Present
USD School of Nursing IRB Representative 2010-Present
Western Institute of Nursing Poster Committee 2011-Present
Fellow, AACN 2010-2011
2009 RADM Mary F. Hall Nursing Publication Award
Council on Accreditation, AANA 2006-2008
Public Relations Committee, AANA 2005-2008
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President, California Association of Nurse Anesthetists, 2002-4
Board of Directors, California Association of Nurse Anesthetists 2000-2004
Golden Key National Honor Society
Surface Warfare Medical Department Officer
Class of2000 Instructor of the Year, Navy Anesthesia Program
Class of2002 Instructor of the Year, Kaiser Permanente School of Nurse Anesthesia
Professional Grants
Burkard, J.F., Skerrett, K, Terry, M.J. (2012, June). Resi.liency Education Program/or
Physi.cians, Advanced Practice Nurses and Therapists: Treating the Wounded
Warrior and their Families. The Sence Foundation Grant submitted 1 June 2012
for the amount of $62,044
Bopp, E.J, Burkard, J.F., Spence, D., Hazen, A.L. (2012, May). Is Combat Exposure
Predictive ofHigher Preoperative Stress in Military Members. TSNRP Graduate
Level grant submitted 30 May 2012 for the amount of$14,004.
Burkard, J.F., Nolan, S. (2012, March). NIH Pain Consortium Centers ofExcellence in Pain
Education (CoEPS) Grant NIH Grant proposed 3 March 2012 for a 3-year plan
for the amount of 275,000.
Burkard, J.F., (2011, December). USD !Pad Classroom Project Proposal. Grant proposal
presented to incorporate iPad technology into the classroom. Faculty Grant
proposed 15 December 2011 for 45 iPads and faculty support for the amount of
20,000.
Burkard, J.F., (2010, February). Will the inclusion ofa PONV-PD NV risk assessment tool
improve PONV measureable outcomes? Grant proposal presented at the ASU
Research Intensive Workshop. Arizona.
Burkard, J.F., (2010, November). Perioperative Outcomes? Faculty grant funded 17
November 2010 for the amount of 4,000.
Burkard, J.F., (2010, April). Will the inclusion of a PONV-PDNV risk assessment tool
improve PONV measureable outcomes? Grant proposal submitted to UCSD
"Innovations in Patient Safety & Quality Improvement". San Diego, California.
(Ongoing) 20,000.
Burkard, J.F., (2009, December). Emergence Delirium in the Combat Veteran. Faculty
grant funded 1 Decem her 2009 for the amount of 3,000.

Professional Papers/Abstracts/Poster/Book Chapters
Gobi, M., Heil, J., & Burkard, J.F. (2012, January). Ultrasound guided paravertebral
analgesia and multimodal pathway for acute pain management after breast cancer
surgery. Accepted for poster presentation, Western Institute of Nursing Meeting,
18-21April2012.
Jones, S., Burkard, J.F. (2012, January). Effects of cofactors on postoperative recovery
times of patients with obstructive sleep apnea. Accepted for poster presentation,
Western Institute of Nursing Meeting, 18-21April2012.
Kim, Y., Howell, J., & Burkard, J.F. (2012, January). Effective geriatric pain education
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program for nursing home staffs: Evidence based practice model. Accepted for
poster presentation, Western Institute of Nursing Meeting, 18-21 April 2012.
Liaguno, M., Burkard, J.F. (2012, January). Priming the pump: Early hand expression of
breast milk in mother's with NICU babies. Accepted for poster presentation,
Western Institute of Nursing Meeting, 18-21April2012.
Maclang, F., Burkard, J.F. (2012, January). Implementation of patient educational
intervention to decrease the occurrence of type II diabetes in the gestational diabetic
mother. Accepted for poster presentation, Western Institute of Nursing Meeting,
18-21April2012.
Nenno, L., Burkard, J.F. (2012, January). Venous thromboembolism assessment and
prophylaxis: A process improvement initiative. Accepted for poster presentation,
Western Institute of Nursing Meeting, 18-21April2012.
Savage, A.I., Burkard, J.F. (2012, January). Impact of the patient-centered medical home
model (PCMH) on selected patient outcomes and staff satisfaction in a primary care
clinic in a military treatment facility. Accepted for poster presentation, Western
Institute of Nursing Meeting, 18-21 April 2012.
Todorova, E., Clark, M.J., & Burkard, J.F. (2012, January). Effects of glycemic
management in cardiac surgery: Evidence based project. Accepted for poster
presentation, Western Institute of Nursing Meeting, 18-21 April 2012.
Savage, A.I., Burkard, J.F. (2011, September). Impact of the patient-centered medical home
model (PCMH) on selected patient outcomes and staff satisfaction in a primary care
clinic in a military treatment facility. Poster presentation, Doctors of Nursing
practice Conference, 28-31 September 2011, New Orleans, LA.
Zamora, Z., Clark, M.J., & Burkard, J.F. (2011). Orthotopic neobladder irrigation:
Competency Assessment through simulation. Urologic Nursing. April 2011.
Burkard, J.F. (2011, April). Perioperative Outcomes Analysis Phase One Analysis
Project. Poster presentation, Western Institute of Nursing Meeting, 13-16 April
2011.
Eckhardt, J., Burkard, J.F., & Sawrey, P. (2011, April). Observation unit efficacy in
decompensated heart failure patients. Poster presentation, Western Institute of
Nursing Meeting, 13-16 April 2011.
Garner, C. & Burkard, J.F. (2011, April). Applying the evidence: Using research based
guidelines in treating patients with diabetes. Poster presentation, Western Institute
of NursingMeeting, 13-16 April 2011.
Ginn, K., Williams, H., Sarter, B. & Burkard, J.F. (2011, April). The relationship of a
diabetes flow sheet on the adherence to national standards in an internal medicine
office. Poster presentation, Western Institute of Nursing Meeting, 13-16 April 2011.
Hyacinth, 0., Sarter, B. & Burkard, J.F. (2011, April). Weight management during
pregnancy utilizing the IOM guidelines. Poster presentation, Western Institute of
Nursing Meeting, 13-16 April 2011.
McPherson, J. & Burkard, J.F. (2011, April). Implementation of high fidelity simulation to
enhance criical thinking skills. Poster presentation, Western Institute of Nursing
Meeting, 13-16 April 2011.
Wolfe, T., Burkard, J.F., & Skerrett, K. (2011, April). Long acting injectables to improve
medication adherence in psychotic disorders. Poster presentation, Western Institute
of Nursing Meeting, 13-16 April 2011.
Nolan, S. & Burkard, J.F. (2010). Effect of morbidity and mortality peer review on nurse
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accountability and ventilator-associated pneumonia. JONA. 40:9, 374-382.
McGuire, J. & Burkard, J.F. (2010). Risk factors for emergence delirium in U.S. military
members. Jour of PeriAnesthesia Nur. 25:6, 392-401.
Burkard, J.F. (2010, October). Evidence Based Practice: Fostering Nursing Scholarship
through Nursing Scholarship. Poster presentation, National DNP Conference
Meeting, 29-30 October 2010.
Burkard, J.F. (2010). Liver failure and nonalcoholic steatohepatitis. In S. Elisha, (Ed),
Case Studies in Nurse Anesthesia. (1" ed., pp. 105-115). Boston: Jones and Bartlett.
Burkard, J.F., & Vacchiano, C.A. (2010). Regional anesthesia: Upper and lower extremity
blocks. In J.J. Nagelhout & K.L. Plaus (Eds.), Nurse Anesthesia. (4"' ed., pp. 1077
1102). St. Louis: Saunders.
Burkard, J.F. (2009). 2009 PONV evidence based consensus guideline update. Anesthesia
Abstracts, 3:9, 1-44.
McGuire, J., & Burkard, J.F. (2010). Risk factors for emergence delirium in U.S. Active
Duty military members. Manuscript submitted for publication.
Arruda, T., Burkard, J. (2010). Predictors of critical care determint factors: Safest patient
flow for emergency department admissions. Poster presentation: Western Institute
of Nursing Meeting, 13-16 April 2010.
Arellano, C., Izuchukwu, I. & Burkard, J. (2010). The use of simulation in improving the
readiness skills of airforce squadron medical technicians in the care of patients with
chest tube drainage systems. Poster presentation: Western Institute of Nursing
Meeting, 13-16 April 2010.
Fernandez, A., Burkard, J. (2010). Screening strategies to improve early diagnosis of
diabetes mellitus in the adult population. Poster presentation: Western Institute of
Nursing Meeting, 13-16 April 2010.
Macauley, K., Clark, M.J., & Burkard, J. (2010). Warfarin therapy management in
primary care. Poster presentation: Western Institute of Nursing Meeting, 13-16
April 2010.
Nolan, S., Davidson, J., & Burkard, J. (2010). The effect of nursing morbidity and
mortality peer review on nursing accountability and ventilator associated
pneumonia rates in the intensive care unit. Poster presentation: Western Institute
of Nursing Meeting, 13-16 April 2010.
Zamora, Z., Clark, M.J., & Burkard, J. (2010). Orthotopic neobladder irrigation:
Competency assessment through simulation. Poster presentation: Western
Institute of Nursing Meeting, 13-16 April 2010.
Burkard, J.F. & McGuire, J. (2009). Survey of Certified Registered Nurse Anessthetists
regarding the concept of emergence delirium. Unpublished manuscript, School of
Nursing, University of San Diego, San Diego, California.
Burkard, J.F., & Vacchiano, C.A. (2010). Regional anesthesia: Upper and lower extremity
blocks. In J.J. Nagelhout & K.L. Plaus (Eds.), Nurse Anesthesia. (4"' ed., pp. 1077
1102). St. Louis: Saunders.
Williamson, W., Burks, D., Pipkin, J., Burkard, J.F., Osborne, L.A., Pellegrini, J.E. (2009).
Effect of timing of fluid bolus on reduction of spinal-induced hypotension in patients
undergoing elective cesarean delivery. AANA Journal, 77:2, 130-136.
Rivera, J.J., Villecco, D.J., Dehner, B.K., Burkard, J.F., Osborne, L.A., Pellegrini, J.E.
(2008). The efficacy of ketorolac as an adjunct to the bier block for controlling post
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operative pain following nontraumatic hand and wrist surgery. AANA Journal,
76:5, 341-345.
Burkard, J.F. (2008). Care of the pregnant patient. In C.B. Drain & J. Odom-Forren
(Ed.), Perianesthesia in nursing: A critical care approach. (pp. 729-737). St. Louis:
Sanders-Elsevier.
The efficacy of ketorolac as an adjunct to the bier block for controlling post-operative pain
following non-traumatic hand and wrist surgery. LT Jesse Rivera, CRNA, LT
Dante Villecco, CRNA, LT Bryan Dehner, CRNA, CDR Joseph Burkard, DNSc,
CRNA, CDR Lisa Osborne, PhD, CRNA, CAPT Joseph Pellegrini, PhD, CRNA
Accepted for publication in the October AANAjournal.
Effect of timing of fluid bolus on reduction of spinal induced hypotension in patients
undergoing elective cesarean delivery. LCDR Walter Williamson, CRNA, LT David
Burks, CRNA, LT Jessica Pipkin, CRNA, CDR Joseph Burkard, DNSc, CRNA,
CDR Lisa Osborne, PhD, CRNA, CAPT Joseph Pellegrini, PhD, CRNA. Accepted
for publication in the AANA Journal.
Prevention and Management of Postoperative Nausea and Vomiting: A Look at
Complementary Techniques. Myrna E. Mamaril. MS, RN, CPAN, CAPA, Pamela
E. Windle, MS, RN, CAN, CPAN, CAPA, Joseph F. Burkard, DNSc, CRNA
Vocal Cord Dysfunction: A Case Report Erik C. Cline, LCDR, NC, USN, MSN, CRNA
Roger Davis, LCDR, NC, USN, MSN, CRNAJoseph F. Burkard, CDR, NC, USN,
CRNA, DNSc, AANA 2006 October journal.
Burkard, J.F. (2006, August). Can Anesthesia Providers Accurately Predict Their Patient's
Preoperative Anxiety? Oral and Poster Presentation, AANA Annual Meeting
Washington, D.C.
Will The Addition ofa Sciatic Nerve Block to a Femoral Nerve Block Provide Better Pain
Control Following Anterior Cruciate Ligament Repair (ACLR) Surgery? Oral and
Poster Presentation, AANA Annual Meeting Washington, D.C.
Burkard, J.F. (2005). Kearns Sayre Syndrome: A Case Report. Accepted for publication in
the GTJNA 2005 Journal.
Burkard, J.F. (2005). A Modification of the Traditional Bier Block: A Case Report.
Accepted for publication in the GTJNA 2005 Journal.
Burkard, J.F. (2005). Propofol-Ketamine Infusion in an Umbilical Hernia Repair: A Case
Report. Accepted for publication in the GTJNA 2005 Journal.
Burkard, J.F. (2005). Vocal Cord Dysfunction: A Case Report. Accepted for publication in
the AANA 2005 Journal.
A comparison of ondansetron and transdermal scopolamine patches for patients identified
to be high risk for the development of post operative nausea and vomiting.
Accepted for publication in the AANA 2005 Journal.
Author chapter 42, Regional Anesthesia, Third edition of Nurse Anesthesia by Nagelhout
and Zaglaniczny.
The effects of fatigue on the performance of anesthesia providers in a simulator setting.
Poster presented at the AANA annual meeting, Seattle, WA 4-11August2004
Effects of fiberoptic versus laryngoscopic intubation as measured by the bispectral index
(BIS). Poster presented at the AANA annual meeting, Seattle, WA 4-11 August
2004
Burkard, J.F. (2003, November). Effect of Air versus Saline in the Loss of Resistance
Technique in Identifying the Epidural Space when placing a Continuous Epidural
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Catheter among the Parturient. Poster presented at the 15th annual Karen Rieder
Poster Session, AMSUS, San Antonio, TX 15-19 November 2003
Burkard, J.F. (2003 November). A comparison ofondansetron and transdermal
scopolamine patches for patients identified to be high risk for the development of
post operative nausea and vomiting. Poster presented at the 15th annual Karen
Rieder Poster Session, AMSUS, San Antonio, TX 15-19 November 2003
Bispectral Analysis and Motor Activity Assessment Scores in Mechanically Ventilated
Patients in the Intensive Care Unit. Poster presented at the 15th annual Karen
Rieder Poster Session, AMSUS, San Antonio, TX 15-19 November 2003
The effects of clonidine added to bupivacaine on analgesia and post-operative outcomes to
femoral I sciatic nerve blocks. Accepted for publication in the AANA 2004 journal.
Published July-August 2004
A comparison of levobupivacaine and ropivacaine in patients undergoing extremity surgery
with brachia! plexus block. Accepted for publication in the AANA 2004 journal.
Comparison of axillary Brachia! Plexus Block success using a 26 Gauge 112 Inch Needle
versus a Standard Gauge 11/2 Inch Needle. Published in the AANA Journal
January 2004
The effects of clonidine added to bupivacaine on analgesia and post-operative outcomes to
femoral I sciatic nerve blocks. Poster presented at the AANA annual meeting,
Orlando, FA 1-8 August 2002
Comparison of axillary Brachia! Plexus Block success using a 26 Gauge 112 Inch Needle
versus a Standard Gauge 11/2 Inch Needle. Poster presented at the AANA annual
meeting, Orlando, FA 1-8 August 2002
A comparison of levobupivacaine and ropivacaine in patients undergoing extremity surgery
with brachia! plexus block. Accepted for publication in the AANA 2004 journal.
Poster presented at the AANA annual meeting, Orlando, FA 1-8 August 2002

Professional Presentations
Burkard, J.F. (2012, May). Joining Forces through Creative Curriculum Approaches: A
Panel Discussion. AACN Leadership Collaboration Webinar. 14 May 2012.
Burkard, J.F. (2012, March). Evidence-Based Practice: I know what it is, but how do I do
it. Scripps 9th Annual Advanced Practice Oncology Providers Symposium: Innovation
Through Practice. San Diego, Ca.
Burkard, J.F. (2012, February). Health Policy for the Advanced Practice Nurse
Anesthetist. Visiting Professor Workshop presentation, Samuel Merritt University
25-27 February 2012.
Burkard, J.F., Skerrett, K., Stanley, L., Suarez, M.J., & Terry, M.J. (2011, December).
Readjustment Strategies for the Wounded Warrior. Military Healthcare Convention
& Conference. Workshop conducted at the Institute for Defense and Government
Advancement, Paradise Point, San Diego, Ca.
Burkard, J.F. (2011, September). APRN's Returning for Doctoral Degrees: Identifying
Health Policy Needs. Podium presentation, Doctors of Nursing practice Conference,
28-31 September 2011, New Orleans, LA.
Burkard, J.F. (2011, September). Research Ethics: Issues Concerning Human Subjects.
Research methods training symposium conducted at Naval Medical Center, San
Diego California.
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Burkard, J.F. (2011, August). CRNA's Returning for Doctoral Degrees: Identifying Health
Policy Needs. Podium presentation, American Association of Nurse Anesthetists
National Meeting 6 August 2011.
Burkard, J.F. (2011, March). Inovation in Anesthesia Practice. Podium presentation,
California Association of Nurse Anesthetists Spring State Meeting 25-27 March
2011.
Burkard, J.F. (2011, February). Health Policy for the Advanced Practice Nurse
Anesthetist. Visiting Professor Workshop presentation, Samuel Merritt University
25-27 February 2011.
McGuire, J. & Burkard, J.F. (2011, March). Post Traumatic Stress in the Combat Surgical
Patient. First Place Award, Academic Research Competition. San Diego California
Burkard, J.F. (2011, January). Preventing and treating PONV: An evidence
approach. Podium presentation, University of California, San Diego 15 January
2011.
Burkard, J.F. (2010, July). Pain and sedation management: state of the art 2010. Podium
presentation, University of California, San Diego 22 July 2010.
Burkard, J.F. (2011, January). Preventing and treating PONV: An evidence
approach. Podium presentation, University of California, San Diego 15 January
2011.
Burkard, J.F. (2011, March). Inovation in Anesthesia Practice. Podium presentation,
California Association of Nurse Anesthetists Spring State Meeting 25-27 March
2011.
McGuire, J. & Burkard, J.F. (2011, March). Post Traumatic Stress in the Combat Surgical
Patient. First Place Award, Academic Research Competition. San Diego California
Burkard, J.F. (2009, December). A Multidisciplinary Expert Forum on Perioperative
Nausea and Vomiting. Panel presentation done at the Institution of Medical
Education and Reseach 15 December, 2009. Miami Florida
Burkard, J.F. (2010, February). Analysis of Health Policy for the Advanced Practice Nurse.
Health Policy Visiting Professor Series. Visiting professor symposium conducted at
Samuel Merritt School of Nurse Anesthesia, Oakland California.
Burkard, J.F. (2010, January). Evaluating the evidence in evidence based practice.
Symposium conducted at the 23"" annual University of California San Diego
anesthesia update, San Diego California.
Burkard, J.F. (2010, March). Fostering Nursing Scholarship Through Academic and
Service Partnership. In S. Hardin panel presentation given during the Janet A.
Rodgers Nursing Leadership workshop. San Diego California
Burkard, J.F. (2010, March). Trauma and Healing Health Policy Issues.. In K. Skerrett
and S. Hardin, Trauma and Healing Workshop. Symposium conducted during the
Hahn School of Nursing Trauma and Healing Workshop March 5'", 2010. San Diego
California
Burkard, J.F. (2009, August). Responsible conduct of research. Research methods training
symposium conducted at Naval Medical Center, San Diego California.
Burkard, J.F. (2009, April). Trauma & ARDS an EBP clinical case study review.
Symposium conducted at the 2009 Critical Care Code Trauma Seminar, San Diego
California.
Burkard, J.F. (2009, April). Responsi.ble conduct ofresearch. Research methods training
symposium conducted at Naval Medical Center, San Diego California.
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Burkard, J.F. (2009, January). Evidence based practice- a model to change practice.
Workshop symposium conducted at the University of San Diego Hahn School of
Nursing, San Diego California.
Burkard, J.F. (2009, January). Post operative nausea & vomiting: Evidence based consensus
guidelines. Symposium conducted at the 22"" annual University of California San
Diego anesthesia update, San Diego California.
Burkard, J.F. (2008, December). Reviewer Chair, Congressionally Directed Medical
Research Programs program for deployment relatd medical research programs
held Decem her 15'", 2008 at Fort Detrick, MD.
Burkard, J.F. (2008, August). Responsible conduct ofresearch. Research methods training
symposium conducted at Naval Medical Center, San Diego Californi
Burkard, J.F. (2007, August). Regional Anesthesia for the Upper and Lower Extremity:
New Trends in Local Anesthetics and Block Techniques. IDAHO Spring 2007
Conference for Nurse Anesthetists
Burkard, J.F. (2007, August). USC Regional Anesthesia for the Upper and Lower
Extremity: New Trends in Local Anesthetics and Block Techniques. USC Spring
2007 Workshop for Nurse Anesthesia Students
Burkard, J.F. (2006, March). USC Regional Anesthesia for the Upper and Lower
Extremity: New Trends in Local Anesthetics and Block Techniques. USC Spring
2006 Workshop for Nurse Anesthesia Students
Burkard, J.F. (2006, August). Funderberg Lecture Series, Samford University,
Birmingham, Alabama, Brachia! Plexus and Upper extremity Blocks for the
Anesthesia Provider, Anesthesia Awareness Monitoring: A controversial Issue in
Anesthesia Practice.
Burkard, J.F. (2005, October). Presentation on Anesthesia Awareness Monitoring: A
Controversial Issue in Anesthesia Practice. My Patient Has a Bleeding Disorder:
Transfusion Guidelines. CANA Anesthesia Update Fall 2005 Monterey, CA
Burkard, J.F. (2005, May). Responsible Conduct I Ethics of Research Presentation. Naval
Medical Center CID Research Series, May 2005
Burkard, J.F. (2005, February). Presented: The incidence of Awareness During
Anesthesia: A Multicenter United States Study. Journal Club NMCSD, February
2005
Burkard, J.F. (2004, October). Presented: Effects on the progress of labor: Do labor
epidurals affect labor outcome. Fall CANA state meeting. Berkeley, Ca, October
2004
Burkard, J.F. (2004, October). Presented: Non-Obstetric surgery during pregnancy: Does
anesthesia increase the risk to the parturient. Fall CANA state meeting. Berkeley,
Ca, October 2004
Burkard, J.F. (2004, August). Presented Two Day Advanced Airway Workshop at the
AANA Annual meeting Seattle, WA, August 2004
Burkard, J.F. (2004, May). Responsible Conduct of Research Presentation. Naval Medical
Center CID Research Series, May 2004
Burkard, J.F. (2004, May). Presented AANA Public Relations Topics at National Rural
Health Association Annual Conference, San Diego, Ca, May 2004
Burkard, J.F. (2004, April). Presented Bispectral Analysis Dissertation Manuscript at
NMCSD Academic Research Competition, April 2004
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Burkard, J.F. (2003, October). Outcomes Research in Regional Anesthesia and Analgesia,
CANA La Jolla, CA, October 10, 2003
Burkard, J.F. (2003, August). AANA National Conference, Boston, Ma Aug 4-5 2003.
Spinal I Epidural Workshop Instructor
Burkard, J.F. (2003, June). Trauma Fluid Resuscitation: An Anesthesia Provider's
Perspective. CANA Las Vegas State meeting 8 June 2003
Burkard, J.F. (2002, May). National Speaker ASPAN Conference San Diego, CA Regional
Anesthesia in the Post Anesthesia Care Unit, April-May 2002
Burkard, J.F. (2002, April). Training for the Future: Technology and the Anesthesia Team,
Kaiser Permanente Anesthesia Symposium, April 2002
Burkard, J.F. (2002, March). Comparison of axillary Brachia! Plexus Block success using a
26 Gauge 112 Inch Needle versus a Standard Gauge 1112 Inch Needle. Naval
Medical Center San Diego Annual Research Competition, March 2002
Burkard, J.F. (2001, October). CANA Speaker, Napa CA on trauma anesthesia, Napa
California, CANA Fall meeting, October 2001
Burkard, J.F. (2001, January). Ethical Decision Making in a Changing Environment.
Surface Warfare Medical Institute Presentation. Point Loma, CA, January 2001
Burkard, J.F. (2000, August). AANA National Conference, Chicago, IL Aug 5-10 2000.
Spinal I Epidural Workshop Instructor
Burkard, J.F. (2000, June). Video Teleconference Pain Management for the PACU Nurse,
Kaiser Permanente, AANA Upper Extremity Workshop Presentation, Chicago, IL,
June 2000
Burkard, J.F. (2000, May). Regional Anesthesia for the Millennium. Regional Anesthesia
of the Lower Extremity Presentation and Workshop. CANA Spring Conference,
Palm Springs, CA, May 2000
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September 20, 2012

AANA Foundation
222 S. Prospect Ave.
Park Ridge, IL 60068

Dear Dr. Lorraine Jordan and the AANA Foundation Grant Selection Committee,

It is with sincere gratitude that I write you this letter extending my appreciation for

awarding me the AANA Baxter Research Doctoral Fellowship Grant. I assure you that
our current project, Psychoneuroimmunology and Chronic Pain, for which I received
your award has developed into a stellar project that is progressing rapidly. The purpose
of this letter is to present you with the plan for utilizing the AAN A Baxter Research
Doctoral Fellowship funds, as well as the funds applied for in this AANA General
Research Grant. I would also like to appraise you of the progress we have made since my
proposal submission in April 2012 when I submitted my Fellowship application.
Since April, we have added an additional psychometric component to the study to reflect
another highly pertinent component of chronic pain symptomatology. After a thorough
literature search and through our collaboration with Dr. Michael Irwin, UCLA Professor
and Director of the Cousins Institute of Psychoneuroimmunology, it was decided that a
measurement of sleep deprivation would be added to the study to provide a more robust
and complete picture of the symptoms experienced by chronic pain patients. Through my
readings of the literature I found that not only is sleep deprivation and pain highly
interrelated, but I have found that inflammation has been evolving throughout this body
ofliterature as well. This is a very pertinent measurement to add to this study, there is
relatively little known about the central inflammation levels related to sleep deprivation
in chronic pain patients and the research is developing now. This is yet another cutting
edge component of this project that not only increases the overall elegance, but also
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makes it one of the most progressive studies on chronic pain, inflammation and the
psychological components associated pain.
I am elated to report that the UCLA Institutional Review Board application is being
submitted and we will have pending status shortly.
I can report that our budget has been comprehensively created to be both cost
conscientious and practical for the volume and scope of laboratory and psychometric
testing we are proposing to accomplish. Through collaboration with our Co-Investigator
Dr. Elizabeth Breen, PhD, Director of the Cousins Inflammatory Biology Laboratory, as
well as our Co-Investigator Dr. Andrea Nicol, MD, MS, Director of Research at the
UCLA Pain Management Clinic, we have formulated a budget that incorporates the
AANA Fellowship Grant monies. The $10,000 AANA Fellowship Grant funds will
cover the total laboratory expenses for approximately half of our desired study population
with three of the five desired cytokines being analyzed. With the funds sought from this
General Research Grant, we would be able to analyze five cytokines on our full study
population of thirty chronic pain patients. This further funding would allow for a
population size that could yield significant results and provide us with the complete five
cytokine analysis necessary to illustrate a comprehensive picture of the inflammation set
forth in the study design. While our budget reflects that the amount still unfunded to run
these laboratory tests is roughly $17,000, we do hope the Grant Selection Committee will
award us considerably more to cover the $7,000 in indirect costs associated with
performing this study at UCLA through USD. If this funding is not currently available
from the AANA Foundation, I humbly request you consider me next spring for another
Fellowship Grant award upon my application.
Of note, the data collected in this cross-sectional study, will serve as both my dissertation
research, as well as a preliminary study for a much more comprehensive longitudinal
study designed to investigate inflammation, chronic pain and the psychological
components of pain. I look forward to presenting the cross-sectional study findings to the
AANA and continuing with Dr. Charles Griffis, CRNA, PhD on expanding this study
into a longitudinal study with compelling results. I cannot express how ecstatic I am to
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be a part of this revolutionary research and sincerely thank you for you assistance in
making this study a reality. Proof is power!

Sincerely,
Sarah Giron, CRNA, MS
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UNIVERSITY OF CALIFORNIA, LOS ANGELES
BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO

Andrea Nicol, M.D., M.S.
Director of Research, UCLA Pain Management Center
Assistant Clinical Professor, Department of Anesthesiology
David Geffen School of Medicine at UCLA
Office Phone: (310) 319-1253
Office Fax: (310) 319-2263

UCLA
SANfA BARBARA • SANT A CRUZ

UCLA Pain Management Center
1245 16'" Street, Suite 225
Santa Monica, CA 90404
Phone: 310-794-1841
Fax: 310-319-2263
2001 Santa Monica Blvd, Suite 860W
Santa Monica, CA 90404
Phone: 310-828-3209
Fax: 310-828-5165

Dr. Lorraine Jordan, CRNA, PhD
222 South Prospect A venue
Park Ridge, Illinois 60068-4001
phone: 847-655-1170
fax: 847-692-6968

September 24, 2012

Dear Dr. Jordan,
It is with great pleasure and enthusiasm that I write you this letter to support the AANA
Foundation General Research Grant application for Sarah E. Giron, CRNA, MS. I have known
Sarah for many years as we were colleagues in lhe Department of Anesthesiology at UCLA. We
both moved on, I to a Pain Management fellowship and Masters in Clinical Research at UCLA
and Sarah to USC and now the University of San Diego for a PhD.

I believe Sarah has what it takes to become a leader in the field of anesthesiology and pain
research. I have worked with many people during my time at UCLA on research projects and
there are many attributes about her that make her unique and special and separate her in a
positive way, from the rest of the pack. She takes the initiative in organizing email discussions,
in-person meetings, and phone conferences and has the ability to unite the entire study team so
that forward progress on projects happens at a very fast pace. She has an affable personality and
is extremely pleasant and engaging to work with.
She is well-regarded by her peers, colleagues, and mentors as evidenced by her many awards and
honors dating back to 2000. Her academic merit and presence is clearly substantiated as
evidenced by the amount of invited lectures and presentations she has given throughout her
career. Her dedication to the advancement of current clinical and basic science evidence based
medicine in our field is without question, given her return to the classroom to complete
coursework and a thesis towards a PhD in Nursing. I have no doubt that she will complete this
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additional educational training with the highest accolades and will have a very bright future in
both the clinical and academic/research realms.
Besides highlighting Sarah's strengths, this letter serves to support her application for a research
grant through the AANA for the project she plans to complete for her PhD dissertation. I was
approached about one year ago by Sarah regarding this project and from the very begirming, I
was extremely excited to take part. I will be serving as a co-investigator on this project, which is
a cross-sectional study that will investigate the emerging relationships between chronic pain
syndromes and the role of central inflammation, as measured by cerebrospinal fluid patterns of
inflammatory mediator molecules. In addition to the CSF patterns, the study will be exploring
the relationships between the psychological responses to pain and then correlated to
cerebrospinal fluid levels of inflammatory markers. This study hopes to gain knowledge of the
relationship between the psychoneuroimmune responses to prolonged pain states propagated by
central inflammatory mechanisms, with the ultimate goal of acquiring the information pertinent
to more effective analgesic and psychological treatment of these patients.
This study is unique, exciting, and unlike any study that has been done before on this topic.
There is a great deal of possible knowledge to be gained from the cross-sectional comparison of
the CSF between chronic pain and non-chronic pain subjects. Sarah and the rest of our team are
extremely hopeful that the data we get from this cross-sectional analysis will provide the
justification to perform a longitudinal analysis on the CSF of chronic pain patients as they
undergo treatment with intrathecal opiates.
It is with great honor and no reservations that I write this letter in support of Sarah Giron' s
application for a research grant from the AANA. Please do not hesitate to contact me if you have
any questions or need further information.

Sincerely,

~,/i/.S
Andrea L. Nicol, MD, MS
Director of Research, UCLA Pain Management Center
Assistant Clinical Professor, Department of Anesthesiology
David Geffen School of Medicine at UCLA
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Cousins Center for Psychoneuroimmunology
Jane & Terry Semel Institute for Neuroscience & Human Behavior

U C LA

Uni.versity of California, Los Angeles
300 UCLA Medical Plaza, Suite 3129
Box 957076
Los Angeles, California 90095-7076

September 24, 2012
Michael Irwin, M.D.
Director

Lorraine Jordan, CRNA, PhD
Executive Director, AANA Foundation
222 South Prospect Avenue
Park Ridge, Illinois 60068-4001
Re: Giron Proposal "Pyschoneuroimmunology and Chronic Pain"

voice (310) 825-8281
fax (310) 794-9247
www.CousinsPNl.org

Dear Dr. Jordan,
I am pleased to write in support of the research proposal being submitted by Ms.
Sarah E. Giron, CRNA, MS, for consideration by the AANA Foundation. Ms. Giron's
proposed study examining psychological and immunological measures in chronic pain
patients represents both a new area of research for our laboratory, and an extension of
previous collaborations on psychoneuroimmunology studies supported by the AANA
Foundation (Dr. Charles Griffis, CRNA, PhD, 2011).
Our Inflammatory Biology Core (IBC) Laboratory of the UCLA Cousins Center for
Psychoneuroimmunology serves as a research resource for investigators wishing to
include assessments of the immune system in their studies. We are able to perform
evaluations of cellular signaling, gene expression, and biomarkers of immune system
activation and/or inflammation. As the Co-Director of the IBC and an immunology
researcher who has investigated immune activation and cytokine biology for more than
twenty-five years, I have extensive experience in the collection, processing, and testing
of immunological samples in clinical and epidemiologic studies. I oversee the day-to
day operations of the IBC Laboratory, review all results for quality control, and work
closely with co-investigators in the interpretation of immunologic data.
I have been providing technical· advice and mentoring to Ms. Giron as she has
developed her study design and research plan, and I express my enthusiastic support
for her application to the AANA Foundation. I hope that we will have the opportunity to
pursue the innovative study of chronic pain and the interaction with the mind and the
immune system that she has outlined in her proposal, and I look forward to a productive
collaboration.

Sincerely,

r:~w~~--

Ettzab~ Crabb Breen, MT(ASCP), PhD

Associate Professor, Department of Psychiatry and Biobehavioral Sciences
Co-Director, Inflammatory Biology Core
UCLA Cousins Center for Psychoneuroimmunology
Office: (310) 206-5738
ebreen@mednet.ucla.edu
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September 26, 2012
Lorraine Jordan, CRNA, PhD
Research Director
AANA Foundation
Re: General Research Grant Application
"Psychoneuroimmunology and Chronic Pain"

Dear Dr. Jordan:
I am writing this letter to recommend the study referenced above for General
Research Grant funding. As I have indicated in my own writing for the AANA
Journal1, chronic pain is a problem of tremendous scope, causing terrible suffering
for millions of Americans and costing our beleaguered health care system billions of
dollars a year. Basic and translational research to advance treatment of chronic
pain syndromes is desperately needed, and I have found a graduate student who
proposes to do just that as a dissertation project. Funding this research is in perfect
alignment with the goals and mission of the AANA Foundation.
Sarah E. Giron, CRNA, MS, has proposed a research study examining the
cerebrospinal fluid (CSF) of chronic pain patients who are having the implantation
of catheters and pumps to allow intrathecal opioid infusion pain treatment.
The study has two specific aims:
Specific Aim #1: This study will examine and characterize the relationships
between chronic pain and pro- and anti-inflammatory mediator molecules.
The study will bring together several talented groups to accomplish this aim. Ms.
Giron is currently a doctoral student at the Hahn School of Nursing, University of
San Diego and has assembled a committee of capable experts to assist her. In the
fields of pain physiology and clinical pain intervention, one of the faculty of the
UCLA Department of Anesthesiology, Santa Monica Pain Group, Andrea Nicol, M.D.
will provide guidance and clinical access. In the area of psychoneuroimmunology,
the UCLA Cousins Center of Psychoneuroimmunology is represented, including Dr.
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Michael Irwin, an internationally known researcher in body-mind phenomena. Dr.
Irwin will focus his efforts on investigating any correlations between the behavioral
manifestations of pain and the levels and type of inflammatory mediator molecules
found in the cerebrospinal fluid of these patients. Elizabeth Breen, PhD, the Director
of the Inflammatory Biology Laboratory, will use her extensive background in
immunological laboratory science to oversee and assist in specimen collection and
analysis.
The CSF samples from patients will be compared to control samples from a bank
established by researchers from the University of California, San Diego in previous
investigations, and which are already stored in the Inflammatory Biology
Laboratory where the analysis will be conducted. Samples will be examined using
ELISA for the presence and levels of immune inflammatory mediator molecules such
as cytokines. The data comparing patients and controls will be analyzed using
parametric and non-parametric inferential statistics.

Specific Aim #2: To investigate relationships between pain levels, anxiety,
depression, sleep deprivation and the expression of inflammatory molecules in the
cerebrospinal fluid of chronic pain patients.
To accomplish this specific aim, Ms. Giron has established a relationship with the
UCLA Cousins Center of Psychoneuroimmunology. Dr. Michael Irwin, mentioned
above, has joined the dissertation team as a committee member. As a consultant on
the grant, he is eager to explore the mind-body connections within the human
response to pain. To that end, Dr. Irwin is prepared to lend his expertise to the
selection and use of appropriate instruments to assess the behavioral impact of
chronic pain, such as anxiety, fear, depression, and sleep deprivation. Dr. Irwin will
then assist in analyzing and interpreting the data, which will be examined for
correlations between the behavioral manifestations of pain, pain severity, and the
expression of inflammatory molecules in the CSF of chronic pain patients.
To date, and to this team's knowledge, there have been less than 10 studies of
chronic pain and CSF inflammatory response in humans, though a large body of pre
clinical data, obtained mostly from rodent models of spinal cord or sciatic nerve
injury, exists to guide the concepts and interventions. The data so far have been
promising. revealing a propensity for the increase of inflammatory molecule
production in CSF of chronic pain patients, yet the data is also contradictory in
places, and sample sizes have been small. Thus our team firmly believes there is
room for further investigation of this phenomenon, especially in view of the
prevalence of chronic pain and the high stakes involved in treatment advances. This
study will add validity, and hopefully provide some more direction in the clinical
search for novel approaches to chronic pain treatment. Hopefully, our results will
further guide new approaches to targeting central inflammation in pain patients,
which as yet have not seen Phase 1 trials.
2
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September 26, 2012

Dr. Lorraine Jordan, CRNA, PhD
Executive Director of the AANA Foundation and AANA Senior Director of Research
222 South Prospect Avenue
Park Ridge, Illinois 60068-4001
phone: 847-655-1170, fax: 847-692-6968
AANA General Research Grant: Letter of Supprt ICO Sarah Elizabeth Giron, CRNA, MS, PhD
Student, USO I Charles A. Griffis, CRNA, PhD
I am writing to express my support for the planned AANA General Research Grant in support of
"Psychoneuroimmunology and Chronic Pain" at the University of San Diego and University of
California Los Angeles. The University of San Diego and University of California Los Angeles
believes the prompt, thorough assessment and treatment of chronic pain is a subject of
paramount importance. This study will investigate the emerging relationships between chronic
pain syndromes and the role of central inflammation, as measured by cerebrospinal fluid patterns
of inflammatory mediator molecules. More specifically, this study will investigate ifthe same
central pro- and anti-inflammatory cytokines found in chronic pain-induced animal models are
found in human chronic pain patients.

As a doctoral student at the University of San Diego Sarah has established herself as an
outstanding student with a strong academic and research focus. Ms. Giron has received the
AANA Palmer Carrier Baxter Scholarship, which has funded the development of her research
proposal, facility costs and study preparation costs. TI1e AANA General Research Grant will
cover laboratory costs and sample analysis.
I enthusiastically look forward to future collaboration and research in this area between the
University of San Diego, UCLA and the AANA. University of San Diego embraces the
interdisciplinary model and the collaboration that will proactively move to the prompt and
comprehensive treatment of chronic pain at not only this facility but also region wide.
I wholeheartedly support this grant application and support Sarah's team in the review process.
chair her dissertation committee and pain team as she prepares for her PhDc proposal defense
and institutional review boards.

Joseph Burkard
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Manuscript III

UNIVERSITY OF SAN DIEGO
Hahn School of Nursing and Health Science

The Role of Central Inflammation in the Chronic Pain Paradigm

Sarah E. Giron, PhD(c), CRNA
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Abstract
There is increasing evidence linking chronic pain to altered levels of central
nervous system (CNS) inflammation and increased levels of perceived pain, anxiety,
depression and sleep disturbance. However the inflammatory molecules responsible for
physiologic and psychological components of chronic pain still warrant identification and
exploration. Using central inflammation as a paramount factor in the creation and
maintenance of chronic pain, this study aimed to investigate and describe the physical
and psychological aspects of chronic pain associated with CNS inflammation.
Using a cross-sectional correlational design, cerebrospinal fluid (CSF)
inflammatory cytokine patterns present in 8 chronic pain participants were compared to
inflammatory cytokine patterns present in 30 control CSF samples using multivariate
analysis of variance (MANOVA), with analysis of variance (ANOVA) analysis as a
follow-up. Levels of depression, anxiety, sleep disturbance and pain were measured in
approximately 8 chronic pain patients and correlated to CSF levels of inflammatory
cytokines using Pearson's r, or Spearman's Rho correlations. Demographic information
was also explored for relationships to central inflammation and descriptive statistics were
examined for responses.
To our knowledge, this is the first study to describe increased CSF levels of
Interleukin-8 (IL-8) in a population of majority Failed Back Surgery Syndrome chronic
pain patients (F (1, 36) ~ 14.89, p < 0.001, partial 11 2 ~ 0.293). Gender (F (1,6) ~ 7.782, p
~ 0.032, 11 2 ~ 0.565), socioeconomic status (r ~ -0.823, p ~ 0.012) and educational level (r
~

0.727, p

~

0.041) were also correlated with central levels of inflammation, indicating
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that central physiologic changes may be related to host sex and psychosocial factors. All
participants reported poor sleep quality and took at least one opioid medication,
indicating that sleep and opioids may scaffold a portion of the chronic pain paradigm.
This study richly describes the dynamic experience of chronic pain through the
lens of Psychoneuroimmunology. Incorporating both physiologic and psychological
aspects of the disease, this study describes an association between chronic pain, central
inflammation, gender, socioeconomic status, opioid medications and poor sleep quality.
Thus, the future of pain treatment must consider these aspects when treating patients and
look to future studies for possible new treatment options which target these factors.

Keywords: inflammation, cytokines, chronic pain, sleep quality, gender, socioeconomic
status
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Chronic pain continues to grow in patient numbers and healthcare costs as a
condition that has relatively few successful treatment options and dismal recovery.
Tolerance to medications, invasive treatment options and debilitating symptoms create a
milieu devastating to the physiologic and psychological wellbeing of the patient.
Multiple processes have been identified as agencies responsible for the creation and
maintenance of chronic pain, one of them being central inflammatory changes brought
upon by glial-mediated activation (Alfonso Romero-Sandoval, & Sweitzer, 2015; Taves,
Berta, Chen, & Ji, 2013; Wang, Couture, & Hong, 2014).
Prior studies have shown through glial-mediated activation, inflammatory
cytokines contribute to the maintenance of chronic pain, as well as tolerance to analgesic
treatment (Dubovy, Jancalek, Klusakova, Svizenska, & Pejchalova, 2006; Raghavendra,
Rutkowski, & DeLeo, 2002; Sacerdote et al., 2008; Sung et al., 2004; Tai et al., 2006;
Zelenka, Schafers, & Sommer, 2005). Interestingly, studies in anxiety, depression and
sleep disturbances have also demonstrated altered levels of central inflammatory
cytokines (Baker et al., 2001; Bonne et al., 2011; Camara et al., 2015; Dauvilliers et al.,
2014; Levine et al., 1999; Lindqvist et al., 2009). However, many of the previous studies
in inflammation have failed to monitor the patterns of central inflammatory cytokines in
relation to the psychological aspects specific to chronic pain. A high perception of pain,
anxiety, depression and sleep disturbances are common within the chronic pain
population (Burke, Mathias, & Denson, 2015; Chuang, Weng, Hsu, Huang, & Wu, 2015;
Irwin et al., 2012) but yet how these psychological effects manifest physiologically is
relatively not well understood. Central inflammation offers one possible mechanism that
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links the physiologic and psychological aspects of the chronic pain paradigm. Thus, the
purpose of this study was to investigate and describe the physical and psychological
aspects of chronic pain associated with central inflammation.
Materials and Methods
Design

A cross-sectional, correlational study design was utilized with a convenience
sample of approximately eight chronic pain patients recruited from the Pain Management
Center at the University of California, Los Angeles (UCLA). One-time collections of
cerebrospinal fluid (CSF) samples were analyzed for 10 inflammatory cytokines and
compared to 30 control CSF samples to discern patterns of inflammation present in
chronic pain. Psychological analysis of pain perception, anxiety, depression and sleep
disturbances in study participants allowed for correlational testing between psychological
and physiologic inflammatory patterns. Demographic data analysis allowed for further
inspection.
Subjects
Study participants. Approximately eight patients with a chronic pain diagnosis and who

were eligible for medical treatment with an intrathecal analgesic infusion pump were
enrolled in this study after informed consent was obtained. All study procedures were
approved by the University of California, Los Angeles (UCLA) Institutional Review
Board (protocol ID: IRB #12-001588). Recruitment and participation in this study
commenced between April 2013 and December 2014. Inclusion criteria for this study
required that participants be 18 years or older and carry a chronic pain diagnosis of> 6
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months. Diagnosis of chronic pain was made on standard clinical criteria, as suggested
by the International Association for the Study of Pain (IASP). Exclusion criteria
incorporated a combination of surgical and experimental criteria; surgical criteria that
would exclude a patient from obtaining an implanted intrathecal analgesic infusion pain
pump included meningitis, active upper respiratory infection/flu or febrile nature, acute
medical or psychiatric disorders, acute psychological or physiologic danger/instability,
altered mental status, pregnancy and the inability to communicate in English.
Experimental exclusion criteria included a diagnosis of cancer, human immunodeficiency
virus (HIV), recent epidural injections for treatment of chronic pain (within six months),
drug abuse, meningitis or history of meningitis, history of blood transfusion(s) and
palliative pain treatment. The inclusion and exclusion criteria were confirmed using
standard clinical and laboratory methods of analysis, not above or beyond the standard of
care, or at any additional burden to study participants. Only one patient who was
approached to participate in the study declined, making the attrition rate for this study
11 %. All study participants were instructed to continue their medications and therapies
without making any changes prior to, or during study involvement.
Control samples. Control samples of CSF were obtained from the California

NeuroAIDS Tissue Network. Thirty random, individual control samples of 1-2 milliliters
(mL) of CSF, collected through the HIV Neurobehavioral Research Center between the
years 2005-2012, were utilized from this tissue bank as a means to compare levels of
central inflammatory cytokines. The control samples of CSF were selected randomly to
include seronegative HIV and hepatitis C virus (HCV) donors, with no history of
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recreational drug use, and an approximate equal distribution of men and women donors.
No other identifying information of the control sample donors was provided to the
research team except the date of collection.
Procedures
Data collection protocol. Approximately eight patients with the diagnosis of chronic

pain were enrolled in this study. After informed consent was obtained using Institutional
Review Board (IRB)-approved forms, participants completed the psychological
instruments to measure their pain perception, depression and sleep deprivation. The
anxiety tool was completed by the practitioner collecting demographic clinical data and
consent for study involvement. Participants underwent a structured interview to compile
their demographic information and all results were number coded to ensure participant
anonymity. Upon completion of the psychological questionnaires, study participants
were given a $25 Visa gift certificate and parking reimbursement for their participation in
the study.
Approximately one month after recruitment, the study participant underwent a
surgical outpatient procedure called an intrathecal analgesic infusion pain pump trial.
The surgical procedure and study procedure of collecting intraoperative CSF samples was
performed in the operating suite at the UCLA Santa Monica Orthopedic Hospital
Outpatient Surgery Center. Strict, standard sterile surgical protocol was followed per the
regulations and policies of the hospital. Intrathecal access was performed with or without
the use of fluoroscopy per surgeons' discretion. Three mL of CSF were collected from
each participant intraoperatively in appropriate polypropylene specimen collection tubes
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before 1300. All specimens were processed, stored and analyzed at the UCLA Cousins
Center for Psychoneuroimmunology Inflammatory Biology Laboratory.
Thirty samples of 1-2 mL ofCSF were utilized from the California NeuroAIDS
Tissue Network as a means to compare levels of central inflammatory cytokines. All
samples were processed, stored and analyzed at the UCLA Cousins Center for
Psychoneuroimmunology Inflammatory Biology Laboratory.
Psychological instruments. To measure the psychological variables associated with

chronic pain, various tools were selected for this study. These questionnaires were
selected for their internal consistency and reliability (reflected in Table 1 as the
Cronbach's us), their ease of completion and their use in previous studies. They were
used to measure the study participants' level of pain perception, anxiety, depression, and
sleep quality.
Assays. To quantify patterns of inflammatory markers in both chronic pain and control
samples of CSF, the Luminex Performance Human High Sensitivity Cytokine Panel
(R&D Systems, Minneapolis, MN) and the Bio-Plex 200 instrument (Luminex®) with
Bio-Plex Manager software version 5.0 were utilized. All CSF samples were received
and centrifuged at 2000G for 10 minutes at 4°C. Samples were then partitioned into 0.25
mL aliquots, labeled for anonymous identification and stored at -80°C until batch
analysis could be performed. Before Multiplex analyses, CSF samples were diluted 1:2,
following the protocol recommended for serum and plasma. All analyses were run in
duplicate per the manufacturer's recommendation. Samples with a coefficient of variation
(CV%) > 20 % between duplicates were evaluated on a case-by-case basis for repeat
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assays and/or modified data analysis. Table 2 indicates the range and mean detection
limits for the cytokines studied.
Data Organization/Statistical Analysis

This study was designed to be a cross-sectional, correlational study. First, a sample size
was calculated using Cohen's d analysis. Cohen's d was selected to estimate the sample
size needed to yield statistically significant results in the testing of the difference between
two means (the CSF cytokine levels between healthy and chronic pain participants).
Using this analysis to estimate the sample size and reduce the risk of a Type II statistical
error aided in estimating the sample size when the population effect size was not known.
The calculated sample size to generate adequate power was far above the actual recruited
participants, limiting the interpretation of our results.
Descriptive statistics were then calculated for all variables in the study and examined for
significant responses. Data were tested for normal distribution and the level of
significance was set at p < 0. 0 5 for all statistical testing. All data are reported as mean ±
standard deviation unless otherwise noted. Cerebrospinal fluid levels of inflammatory
cytokines in study participants were compared to controls using parametric statistics for
normally distributed variables to include multivariate analysis of variance (MANOV A)
for related dependent variables and one-way analysis of variance (ANOVA) for
additional follow-up. Differences in gender, race, diagnosis and medications between
CSF cytokines were also analyzed using MANOV A and ANOV A. Correlations were
calculated to explore relationships between psychological instrument measures,
demographics, and CSF levels of cytokines using Pearson's r or Spearman's Rho
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Correlations. Calculations were accomplished with SPSS software version 22 (SPSS,
IBM Inc., Armonk, NY).
Results
Demographics

Of the eight chronic pain patients who participated in the study, five participants
were female, three participants were male. The age range for the study participants was
41-74 years of age, with a mean age of 53.50 ± 10.53 years. The mean body mass index
(BMI) of study participants was 32.35 ± 4.21 kg/m 2, indicating that the majority of
participants in this study were obese. The mean metabolic equivalents (METS) reported
by participants was 3.38 ± 1.51 indicating participants could complete moderate intensity
activities. The majority of the patients suffered from Failed Back Surgery Syndrome
(FBSS) with a mean length of diagnosis of 9.31 ± 7.75 years. The most frequently
reported medications for treatment of chronic pain were gabapentin, oxycodone and a
fentanyl patch, respectively, with the mean usage of medications 3.50 ± 4.59 years.
Table 3 summarizes the demographics of the study participants.
Psychological Results

The eight study participants self-reported a mean pain rating index (PRI) of 22.88
± 7.1 out of a total score of 45. The mean present pain intensity (PPI) was 3.57 ± 1.13

out of 5, and visual analog scale (VAS) score was 7.38cm ± l.32cm out of 10 cm. The
latter two of these variables had one missing data point that was omitted in analysis and
not replaced secondary to the small population size. Participants self reported a mean
depression score of 19.75 ± 10.51 indicating an overall group level of mild-moderate
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depression. The Hamilton Anxiety Rating Scale was administered by a total of four
researchers and yielded a mean score of 20. 75 ± 11.31 indicating mild-moderate anxiety
levels. Table 4 summarizes the psychological data. Of note, the self-reported mean sleep
quality was found to be 15.50 ± 3.16, indicating poor overall sleep quality in the chronic
pain study population; every participant reported poor sleep quality.
Cytokine Results
A total of 10 cytokines were assessed using Multiplex assay analyses, including
Inerleukin-IB (IL-IB), IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor-alpha (TNF
u), Interferon Gamma (IFN-g), Vascular Endothelial Growth Factor (VEGF) and
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Three cytokines
yielded measurable quantities; IL-6, IL-8 and GM-CSF. Interleukin-IB, IL-2, IL-4, IL
10, TNF-u, IFN-g and VEGF were undetectable in the majority of samples. While CSF
from control samples yielded some within-range values for IL-2 and IL-10, they were
found at the lower level of detection and were therefore excluded from analysis. Missing
values for GM-CSF were replaced with the mean of the data series. Table 5 summarizes
CSF cytokine levels detected via Multiplex assay. Figures 1, 2 and 3 display box plots
for those cytokines that were detected with Multiplex assay analysis.
Analysis ofIL-6, IL-8 and GM-CSF in Chronic Pain
Data was screened and monitored for normality, linearity and homoscedasticity,
and descriptive data was inspected. Both IL-6 and IL-8 were found to be non-normally
distributed and transformed using a log transformation. Granulocyte-Macrophage
Colony-Stimulating Factor data were found to be normally distributed between
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population samples and required no transformation. The dependent variables (IL-6, IL-8
and GM-CSF) were then monitored for association through correlation. With a low
correlation between dependent variables, MANOVA was nonetheless conducted to
investigate significant differences between study and control samples of CSF cytokines to
decrease the rate of a type I statistical error of multiple ANOVA tests.
A one-way MANOVA was conducted to determine IL-6, IL-8 and GM-CSF
differences in pain categories. Multivariate analysis of variance results revealed
significant differences among the pain categories on the cytokines, Wilks'

Jc~

0.676, F

(2,34)~ 5.436,p ~ 0.004, multivariate 11 2 ~ 0.324. Analysis of variance was then

conducted on each cytokine as a follow-up test to MANOV A. Pain differences were
found to be significant for IL-8, F (1, 36) ~ 14.89, p < 0.001, partial 11 2 ~ 0.293. The
calculated effect size indicated a decent proportion of IL-8 variance was accounted for by
the presence or absence of chronic pain. Differences in IL-6 and GM-CSF were not
significant, p

~

0. 759 and p

~

0.581 respectively.

Analysis of Psychological and Demographic Data
Correlations were analyzed to determine significance between demographic data,
psychological data and CSF levels of IL-6, IL-8 and GM-CSF. Pearson's r correlations
were utilized to assess significance of interval/ratio-level independent variables.
Spearman's Rho correlations were utilized to determine significance of ordinal-level
independent variables. Tables 6 and 7 summarize correlation analysis and indicate
significance.
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No significance was found between psychological data and levels ofIL-6, IL-8 or
GM-CSF, but all participants did report poor sleep quality. Factors that were found to
have significant or near-significant positive correlations to cytokines included age (p
0.069), length of diagnosis (p

~0.082)

and educational level (p

~

~

0.041). Socioeconomic

status (SES) was found to have a significant negative correlation (p

~

0.012).

Multivariate analysis of variance and ANOV A were used to assess significance of
gender, race, diagnosis and medications to cytokines. Analysis of variance results
displayed significant gender differences for IL-6, F (1,6) ~ 7. 782, p ~ 0.032, 11 2 ~ 0.565.
The calculated effect size for gender indicated a moderate proportion of IL-6 variance
was accounted for by sex. Figures 4, 5 and 6 are box plots that illustrate differences of
cytokines and sex. No significant differences were found between race, diagnosis and
medications with respect to inflammation, but all participants did report taking at least
one opioid medication.
Discussion
The Relationship Between Chronic Pain and Inflammation

Developing research demonstrates mounting evidence of alternative pain
pathways that perpetuate the chronic pain state via physiologic self-propagating
mechanisms. A barrage of aberrant pathways contributes to the maintenance of
nociception in chronic pain states and one of the mechanisms responsible for, and
described in the literature is through glial cell activity (Fleming et al., 2006; Loggia et al.,
2015).

Investigative work on glial cells has identified a selection of various molecules

involved in positive feedback loops responsible for chronic pain, and has established that
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the underlying mechanisms involved render our current methods of fighting pain
ineffective. Some of the proposed responsible molecules secreted by glial cells are
inflammatory mediator molecules, specifically interleukins and tumor necrosis factoralpha (TNF-u). All of these inflammatory cytokines have been shown to excite pain
transmission and experience (Kreutzberg, 1996; Watkins, Milligan, & Maier, 2001 );
inflammatory cytokines can ramp up dorsal horn neurons in pain transmission (Reeve,
Patel, Fox, Walker, & Urban, 2000; Samad, Wang, Broom, & Woolf, 2004), they
increase the release of neurotransmitters from sensory afferent nerves responsible for
pain response (Inoue et al., 1999; Morioka et al., 2002) and may enhance pain via
upregulation of AMPA (2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4-yl) propanoic acid)
and NMDA (N-Methyl-D-aspartate) receptor expression and activity (Beattie et al., 2002;
Samad et al., 2004, Viviani et al., 2003; Wang, et al., 2005).
To adequately assess the level of inflammatory cytokines released from glial cell
activation in response to established chronic pain syndromes, CSF was gathered from
eight chronic pain patients and analyzed in this study. As a means for comparison, study
participant CSF was compared to the CSF of 30 healthy controls. Interleukin-6, IL-8 and
GM-CSF was detectable in CSF through Multiplex assay analyses. Only IL-8 was found
to be significantly higher in chronic pain patients. Thus, this study details the
significance between chronic pain and increased central IL-8 levels.
While the majority of study participants for this study were FBSS patients, other
studies have documented increased CSF levels ofIL-8 in osteoarthritis (Lundborg, Hahn
Zoric, Biber, & Hansson, 2010), postherpetic neuralgia (Kikuchi et al., 1999; Kotani et
246

al., 2000; Rijsdijk et al., 2013), sciatica (Brisby, Olmarker, Larsson, Nutu, & Rydevik,
2002) and fibromyalgia (Kadetoff, Lampa, Westman, Andersson, & Kosek, 2012). Other
studies that utilized FBSS participants indicated increases in IL-6 (Zin, Nissen,
O'Callaghan, Moore, & Smith, 2010) and increased levels of the neurotrophic factors
Brain-Derived Neurotrophic Factor (BDNF) and VEGF (McCarthy, Connor, & McCrory,
2013 ). A complete review of these studies was summarized by Bjurstrom et al. in 2014
(Bjurstrom, Giron, & Griffis, 2014). The current study is the first to document increased
CSF levels ofIL-8 in a majority ofFBSS patients.
The Relationship Between Chronic Pain and Sleep

The complex relationship between pain and poor sleep quality is one that has been
extensively documented in the literature, but its causality not fully understood. Both
processes of pain causing poor sleep, and poor sleep causing pain illustrate the
bidirectional relationship between pain and sleep. From the protective sickness
behavior/sickness response theory, sleep has been suggested as a critical component in
the restorative process of healing (Dantzer, 2001; Hart, 1988; Watkins & Maier, 2000).
Counterproductively, in the presence of chronic pain pathophysiology, the restorative
process is impaired by a lack of sleep: In a complex, detrimental dynamic, pain itself
causes sleep deprivation and sleep deprivation has been shown to increase pain
perception (Chiu et al., 2005; Lautenbacher, Kundermann, & Krieg, 2006; Moldofsky,
2001; Smith & Haythornthwaite, 2004). Up to 53% of chronic back pain patients and
88% ofneuropathic pain patients report sleep disturbances (Meyer-Rosberg et al., 2001;
Tang, Wright, & Salkovskis, 2007). Furthermore, patients with chronic lower back pain
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are 18 times more likely than normal control subjects to experience clinical insomnia
(Tang et al., 2007). Thus, literature supports that sleep and pain do interact with one
another, the abnormalities of sleep are frequently reported by the chronic pain population,
and the effects are not benign: The effects of sleep disturbances have been linked with
poor physical and psychological outcomes, absence from work, decreased performance,
difficulty with personal relationships, accidents and cognitive decline (Fulda & Schulz,
2001 ). Even in healthy individuals, sleep deprivation has been noted to cause
spontaneous pain (Smith, Edwards, McCann, & Haythornthwaite, 2007).
The data linking central inflammation and sleep disturbances has been primarily
found in preclinical reports. Repeated animal studies have shown that upon central
administration of IL-1 to both rabbits and rats, the result is an increase in various aspects
of sleep (Krueger, Walter, Dinarello, Wolff, & Chedid, 1984; Tobler, Borbely, Schwyzer,
& Fontana, 1984) independent of, but similar to the somnogenic effects of TNF-a

(Shoharn, Davenne, Cady, Dinarello, & Krueger, 1987; Kapas et al., 1992). The data on
central inflammation, sleep and pain however is very lacking. In human pain populations
there exists almost a complete deficiency of data comparing inflammatory markers, sleep

and pain. A study by Heffner and colleagues, substantiates that patients with chronic
lower back pain were found to have higher levels of plasma IL-6 than healthy control
subjects. In the chronic pain population studied, poor sleep quality was found to be
associated with greater pain on the following morning (Heffner, France, Trost, Ng, &
Pigeon, 2011 ). The current study is one of the first to inspect central cytokine levels for
associations with psychological factors known to contribute to the chronic pain
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expenence. While data collected from the Pittsburgh Sleep Quality Index (PSQI) did not
provide statistically significant correlations to levels of the central cytokines measured, it
should be noted that all participants scored poor on the sleep measurement tool. Further
inspection on the physiologic link between chronic pain and sleep must be explored.
Socioeconomic Differences in Chronic Pain

Socioeconomic status is well described in the literature as a prominent factor
affecting health trajectories and outcomes, and studies in pain literature echo the same
sentiment. Of those living in lower SES areas, worse pain severity and outcomes are
frequently reported (Brekke, Hjortdahl, & Kvien, 2002; Davies et al., 2009; Fuentes,
Hart-Johnson, & Green, 2007; Green & Hart-Johnson, 2012). Studies on SES have
indicated there is a difference in treatment patterns between the rich and the poor (Haider,
Johnell, Weitoft, Thorslund, & Fastbom, 2009; Thorell, Skoog, Zielinski, Borgquist, &
Halling, 2012; van Doorslaer, Koolman, & Jones, 2004; Vikum, Bj0rngaard, Westin, &
Krokstad, 2013), there is an increased association between work disability related to
chronic pain in the poor (Bergman et al.,2001; Kronborg, Handberg, & Axelsen, 2009;
Patel et al., 2012), and ultimately chronic pain is associated with poorer SES (Jiiud et al.,
2014). Some of the causal factors associating pain to SES in the literature are income,
employment status, social status and education (Bergman et al., 2001; Doran, Drever, &
Whitehead, 2004; Saastamoinen, Leino-Arjas, Laaksonen, & Lahelma, 2005). In this
study, socioeconomic status was found to have a strong negative correlation (r
p

~

~

-0. 823,

0. 012) to inflammation indicating that as socioeconomic status goes down,

inflammation goes up. This could be related to treatment modalities; higher SES
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participants have been found to utilize specialized services, verses the poor who routinely
utilize pharmaceuticals (Haider et al., 2009; van Doorslaer et al., 2004; Vikum et al.,
2013; Thorell et al., 2012). This could be secondary to the type of strenuous manual
labor that is frequented by lower SES persons (Hagen, Holte, Tambs, & Bjerkedal, 2000;
Hagen, Zwart, Svebak, Bovim, & Jacob Stovner, 2005). What is not clear is that contrary
to previous studies that link a lower educational level to chronic pain, the current study
describes educational level to be positively correlated with inflammation (r

~

0.727, p

~

0.041). This could be due to an unanticipated bias in study recruitment; patients were
recruited from a specialized pain service, and were undergoing a specialized and costly
procedure in an affluent part of Los Angeles. This result could also reflect a lack in
participant variability with respect to educational levels: The majority of participants in
this study were highly educated. Further inspection of pain clinics from a large multi
institutional health system, in multiple languages would aid assessing the relationship
between pain, inflammation, SES and educational level.
Gender Differences in Chronic Pain

Gender differences with respect to pain are well documented, but a relatively new
research topic. Owing to a 1990 National Institute of Heath policy suggesting
participation of women in medical and behavioral research, the relationship of gender and
pain are just now starting to be included. Women report pain more frequently (Fillingim,
King, Ribeiro-Dasilva, Rahim-Williams, & Riley, 2009), the prevalence of several
common chronic pain syndromes are found more often in women than men (Mogil,
2012), and literature demonstrates that women consistently report higher pain ratings
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compared to men across different diagnoses (Ruau, Liu, Clark, Angst, & Butte, 2012).
Likewise their response to pain interventions are also different; women exhibit different
responses to opioid analgesics than men (Niesters et al., 2010) and have been reported to
take 3 months longer than men to show improvement of painful symptoms after pain
management (Keogh, McCracken, & Eccleston, 2005). Postulated mechanisms that
influence the difference in pain sensation and treatment include sex hormones (Craft,
2007), differences in cerebral processing of pain (Berman et al., 2006; Derbyshire,
Nichols, Firestone, Townsend, & Jones, 2002; Paulson, Minoshima, Morrow, & Casey,
1998), differing endogenous opioid systems (Smith et al., 2006; Zubieta et al., 2002),
endogenous dopaminergic differences (McEwen, 2001 ), and a multitude of psychosocial
mechanisms including gender roles (Defrin, Shramm, & Eli, 2009; Robinson, Gagnon,
Riley, & Price, 2003; Wise, Price, Myers, Heft, & Robinson, 2002).
In the current study, females were shown to have significantly lower CSF IL-6
levels, and nearly significant lower levels of CSF IL-8 (p

~

0.111) when compared to

men. If women are reporting more pain and experiencing more chronic pain diagnoses
than men, this study's findings do not support that the inflammatory cytokines are
responsible pain in females. However, it should be noted that inflammatory cytokines do
offer one possible physiologic mechanism for the difference in pain experiences between
the sexes. Perhaps the decreased levels of inflammation are responsible for the varied
responses to treatment. Nevertheless, further research is needed to examine the gender
differences with respect to central inflammation and chronic pain.
Opioid Medication in Chronic Pain
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It cannot be overlooked that all participants in this study took at least one opioid

medication. This is consistent with the general chronic pain population and current
national treatment averages (Ahlbeck, 2011; Ballantyne & Mao, 2003; Mehendale,
Goldman, Mehendale, & Rana, 2013). Because data from this study describe an increase
in at least one inflammatory cytokine, one must consider the relationship between opioids
and inflammatory cytokines. Multiple studies have shown that upon administration of
chronic opioids to pain-induced rodents, there was an increase in glial cell activity in the
CNS (Raghavendra et al., 2002; Song & Zhao, 2001; Tai et al., 2006). Glia have also
been shown to upregulate pro-inflammatory cytokine production and release in the CNS
when the organism is treated with longstanding systemic or intrathecal opioids; this
increase of cytokine production and release in the CNS has been shown to contribute to
opioid tolerance and withdrawal induced pain enhancement (Johnston et al., 2004;
Raghavendra, Tanga, & DeLeo 2004; Song & Zhao, 2001). Literature has repeatedly
championed a relationship between central cytokines and opioid medications, and
perhaps it is this relationship that could be exploited for new treatments.
Hutchinson and colleagues' preclinical study demonstrated that by blocking IL-1,
the length of time of opioid analgesia was significantly increased. The study also
demonstrated that an approximate seven-and-a-half-fold increase in analgesic efficacy
with morphine was possible by co-administrating the opioid with a receptor blocker of
IL-1 (Hutchinson et al., 2008). In another preclinical study, Johnston and colleagues
indicated that by blocking IL-1 in the CNS, the analgesia of an intrathecally administered
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opioid was enhanced, opioid tolerance was blunted and both newly developed and
established allodynia and hyperalgesia were reduced (Johnston et al., 2004).
Study Limitations
Because of the cross-sectional, correlational nature of this study's design,
causality of chronic pain and the causal relationships between levels of pro- or anti
inflammatory cytokines, chronic pain, anxiety, depression and sleep deprivation were not
determined. The study design itself limited the findings to providing support for prior
studies and serving as a basis for developing future studies. Given the specific criteria
and study population of this cross-sectional study, this study design also limited the
ability to generalize the results.
The small sample size also limited study findings: While a power analysis was
performed and a target of 30 study participants was determined, this study was only able
to include eight study participants. This was due to changes in study and pain center
personnel, and a trend towards clinically prescribing a different implantable pain device
for treatment of chronic pain. While the small sample size does decrease the
interpretation of the study results, it should be noted that due to the difficulty in obtaining
CSF, this study describes rich results. Other studies with smaller samples sizes have been
common in the pain literature that analyzes human CSF, highlighting the incredibly
valuable data CSF contains (Alexander, Perreault, Reichenberger, & Schwartzman, 2007;
Alexander, van Rijn, van Hilten, Perreault, & Schwartzman, 2005; Backonja, Coe,
Muller, & Schell, 2008; Kadetoff et al., 2012; McCarthy et al., 2013; Nagashima, Morio,
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Yamane, Nanjo, & Teshima, 2009; Rijsdijk et al., 2013; Yeager, Lunt, Arruda, Whalen,
Rose, & DeLeo, 1999).
Obtaining the control samples from an outside source was also a limitation of this
study. While obtaining these samples confirmed that 30 healthy CSF samples could be
obtained, it decreased the time to acquire the CSF samples, lessened the participant
burden and cost of recruiting participants to obtain these samples, these control CSF
samples only came with a limited description and external assurance. The control
samples may not adequately represent the CSF of healthy participants in the general
public.
Three of the four psychological questionnaires utilized by this study were from
direct participant report, while the Hamilton Anxiety Rating Scale was completed by a
research practitioner that consented and obtained demographic information from study
participants. While this study tried to limit the number of practitioners completing the
scales on the participants, to limit inter-reporter variability, a total of four practitioners
ultimately completed the Hamilton Anxiety Rating Scale for this study. This number of
practitioners may have skewed the results for this psychological variable.
Conclusion

This is the first study to describe increased CSF levels ofIL-8 in a majority FBSS
chronic pain population. The study provided supportive evidence that there may be a
relationship between chronic pain and central inflammation in humans, but clearly the
responsible cytokines need further inspection with a larger study population. This data
also provides a rich description of the relationship between gender and central
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inflammation in chronic pain. Psychosocial variables such as educational level and
socioeconomic status were also described in relationship to central inflammation, which
illustrates the complex paradigm chronic pain is. All of the study participants took at
least one opioid medication for treatment of their pain and reported poor sleep quality,
illustrating the need to investigate possible mechanisms of association. This study clearly
demonstrates the need for further inspection of both physiologic and psychological
attributes of chronic pain. Thus, with a greater understanding of the complete chronic
pain picture, the entire patient may find relief in therapy that addresses all facets of the
disease.
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Table 1

Summary ofPsychological Tools Utilized
Behavioral
Measures
Pain

Measurement

Scale

Cronbach's a

The Short FormMcGill Pain
Questionnaire
(SF-MPQ)

'0.73-0.89
b0.96

Anxiety

The Hamilton
Anxiety Rating
Scale
(HAM-A)

Depression

The Beck
Depression
Inventory-II (BDI
II)
The Pittsburgh
Sleep Quality Index
(PSQI)

Scores for the questionnaire can
range from 0 to 45 on the Pain
Rating Index, from 0 to 5 on the
Present Pain Intensity, and from 0 to
10 centimeters on the Visual Analog
Scale. No established scoring noted
liy_ authors
A total anxiety score of <17
indicates mild anxiety levels; 18 to
24 mild-moderate anxiety levels; and
25 to 30 indicates moderate-severe
anxiety levels
0-13: minimal depression; 14-19:
mild depression; 20-28: moderate
depression; and 29-63: severe

Sleep
Quality

'0.89

d0.91

d~ession

Nineteen components that yield a
global score of 0-21, with a total of_:=::_
5 associated with good sleep quality
and> 5 associated with poor sleep

'0.83

_g_uali~

Note.

a

Taken from Burckhardt & Jones, 2003,.b Reported as an Intraclass Correlation

Coefficient for total pain score by Grafton, Foster, & Wright, 2005;' Taken from
Kummer, Cardoso, & Teixeira, 2010;dReported as a Coefficient Alpha by Beck, Steer,
Ball, & Ranieri, 1996; 'Reported by Buysse, Reynolds, Monk, Berman, & Kupfer, 1989.
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Table 2

Summary ofthe Luminex!EJ Performance Human High Sensitivity Cytokine Panel for
Laboratory Analysis
Analytes

Sensitivity (pg/mL)

High Standard Value (pg/mL)

IL-I beta

0.18

1,500

IL-2

0.28

2,450

IL-4

2.54

7,000

IL-5

0.12

1,600

IL-6

0.31

4,050

IL-8

0.07

3,200

IL-10

0.24

2,100

IL-12

2.96

24,500

GM-CSF (GranulocyteMacrophage Colony-Stimulating
Factor)

0.13

1,575

IFN-g (Interferon Gamma)

0.08

1,350

INF-alpha

0.54

3,350

VEGF (Vascular Endothelial
Growth Factor)

1.35

2,000

Note. Accessed from manufacturer's website on March 7, 2015
http ://rndsystems.com/Products/FCS T09
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Table 3

Characteristics ofChronic Pain Population
Gender

Age

F
M

74
54

AA

w

Education
Level
Doctorate
College

F

43

Asian

Master's

F

52

w

Part

Race

Coll~e

Note.

F

41

Hispanic

F

52

AA

M

50

w

Part
College
<High
School
Master's

M

62

Hispanic

College

SES~

METs

BMI

NIR
$100
$149K
$100
$149K
$100
$149K
$80
$89K
<$!OK

1
6

(ki!/m
25.3
35

3

$100
$149K
$60
69K

FBSS
DPN

>5 years

FP,G,O
O,G

Length of
Medication
>2_y_ears
> 1 year

28.9

FBSS

8 years

FP,M,OA

6 years

3

30

FBSS

>lOyears

2 years

2

33.8

S&AS

>6 months

Mor, Pre,
HA, Mel
Flex, Mor

4

35.1

FBSS

2 years

4

38.7

FBSS

25 years

4

32

FBSS

14 years

Diagnosis
2

)

Socioeconomic Status, METF Metabolic Equivalent of Tasks,

W~White, N/R~not

Spondylitis,

SES

reported,

FP~Fentanyl

FBSS~Failed

Patch,

Back Surgery Syndrome,

BMI~

Length of
Dil.!_g_nosis

Medication

>IO~ars

0, Dil, Rob,
G
OA, !bu,
Tap, Die
Cym, Lex,
FP, G,HA,
Rob

Body Mass Index,

DPN~Diabetic

AA~

Polyneuropathy,

>6 months

2 years
> 6 months
14 years

African-America,

S~Sacroiliitis, AS~Ankylosing

G~Gabapentin, O~Oxycodone, M~Methadone, OA~Oxycodone/ Acetaminophen,

MoFMorphine,

Pre~Pregabalin, HA~Hydrocodone/ Acetaminophen, Mel~Meloxicam, Flex~Flexeril, Dil~Dilaudid, Rob~Robaxin, Ibu~Ibuprofen,
Tap~Tapentadol, Dic~Diclofenac, Cym~Cymbalta, Lex~Lexapro

Table 4

Psychological Data
ID

1

Pain
Rating
Index
27

2

22

3
4

28
33

5
6

27
18

7

12

8

16

Note.

PPI~Present

PPI

Quality Index;

HAM-A

BDI-11

PSQI

28
19 Poor
Moderate
19 Mild10
16 Poor
4
6.8
Moderate
Minimal
39 Severe
38 Severe
13 Poor
4
7.0
17 Poor
7 Mild
4
7.9
21
Moderate
N/R
N/R
10 Mild
18 Poor
7 Minimal
36 Severe
5
9.6
20
16 Poor
Moderate
2
5.9
20 Mild10
9 Poor
Moderate
Minimal
2
6.1
18 Mild16 Poor
24
Moderate
Moderate
Pain Intensity; V AS~Visual Analog Scale; HAM-A~Hamilton

Anxiety Rating Scale;

4

VAS
(cm/10
cm)
8.4

BDI-II~Beck

N/R~Not

17 Mild

Depression Inventory-II;

PSQI~Pittsburgb

Sleep

Reported.
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Table 5

Cerebrospinal Fluid Cytokine Levels
Cytokine

Healthy Controls
Chronic Pain
(pg/mL)
(pg/mL)
IL-I
OOR
OOR
IL-2
OOR
OOR
IL-4
OOR
OOR
1.19 ± 0.26
1.33 ± 0.58
IL-6
49.49 ± 12.81
63.04 ± 12.16
IL-8
IL-10
OOR
OOR
TNF-a
OOR
OOR
IFN-g
OOR
OOR
VEGF
OOR
OOR
0.26 ± 0.07
0.24 ± 0.07
GM-CSF
Note. OOR denotes values were out of range of Multiplex Assay

pvalue

_p_~ 0.50
_p_< 0.001

p ~ 0.58
Analyses.
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Table 6

Pearson's r Correlations for Interval/Ratio Variables
Psychological Tools
Pain Ratit~ Index
Present Pain Intensity

IL-6 a
-0.458
-0.515

IL-8 a
-0.289
-0.393

GM-CSF
-0.517
0.153

-0.411
-0.271

-0.609
0.109

0.529
0.409

-0.089

0.113

0.139

-0.179

-0.370

0.080

b

Visual Anal~ Scale
Hamilton Anxiety
Ratil_!g_ Scale
Beck Depression
Inventory-II
Pittsburgh Sleep
Quali.!Y_Index

c

Dem~~hics

0.670(!
0.427
0.447
A__g_e
-0.040
Body Mass Index
0.095
0.08
0.648 e
-0.007
0.524
Length of Diag_nosis
0.288
0.046
0.183
Length of Medication
..
a
b
Note. Values analyzed usmg log transformation, One value omitted from analysis,
One value omitted from analysis;

dp

c

~ 0.069; 'p ~ 0.082.
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Table 7

Spearman 's Rho Correlations for Ordinal Variables
IL-8 a
IL-6"
GM-CSF
Demographics
Educational Level
0.727'
-0.007
0.341
0
-0.823°
Socioeconomic Status
-0.013
0.650
Metabolic E_g_uivalents
0.568
0.393
0.105
a
.o
Note. Values analyzed usmg log transformat10n, One value omitted from analysis,

c

Statistical significance at p ~ 0.041; d Statistical significance at p ~ 0.012.
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Appendix A
University of California, Los Angeles Institutional Review Board-Approved Consent

Fonu
UNIVERSITY OF CALIFORNIA LOS ANGELES
CONSENT TO PARTICIPATE IN RESEARCH

Psychoneuroimmunology and Chronic Pain

INTRODUCTION

Dr. Irene Wu, and associates from the Department of Anesthesiology/Pain Management
Clinic and Cousin's Center for Psychoneuroimmunology at the University of California,

Los Angeles are conducting a research study.
The researchers will explain this study to you. Research studies are voluntary and
include only people who choose to take part. Please take your time about deciding
whether to participate in this study. Before deciding:
• You can discuss this study with friends and family.
• You can also discuss it with your health care doctor or request a second opinion.
• If you have any questions, you can ask the researchers for more information before
deciding to participate.
The research team is asking you to be in this study because you have been diagnosed
with a chronic pain syndrome and are scheduled to have a trial of opioid pain
medication administered to you through a tube (catheter) that is placed in your
cerebrospinal fluid (CSF). The CSF is located in an area of your body called the thecal
sac. Since the catheter is placed inside the thecal sac, this procedure is called an
intrathecal opioid catheter trial. Should you respond favorably to the trial, you will be
considered to be a candidate for permanent implantation of a pain pump. This pain
pump is called an intrathecal pain pump. An intrathecal pain pump is a surgically
implanted device that continuously infuses and delivers opioid pain medications into
your CSF for the treatment of chronic pain.
WHY IS THIS STUDY BEING DONE?
The purpose of this research study is to investigate the relationships between pain,
inflammation, anxiety, depression and sleep patterns.
Changes in inflammation particles found in the fluid surrounding the brain and spine
(cerebrospinal fluid or CSF) and blood, and psychological responses related to chronic
pain will be analyzed over the treatment period that encompasses 1) the intrathecal
opioid catheter trial, 2) the permanent insertion of an intrathecal opioid infusion pain
pump, and 3) at three to six months post insertion of an intrathecal opioid infusion pain

pump.
This study is being funded by the American Association of Nurse Anesthetists and a
CTSI grant funded through the UCLA Cousins Center of Psychoneuroimmunology.
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HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?
Approximately 30 people will take part in this study at UCLA
WHAT WILL HAPPEN IF I TAKE PART IN THIS STUDY?
Before you begin the study:
Before you begin the study, you will need to be diagnosed with a chronic pain condition
and as part of your standard clinical care be scheduled to have an intrathecal opioid
catheter trial and possible insertion of intrathecal pain pump for the treatment of your
pain.
During the study:
If you take part in this study, you allow the researchers to collect a small amount of the
fluid that surrounds the brain and spine (cerebrospinal fluid or CSF) which VllOUld
otherwise not be collected during the intrathecal opioid catheter trial and the permanent
placement of the intrathecal pain pump. Specifically, less than a teaspoon of your CSF
will be collected for inflammation analysis on three separate occasions, during your 1)
intrathecal opioid catheter trial, 2) permanent pump insertion and, 3) at your pump refill
visit.
As part of this research, no additional needles sticks are necessary for the collection of
this fluid except on the pump refill visit, which will take place 3-6 months after the
permanent insertion. However, should it be determined that you are not a candidate for
permanent insertion of the pain pump, you will not proceed with the study after the
intrathecal catheter trial.
During the pump refill visit, which is part of your clinical care, there will be an extra
procedure for research purposes only. Researchers will use fluoroscopy (a live x-ray
machine) to guide a very small needle to draw less than a teaspoon of CSF from your
implanted pump. This should not take more than five minutes of additional time.
During all three visits where your CSF is collected, approximately 2-3 teaspoons of
blood will be collected from the IV started for the procedure or through venopuncture (a
procedure where a small needle is used to withdraw the blood from your vein).
Additionally, the researcher(s) will ask you to fill out three questionnaires at or during
three doctor visits: 1) prior to the intrathecal catheter trial either on the day you are seen
in clinic or the day of your intrathecal opioid catheter trial, 2) preoperatively the day of
your permanent pump insertion and, 3) the day you return to have your pump refill.
These questionnaires will evaluate your mood, anxiety, sleep patterns and level of pain.
You will also be asked to complete forms or ansvver questions related to your
demographic information and diagnosis of chronic pain. Your responses to these
questions will be kept strictly confidential and will not become part of your UCLA
medical record. Also, the way you answer the questions on the questionnaires will not
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influence the medical care you receive. Answering all of the questionnaires should take
approximately 20-30 minutes during each visit..
Should a participant be determined to not be a candidate for permanent implantation of
intrathecal pump based on clinical information gathered at the time of trial (no
improvement in pain response to the intrathecal pain medications or significant side
effects to the pain medication), the participant will not proceed with the treatment course
of a permanent intrathecal pump and any further study procedures. Should the
participant not respond to the trial, and the permanent pump is not implanted, the
patient's cerebrospinal fluid will be analyzed for the presence of the inflammation
particles and only the initial three questionnaires on levels of anxiety, depression and
sleep patterns will be used for research purposes.

HOW LONG WILL I BE IN THIS STUDY?
This study will last approximately one year.
WHAT KINDS OF RISKS OR DISCOMFORTS COULD I EXPECT?
Known risks and discomforts:
The possible risks and/or discomforts associated with the procedures described in this
consent form include:

Cerebrosp1nal Fluid CCSF) Samol1na Your treatment involves undergoing a surgical
procedure called an intrathecal opioid catheter trial with possible permanent intrathecal
pain pump insertion. During these procedures, the sac containing CSF is punctured
and a catheter is inserted in order for opioid pain medications to be infused. Prior to
and during the placement of the catheter, a small amount of CSF is normally lost or
drained through the needle. This drainage is a known and accepted component of
performing this surgical technique.
Your participation in the study involves allowing us to collect three milliliters (less than a
teaspoon) of CSF from the needle that is placed. Collection of the CSF will not
significantly increase the risks or reduce the benefits of your already scheduled surgical
procedure to place the trial catheter or permanently implant the pump. Hovvever, you
should be aware that there are risks during the collection of the last CSF sample once
the pump is permanently in place.
During the final CSF draw at the pump refill visit, a 25-guage needle will be inserted
precisely (using an x-ray called fluoroscopy) through the study participant's surgically
prepped and draped abdomen into the catheter access port on the Medtronic
SynchroMed® II Pain Pump. Two milliliters (less than a teaspoon) of CSF will be drawn
out and this specimen collection procedure is anticipated to take less than five minutes
of surgical time. This CSF sample represents the only amount of CSF that is above and
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beyond the surgically anticipated surgical CSF loss and represents a minimal amount of
CSF present in the adult central nervous system (CNS).
The 2 milliliters (less than a teaspoon) sample of CSF necessary for study analysis and
the five minutes of surgical time to collect this sample represent a small but notevvorthy
participant burden. The risk of developing a spinal headache from the 2 milliliters of
CSF sampled is a small, but a serious risk to the study participant. A spinal headache
is a severe headache that can increase in severity when one sits up or changes
positions abruptly. Usually persons with spinal headaches report that the headache is
less severe when lying down. Most of the time spinal headaches resolve on their own
but occasionally a spinal headache requires treatment. Treatments for spinal
headaches include a procedure called an epidural blood patch. This treatment involves
taking a sample of blood and injecting it into the epidural space to stop the leakage of
CSF and thus, the spinal headache.
Infection: During the final CSF collection from the implanted pump, participants will
receive an additional needle stick. The needle stick will be performed utilizing the same
surgical sterile preparation and draping as the pump refill procedure but this collection
of CSF does represent an additional risk of infection. An infection after a 25-gauge
needle stick is rare, but does represent a potential additional risk to the participant. Should
an infection occur, treatment including antibiotics or additional surgery may be necessary.
Radiation: During the pump refill visit in which CSF will be withdrawn from the catheter
access port of the Medtronic SynchroMed® II Pain Pump, fluoroscopy will be utilized to
locate the catheter access port of the device. Fluoroscopy will be utilized to minimize
the number of needle sticks necessary to access and precisely locate the catheter
access port of the pain pump. This is both for your comfort and safety.
You are exposed to radiation on a daily basis, both from natural (sun and earth) and
manmade sources. The estimated radiation dose that you will receive as a volunteer for
this type of research has been compared to the limits allowed for a radiation vvorker.
This limit is low and is not expected to be harmful. The person obtaining your consent
can ansvver any questions you have, and provide detailed written information about the
amount of radiaiton resulting from this study.
Pain Pump Reprogramming Malfunction: During the final visit for the pump refill of pain
medication, CSF will be collected from a port on the Medtronic SynchroMed® II Pain
Pump. Once the CSF has been collected, the pump will need to be refilled and
electronically reset with the approved Medtronic N'Vision® 8840 Programmer to ensure
the proper rate of pain medication infusion via the pain pump and intrathecal catheter.
Although unlikely, malfunctioning of the repriming and reprogramming of the Medtronic
SynchroMed® II Pain Pump can result in a wide spectrum of side effects expectant from
an overdose of narcotic medications ranging from pruitis (itching) to ventilatory
depression (difficulty breathing) to death if incorrectly programmed and left untreated.
The UCLA Pain Management medical doctors that perform intrathecal opioid infusion
pain pump maintenance, including pump refills, have done so in hundreds of past
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patients in chronic pain treatment endeavors with no adverse events related to
repriming and reprogramming of the intrathecal catheter or pain pump.

Bleeding: It is possible, though unusual, to experience a bleeding episode through a 25
gauge needle stick. Should bleeding occur, it may require emergency treatment to drain
accumulated blood called a hematoma.
Scarring: In rare cases, scarring from a 25-gauge needle stick may result. This
represents a small but additional risk to study participants. There is no treatment for
this risk.
Blood Sampling:
Infection. Before the surgical procedure where study samples of CSF will be collected,
there is a risk of infection upon insertion of an intravenous catheter or upon
venopuncture. An infection after an intravenous catheter insertion or venopuncture is
rare, but does represent a potential risk. Should an infection occur, treatment including
antibiotics or additional surgery may be necessary.
Bleeding. It is possible, though unusual, to experience an excessive bleeding through
an intravenous needle stick or venopuncture site. The smallest appropriate catheter or
venopuncture needle will be used in every effort to minimize bleeding and discomfort for
study participants. Should bleeding occur, it may require emergency treatment to drain
accumulated blood called a hematoma.
Scarring. In rare cases, scarring from an intravenous needle stick or venopuncture may
result. This represents a small risk to study participants.
Unknown risks and discomforts:
The experimental procedure may have side effects that no one knows about yet. The
researchers will let you know if they learn anything that might make you change your
mind about participating in the study.
ARE THERE ANY BENEFITS IF I PARTICIPATE?
Possible benefits to me:
You will not benefit directly from participating in this study.
Possible benefits to others or society:
This study will help the researchers learn more aOOut inflammation and chronic pain,
depression, anxiety and sleep deprivation. Hopefully this information will help in the
treatment of future patients with chronic pain like yours.
WHAT OTHER CHOICES DO I HAVE IF I DON'T WANT TO PARTICIPATE?
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If you decide not to take part in this study, or if you withdraw from this study before it is
completed, the following alternative procedures or courses of treatment are available:
Your alternative is not to participate in the research. You can proceed with the same
procedures and treatments for your pain without participating in the research.
CAN THE RESEARCHERS REMOVE ME FROM THIS STUDY?
The researchers may end your participation in this study for a number of reasons, such
as if your safety and welfare are at risk, if you do not follow instructions or if you miss
scheduled visits. The researchers or the study sponsor might also decide to stop the
study at any time.
If you decide to stop being in the study, or are removed from the study, or the study is
stopped the researcher will ask you to submit in writing your intent to discontinue your
involvement in this study.
HOW WILL INFORMATION ABOUT ME AND MY PARTICIPATION BE KEPT
CONFIDENTIAL?
The researchers will do their best to make sure that your private information is kept
confidential. Information about you will be handled as confidentially as possible, but
participating in research may involve a loss of privacy and the potential for a breach in
confidentiality. Study data will be physically and electronically secured. As with any use
of electronic means to store data, there is a risk of breach of data security.
Use of personal information that can identify you:
•The researchers will make every attempt to protect your confidentiality and to make
sure that your personal identity does not become known. This signed consent form will
be stored in a locked file that will be accessible only to a very small number of
authorized people involved in this project. The research team will carefully follow the
coding, storage, and data sharing plan explained below.
How information about you will be stored:
• No identifiable information about you will be kept with the research data.
•All identifiable information about you will be replaced with a code. A list linking the
identifiable information and associated code will be locked in tv-Jo secure locations.
•Some research data and records will be maintained in a secure location at UCLA.
Only authorized individuals will have access to it.
•Some research data and records will be stored on a laptop computer that is passcode
protected and your identifiable information will be kept separate from the research data.

People and agencies that will have access to your information:
The research team and authorized UCLA personnel may have access to study data and
records to monitor the study. Research records provided to authorized, non-UCLA
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personnel will not contain identifiable information about you. Publications and/or
presentations that result from this study will not identify you by name.
How long information from the study will be kept:
•The researchers intend to keep the research data and records until the research is
published and/or presented or until the analysis of the records are complete, whichever
is longer.
• In the future, data collected for this study may be shared with other researchers for
other studies that are unknown at this time. Any data shared with other researchers, will
not include your name or other personal identifying information.

ARE THERE ANY COSTS FOR TAKING PART IN THIS STUDY?
You or your insurer will be billed for the costs of any standard medical care you receive
during your participation in the study and you will be responsible for any associated co
payments and deductibles. Above the standard medical care costs, there are no
additional cost burdens to you. You will not be charged for the laboratory tests that will
be run on the CSF samples we collect from you.

WILL I BE PAID FOR MY PARTICIPATION?
You will be given a $25 VISA pre-paid gift card for your participation in this study at the
time of enrollment. Should it be determined that you are not a candidate for f:ermanent
pain pump insertion, you will not proceed with the remainder of the study and will not
receive any further compensation. Should you proceed to the remaining steps of the
study and complete the study, you will receive an additional $25 VISA pre-paid gift card
at the time of your last CSF draw visit.
You will be reimbursed for the following out of pocket expenses that you might have:
Parking fees for each doctor visit that is research related.
WHAT OTHER THINGS SHOULD I CONSIDER BEFORE PARTICIPATION?
Use of My Specimens:

Any specimens (e.g., CSF or blood) obtained for the purposes of this study will become
the property of the University of California. Once you provide the specimens you will not
have access to them. The University may share your specimens in the future with other
researchers or outside institutions. Information that identifies you will not be shared with
anyone outside of UCLA. The specimens will be used for research and such use may
result in inventions or discoveries that could become the basis for new products or
diagnostic or therapeutic agents. In some instances, these inventions and discoveries
may be of potential commercial value and may be patented and licensed by the
University. You will not receive any money or other benefits derived from any
commercial or other products that may be developed from use of the specimens.
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All of the specimens of cerebrospinal fluid will be labeled with a numeric code rather
than any personal identifiers to maintain your anonymity. Only limited research
personnel will have access to the list that links your personal information to your
numeric code and this list will be destroyed once the research is published and/or
presented or until the analysis of the records are complete, whichever is longer.
WHO CAN I CONTACT IF I HAVE QUESTIONS ABOUT THIS STUDY?
The Research Team:
You may contact Dr Irene Wu and Dr Michael Ferrante at (310) 794-1841 with any
questions or concerns about the research or your participation in this study. You can
also call the UCLA Page Operator at (310) 825-6301 to reach Dr Irene Wu 24 hours a
day, 7 days week.

UCLA Office of the Human Research Protection Program (OHRPP):
If you have questions about your rights while taking part in this study, or you have
concerns or suggestions and you want to talk to someone other than the researchers
about the study, you may contact the UCLA OHRPP by phone: (310) 825-5344; by
email: mirb@research.ucla.edu or U.S. mail: UCLA OHRPP, 11000 Kinross Ave., Suite
211, Box 951694, Los Angeles, CA 90095-1694.
WHAT HAPPENS IF I BELIEVE I AM INJURED BECAUSE I TOOK PART IN THIS
STUDY?
It is important that you promptly tell the researchers if you believe that you have been
injured because of taking part in this study. You can tell the researcher in person or call
him/her atthe number(s) listed above.
If you are injured as a result of being in this study, UCLA will provide necessary medical
treatment. The costs of the treatment may be covered by the University of California, or
billed to you or your insurer just like other medical costs, depending on a number of
factors. The University and the study sponsor do not normally provide any other form of
compensation for injury. For more information about this, you may call the UCLA Office
of the Human Research Protection Program at 310-825-5344 or send an email to
mirb@research.ucla.edu.
WHAT ARE MY RIGHTS IF I TAKE PART IN THIS STUDY?
Taking part in this study is your choice. You can choose whether or not you want to
participate. Whatever decision you make, there will be no penalty to you and you will not
lose any of your regular benefits.
• You have a right to have all of your questions answered before deciding whether to
take part
• Your decision will not affect the medical care you receive from UCLA.
• If you decide to take part, you can leave the study at anytime.
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•

•

If you decide to stop being in this study you should notify the research team right
away. The researchers may ask you to complete some procedures in order to
protect your safety.
If you decide not to take part, you can still get medical care from UCLA.

HOW DO I INDICATE MY AGREEMENT TO PARTICIPATE?
If you agree to participate in this study you should sign and date below. You have been
given a copy of this consent form and the Research Participant's Bill of Rights to keep.
You will be asked to sign a separate form authorizing access, use, creation, or
disclosure of health information about you.
SIGNATURE OF THE PARTICIPANT

Name of Participant

Signature of Participant

Date

SIGNATURE OF PERSON OBTAINING CONSENT

Name of Person Obtaining Consent

Contact Number

Signature of Person Obtaining Consent

Date
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Appendix B

Measurement of Pain Perception

SHORT·FORM McGILL PAIN QUESTIONNAIRE
RONALD MELZACK

DATE:

PATIENT'S NAME:
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Appendix C
Measurement of Anxiety

I Hamilton Anxiety Rating Scale (HAM-A)
Below is a list of phrases that describe certain feeling that people have. Rate the patients by finding the answer which best describes the extent
to which he/she has these conditions. Select one of the five responses for each of the fourteen questions.
0 = Not present,

I =Mild,

2 = Moderate,

Anxious mood
Worries. anticipation of the worst, fearful anticipation, irritability.

8

3 = Severe,

4 =Very severe.

Somatic (sensory)

Tinnitus, blurring of vision , hot and cold flushes, feelings of weakness,
pricking sensation.

2

Tension

Feelings of tension. fatigability. scrtle response. moved to tears
easily, trembling, feelings of restlessness, inability to relax.

9

Cardiovascular symptoms

Tachycardia, palpiCltions, pain in chest, throbbing of vessels, fainting
feelings, missing beat.

3

Fears

Of dark. of strangers. of being left alone. of animals. of traffic. of
crowds.
4

Insomnia

I0

Respkatory symptoms

Pressure or constriction in chest. choking feelings. sighing. dyspnea.
II

Gasfrointestinal symptoms

[]]

DJ [}]

[I] [1J

Difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue

Difficulty in swallov.ing. wind abdominal pain. burning sensations.

on waking, dreams, nightmares, night terrors.

abdominal fullness, nausea, vomiting, borborygmi, looseness of

bowels. loss of weight. constipation.

s

Intellectual

Difficulty in concentration. poor memory.

12

Genitourinary symptoms

Frequency of micturition, urgency of micturition, amenorrhea,

6

Depressed mood

Loss of interest, lack of pleasure in hobbies, depression, early waking,

diurnal swing.
7

Somatic (muscular)

Pains and aches, tv.ritching, stiffness, myoclonic jerks, grinding of
teeth, unsteady voice, increased muscular tone.

menorrhagia, development of frigidity, premature ejaculation, loss of
libido, impotence.

13

Autonomic symptoms

Dry mouth. flushing. pallor. tendency to sweat, giddiness. tension
headache, raising of hair.

14

Behavior at interview

Fidgeting. restlessness or pacing. tremor of hands. furrowed brow.
strained face, sighing or rapid respiration. facial pallor. swallowing.
etc.
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AppendixD

Meamranent ofD~press'io11
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Appendix E
Measnrement of Sleep Quality
Page 1 of 4

AM

Subject's lnitials_ _ _ _ _ _ _ID#_ _ _ _ _ _ _ _Date_ _ _ _ _ _ _Time_ _PM

PITTSBURGH SLEEP QUALITY INDEX
INSTRUCTIONS:
The following questions relate to your usual sleep habits during the past month only. Your answers
should indicate the most accurate reply for the majority of days and nights in the past month.
Please answer all questions.

1.

During the past month, what time have you usually gone to bed at night?
BED TIME _ _ __

2.

During the past month, how long (in minutes) has it usually taken you to fall asleep each night?
NUMBER OF MINUTES _ _ __

3.

During the past month, what time have you usually gotten up in the morning?
GETTING UP TIME _ _ __

4.

During the past month, how many hours of actual sleep did you get at night? (This may be
different than the number of hours you spent in bed.)
HOURS OF SLEEP PER NIGHT _ _ __

For each of the remaining questions, check the one best response. Please answer all questions.

5.

During the past month, how often have you had trouble sleeping because you .

a)

Cannot get to sleep within 30 minutes
Not during the
Less than
past month _ _ once a week__

b)

Three or more
times a week_ _

Wake up in the middle of the night or early morning
Not during the
Less than
past month _ _ once a week__

c)

Once or twice
a week_ _

Three or more

Once or twice
a week_ _

times a week_ _

Once or twice
a week_ _

times a week_ _

Have to get up to use the bathroom
Not during the
Less than
past month _ _ once a week__

Three or more
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d)

Cannot breathe comfortably
Not during the
Less than
past month_ _ once a week_ _

e)

Three or more
times a week_ _

Once or twice
a week_ _

Three or more
times a week_ _

Once or twice
a week_ _

Three or more
times a week_ _

Once or twice
a week_ _

Three or more
times a week_ _

Have pain

Not during the
Less than
past month_ _ once a week_ _

j)

Once or twice
a week_ _

Had bad dreams
Not during the
Less than
past month_ _ once a week_ _

i)

Three or more
times a week_ _

Feel too hot
Not during the
Less than
past month_ _ once a week_ _

h)

Once or twice
a week_ _

Feel too cold
Less than
Not during the
past month_ _ once a week_ _

g)

Three or more
times a week_ _

Cough or snore loudly
Not during the
Less than
past month_ _ once a week_ _

f)

Once or twice
a week_ _

Other reason(s), please describe

How often during the past month have you had trouble sleeping because of this?

Not during the
Less than
past month_ _ once a week_ _

6.

Once or twice
a week_ _

Three or more
times a week_ _

During the past month, how would you rate your sleep quality overall?

Very good
Fairly good _ _ _ __
Fairly bad
Very bad
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7.

During the past month, how often have you taken medicine to help you sleep (prescribed or
"over the counter")?
Not during the

Less than

Once or twice

past month ___ once a week__ a week_ __
8.

During the past month, how often have you had trouble staying awake while driving, eating
meals, or engaging in social activity?
Not during the

Less than

Once or twice

past month ___ once a week__ a week_ __
9.

Three or more
times a week_ __

Three or more
times a week_ __

During the past month, how much of a problem has it been for you to keep up enough
enthusiasm to get things done?
No problem at all
Only a very slight problem
Somewhat of a problem
A very big problem

10.

Do you have a bed partner or room mate?
No bed partner or room mate
Partner/room mate in other room
Partner in same room, but not same bed
Partner in same bed

If you have a room mate or bed partner, ask him/her how often in the past month you
have had .
a)

Loud snoring
Not during the
Less than
past month ___ once a week__

b)

Three or more
times a week_ __

Long pauses between breaths while asleep
Not during the
Less than
past month ___ once a week__

c)

Once or twice
a week_ __

Once or twice
a week_ __

Three or more
times a week_ __

Once or twice
a week_ __

Three or more
times a week_ __

Legs twitching or jerking while you sleep
Not during the
Less than
past month ___ once a week__
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d)

Episodes of disorientation or confusion during sleep
Not during the
Less than
past month___ once a week_ __

e)

Once or twice
a week_ __

Three or more
times a week_ __

Other restlessness while you sleep; please describe_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Not during the
Less than
past month___ once a week_ __

Once or twice
a week_ __

Three or more
times a week_ __

©1989, University of Pittsburgh_ All rights reserved_ Developed by Buysse,D_J_, Reynolds,C_F_, Monk,T_H_, Berman,S_R., and
Kupfer,D_J_ of the University of Pittsburgh using National Institute of Mental 1-iaalth Funding
Buysse OJ, Reynolds CF, Monk TH, Berman SR, Kupfer OJ: Psvchiatry Research, 28:193-213, 1989.
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Appendix F
Demographic Clinical Data Questionnaire

Code:

To Be Filled Out by Research Practitioner:

Cause/Diagnosis of Chronic Pain (i.e. Failed Back):
Length of Chronic Pain Diagnosis: _ _ _ _ _ _ _ _ _ _ _ _ __

Types of Medications Taken by Patient for Treatment of Chronic Pain:

Length of Time Patient Has Been Taking Medications:

303

Appendix G
Demographic Data Questionnaire
Code: - - - - Please Do Not Flll in Above
Age:_ _ __

Height:
Gender: M

Weight:_ _ _ _ __

F (Please Circle One)

Race: White

White, Non-Hispanic

Asian-Pacific Islander

Native American

African-American

Hispanic

(Please Circle One)

Education Level: (Please Circle One)
Less than High School
High School/GED
Some College
2-year College Degree (Associates)
4-year CollegeDegree (BA, BS)
Master's Degree
Doctoral Degree
Professional Degree (MD, JD)

Total Household Income: (Please Circle One)
Less than $10,000
$10,001-$19,999
$20,000-$29,999
$30,000-$39,999
$40,000-$49,999
$50,000-$59,999
$60,000-$69,999
$70,000-$79,999
$80,000-$89,999
$90,000-$99,999
$100,000-$149,999
>$150,000
Physical Activity Level (Please Circle Highest Level of Current Activity You Can Complete
Without Stopping)

Sit Upright

2

Eat, dress, use toilet, make bed
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3
4

Walk around house, shower
One flight stairs, walk up hill, walk flat - 2 block, 2mph
Light house work, dust, wash dishes, golf, bowl

5
6

Two flights stairs, walk on flat at 4mph, Sex
Scrubbing floors, move furniture
weight lifting
Shovel Snow
Doubles teruris, swing dancing
Singles teruris, soccer, basketball, skiing, running
Competitive Sports

7

8
9
10
12+
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University of California, Los Angeles Institutional Review Board Approval
~/17/H

11:12AM

Univers~y of California Los Angeles
11000 Kinross Avenue. Suite 211
Los Angeles. CA 90095-1694

http://ohrpp. research. ucla .ed u
GC-IRB (310) 825-7122
M-IRB (310) 825-5344

APPROVAL NOTICE
New Study
DATE:
TO:
FROM:
RE:

1212012012
ANDREA NICOL
ANESTHESIOLOGY
JAMES MC GOUGH. MD
Chair. MIRB3
IRB#l 2-001588
Psychone1U0immunology and Chronic Pain
Version: 1112312012 >&.O

The UCLA Institutional Review Board (UCLA IRS) has approved the above-referenced study. The UCLA IRB's
FederalwideAssurance (FVV~ w~h Department of Health and Human Services is FW)l()0004642 (IRED0004473).
Submission and Review Information
Type of Review

Full Board Review

Approval Date

12/2012012

Expiration Date of the Study 1211212013

Funding Source( s)

1) AMERICAN ASSOCIATION OF NURSE
jANESTHETISTS FOUNDATION
Grant Title: Psychoneuroimmune Resp::mses
land Chronic Pain

Specific Conditions for Approval
-- Research Participants Bill of Rights - By California law, a copy of the
Research Participants Bill of Rights in a language in which the participant is fluent
must be given to all research participants in this study as there is a real or
lforeseeable risk of biomedical harm. Numerous translations are available for
download on the HRPP website at http:l/www.ohrpp.research.ucla.edu/pageslbill
of-rig_hts.

http s: I /We bi rb .re sear<:h.uda.ed u/\\~ bl Rt/ Do<:/ 01 E.NS4P<I 9C~2 Kttl#C7S68C9D7&/fromS tring. html
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3/17/ 131112AM

Documents Reviewed included, but were not limited to:

!Document Name
12-001588 ....C..onse!Jlv3. O....C..SF

~df...12.df

l!Jocurnentj
!version#
tJ:o1

Important Note: Approval by the Institutional Review Board does not, in and of itself, constitute approval for the
implementation of this research. Other UCLA clearances and approvals or other external agency or collaborating
institutional approvals may be required before study activities are initiated. Research undertaken in conjunction with
outside entities, such as drug or device companies, are typically contractual in nature and require an agreement between
the University and the entity.
General Conditions of Approval
As indicated in the Pl Assurances as part of the IRB requirements for approval, the Pl has ultimate responsibility for the
conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects,
and strict adherence to any stipulations imposed by the IRB.
The Pl and study team will comply with all UCLA policies and procedures, as well as with all applicable Federal, State, and
local laws regarding the protection of human subjects in research, including, but not limited to, the following:
•
•

•

•
•

•

Ensuring that the personnel performing the project are qualified, appropriately trained, and will adhere to the
provisions of the approved protocol,
Implementing no changes in the approved protocol or consent process or documents without prior IRB approval
(except in an emergency, if necessary to safeguard the well-being of human subjects and then notifying the IRB as
soon as possible afterwards),
Obtaining the legally effective informed consent from human subjects of their legally responsible representative,
and using only the currently approved consent process and stamped consent documents, as appropriate , with
human subjects,
Reporting serious or unexpected adverse events as well as protocol violations or other incidents related to the
protocol to the IRB according to the OHRPP reporting requirements.
Assuring that adequate resources to protect research participants (i.e., personnel, funding, time, equipment and
space) are in place before implementing the research project, and that the research will stop if adequate resources
become unavailable.
Arranging for a co-investigator to assume direct responsibility of the study ifthe Pl will be unavailable to direct this
research personally, for example, when on sabbatical leave or vacation or other absences. Either this person is
named as co-investigator in this application, or advising IRB via weblRB in advance of such arrangements.

https / /w@bi(b.f@S@an:h .w.:la.@d u/ W@blRB /Doc_/O/ENS4P49CMJ2 KBBNVG 7568G907B/ from5Uir1g .html

Pag@ 2 of 2
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Appendix I

University of California, Los Angeles Institutional Review Board Continuation
Approval 2013
2/18115, 11 :25 AM

University of California Los Angeles
11000 Kinross Avenue, Suite 211
Los Angeles, CA90095-1694
bll1lJLgbrp.p res•arch qc!a odq
GC-IRB (310) 825-7122
M-IRB (310) 825-5344

APPROVAL NOTICE
DATE:
TO:
FROM:
RE:

12/ll/2D13
IRENE WU
ANESTHESIOLOGY
JAMES MC GOUGH, MD
Chair, MIRID
IRB#12-DD1588-CR-DDDD1
2D13 Review for IRB#12-DD1588
Psychoneuroimmunologyand Chronic Pain
Version ll/23/2D12 v2.D

The UCLA lnsiitutional Review Board (UCLA IRB) bas approved the above-referenced siudy. The UCLA IRB's
FederaM!ide Assurance (FWA) with Department of Health and Human Services is F\/\IA00004642 (IRB00004473).
Submission and Review lnformalion

ffype of Submission
ffype of Review
jApproval Date
Expiration Date of the Study

Funding Source(s)

Continuing Review
Full Boa rd Review
12/11/2D13
1D/9/2D14
1) AMERICAN ASSOCIATION OF NURSE
ANESTHETISTS FOUNDATION
Grant Title: Psychoneuroimmune Responses
and Chronic Pain
2) Other: UCLA Cousins Center for
Psychoneuroimmunology I UCLA CTSI
Grant Title: Interdisciplinary Seed Grant
Program of the Cousins Center for
Psychoneuroimmunology
Grant Number: UCLA CTSI Grant Number
ULlTRDDD124

Specific Conditions for Approval
nnps :l/'lteOlrtl .reGesrcn.ucla.eQJ/WeO IR 8'0oc/O/OV4 HOOS EM8P4H09GA3KNLN3N2E/fromSV'lng.mml

Psge1of2
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2118115, 11,25 AM

- Research Participants Bill of Rights - By California law, a copy of the Research
Participants Bill of Rights in a language in which the participant is fluent must be
iv en to all research participants in this study as there is a real or foreseeable risk
fbiomedical harm. Numerous translations are available for download on the HRPP
ebsite at htt ://www.ohr .research.ucla.edu/ a es/bill-of-ri hts.
Documents Reviewed included, but were not limited to:

!Document Name
12-001588 Final Consentv5 Cleanllil[_llilf

!Docurnentj
!version #
fl,02

Important Note: Approval by the Institutional Review Board does not, in and of itself, constitute approval for the
implementation of this research. Other UCLA clearances and approvals or other external agency or collaborating
institutional approvals may be required before study activities are initiated. Research undertaken in conjunction with
outside entities , such as drug or device companies, are typically contractual in nature and require an agreement between
the University and the entity.

General Conditions of Approval
As indicated in the Pl Assurances as part of the IRB requirements for approval , the Pl has ultimate responsibility for the
conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects , and
strict adherence to any stipulations imposed by the IRB.
The Pl and study team will comply with all UCLA policies and procedures, as well as with all applicable Federal , State, and
local laws regarding the protection of human subjects in research, including, but not limited to, the following:
•
•

•

•
•

•

Ensuring that the personnel performing the project are qualified, appropriately trained, and will adhere to the
provisions of the approved protocol ,
Implementing no changes in the approved protocol or consent process or documents without prior IRB approval
(except in an emergency, if necessary to safeguard the well-being of human subjects and then notifying the IRB as
soon as possible afterwards),
Obtaining the legally effective informed consent from human subjects of their legally responsible representative ,
and using only the currently approved consent process and stamped consent documents, as appropriate, with
human subjects,
Reporting serious or unexpected adverse events as well as protocol violations or other incidents related to the
protocol to the IRB according to the OHRPP reporting requirements.
Assuring that adequate resources to protect research participants (i.e., personnel, funding, time, equipment and
space) are in place before implementing the research project, and that the research will stop if adequate resources
become unavailable.
Arranging for a co-investigator to assume direct responsibility of the study ifthe Pl will be unavailable to direct this
research personally, for example, when on sabbatical leave or vacation or other absences. Either this person is
named as co-investigator in this application , or advising IRB via weblRB in advance of such arrangements.

http s ://web irb. res earch. u cl a. e d u!We b IR BID oc/O / OV 4H 0 C 8EM 8 P 4H 0 9 GA3 K N L N 3N 2 E/ fromStri n g .ht m l
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Appendix J
University of California, Los Angeles Institutional Review Board Continuation
Approval 2014
2/181'1 S. 11 :24 AM

University of California Los Angeles
11000 Kinross Avenue, Suite 211
Los Angeles. CA90095-1694

bllllJLgbrpp res•arch qcla odq
GC-IRB (310) 825-7122
M-IRB (310) 825-5344

APPROVAL NOTICE
DATE:

8/7/2014

TO:

IRENE WU
ANESTHESIOLOGY & PERIOPERATIVE MEDICINE

FROM:

JAMES MCGOUGH. MD
Chair. MIRE3

RE:

I RB#l2-001588-CR-00002
2014 Review for IRB#l2-001588
Psychoneuroimmunology and Chronic Pain
Version 11123/2012 v2.0

The UCLA lns1itutional Review Board (UCLA I RB) has approved the above-referenced siudy. UCLA's F ederaMlide
Assurance (FW~ with Department of Health and Human Services is FW)l()0004642 ( IRB00004473).

Submission and Review Information

[ype of Submission
[YJl8 of Review

~proval Date
Expiration Date of the Study

Funding Source(s)

Continuing Review
Full Boa rd Review

817/2014
7/23/2015
1) AMERICAN ASSOCIATION OF NURSE
ANESTHETISTS FOUNDATION
Grant Pl SARAH GIRON
Grant Title: F\iychoneuroimmune Responses
and Chronic Pain
2) Other: UCLA Cousins Center for
Psychoneuroimmunology I UCLA CTSI
Grant Pl IRENE WU
Grant Title: Interdisciplinary Seed Grant
Program of the Cousins Center for

nnps :llvt«>lrtl .reisesrcn.uc1a.eOJ/weo 1R 8'0oc/OIKF8FPPSNKCOK7E67Q218 F0641 1/fromS11"1ng.rnm1

Psge1of3

310

2118115, 11,24 AM

Psychoneuroirnmunology
Grant Number: UCLA CTSI Grant Number
ULl TROOOl 24

Specific Conditions for Approval

- UCLA Serving as Reviewing IRB - The UCLA IRB has agreed to serve as the
eviewing IRB for University of California San Diego's involvement in this research
jaccording to the provisions of the UC MOU.
- Research Participants Bill of Rights - By California law, a copy of the Research
Participants Bill of Rights in a language in which the participant is fluent must be
~i_ven to all research participants in this study as there is a real or foreseeable risk
~fbiomedical harm. Numerous translations are available for download on the HRPP
tvve bsite at http://www.ohrpp.re search. ucl a .edu /page s/bil I-of-rights.
- UCLA HIPAAAuthorization is required for this research. Copies in English and
t-tarious translations are available at
I:!_ttp :/lo ra. research .u cla. edu/OH R PP/Pages/PH I Permission Forms .aspx
Documents Reviewed included, but were not limited to:

pocurnentj

Pocurnent Name

~rsion #

12-001588 UCSD Studx Consentv2.lli!Ludf
12-001588 Final Consent v5 Cleanlli!Lllilf

P.02
[l.03

Important Note: Approval by the Institutional Review Board does not, in and of itself, constitute approval for the
implementation of this research. Other UCLA clearances and approvals or other external agency or collaborating
institutional approvals may be required before study activities are initiated. Research undertaken in conjunction with
outside entities, such as drug or device companies, are typically contractual in nature and require an agreement be\\Neen
the University and the entity.
General Conditions of Approval
As indicated in the Pl Assurances as part of the IRB requirements for approval, the Pl has ultimate responsibility for the
conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects, and
strict adherence to any stipulations imposed by the IRB.
The Pl and study team will comply with all UCLA policies and procedures, as well as with all applicable Federal, State, and
local laws regarding the protection of human subjects in research, including, but not limited to , the following:
•
•

•

Ensuring that the personnel performing the project are qualified, appropriately trained, and will adhere to the
provisions of the approved protocol,
Implementing no changes in the approved protocol or consent process or documents without prior IRB approval
(except in an emergency, if necessary to safeguard the well-being of human subjects and then notifying the IRB as
soon as possible afterwards) ,
Obtaining the legally effective informed consent from human subjects of their legally responsible representative,
and using only the currently approved consent process and stamped consent documents, as appropriate, with
human subjects,

htt ps:/ / web irb .res e arch .u c! a .e du/Web IR B/ D oc/O / KF 6FPP 5 NKCO K7 E6 7Q2!8 F06411 / fromString . htm l
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•

Reporting serious or unexpected adverse events as well as protocol violations or other incidents related to the
protocol to the IRB according to the OHRPP reporting requirements.
• Assuring that adequate resources to protect research participants (Le,, personnel, funding, time, equipment and
space) are in place before implementing the research project, and that the research will stop if adequate resources
become unavailable.
• Arranging for a co-investigator to assume direct responsibility of the study ifthe Pl will be unavailable to direct this
research personally, for example, when on sabbatical leave or vacation or other absences. Either this person is
named as co-investigator in this application, or advising IRB via weblRB in advance of such arrangements.

https://web1rb.research.ucla.edu/WeblRB/Doc/O/KF6FPP5NKCOK7E670218FD6411/fromString.html
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University of San Diego Institutional Review Board Approval
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Institutional Review Board
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Note: Approval expires one year after this date.
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__Modification
Action:

_X_Approved

Project Number:
Researcher(s):
Project Title:

_Approved Pending Modification

_

Not Approved

2013-04-154
Sarah Giron Doc SON
Dr. Joseph Burkard Fae SON
Psychoneuroimmunology and Chronic Pain

Note: We send /RB correspondence regarding student research to the faculty advisor. who bears
the ultimate responsibility for the conduct of the research. We request that the faculty
advisor share this correspondence with the student researcher.

Modifications Required or Reasons for Non-Approval
None

The next deadline for submitting project proposals to the Provost's Office for full review is N/A. You may submit
a project proposal for exped ~ed review at any time.

b~~1L.:A

Dr T homas R. Herrinton
Administrator, lnstitutonal Review Board
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5998 Alcala Park
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